

Index of site specific tables

Initial assessments of study group patients

SS1	Data availability for simple comparison of patients proceeding from initial contact or referral to initial assessment
SS2	Completeness of usable data in Study Group patient records in datasets supplied by sites
SS3	Patient progress overview by site
SS4	Age specific rates for engagement with the service, women
SS5	Age specific rates for engagement with the service, men
SS6	Age specific gender ratios, all study group patients, by site
SS7	Numbers of study group patients by ethnic group and site
SS8	Indirectly age-standardised ratios for entry to study group for ethnic groups by gender
SS9	Disabilities and spoken English status of study group members by site.
SS10	Sources of referral of study group members by site
SS11	Initial employment and social security benefit status of study group members.
SS12	Primary diagnoses: completeness and pattern by site
SS12a	Mean initial PHQ9 and GAD7 scores for study group patients with diagnoses indicated as either primary or secondary diagnosis.
SS13	Completeness and caseness levels, initial symptom and W&SAS scores
SS14	Initial symptom and W&SAS scores: medians and inter quartile ranges for sites

Treatment and outcomes

SS15	Totals for the three counts of patient contacts by site, and average contacts per patient.
SS16	Numbers of therapist contact sessions reported by staff grade
SS17	Totals for treatment sessions by type of therapy reported by sites for study group patients.
SS18	Pattern of treatments for study group patients with finished episodes of care who received at least some treatment.
SS19	Patterns of low intensity treatments received by study group patients with finished episodes
SS20	Patterns of high intensity treatments received by study group patients with finished episodes
SS21	Reasons for ending care episodes, all study group patients with completed episodes
SS22	Numbers of recorded contacts for treatment by broad treatment category
SS23	Treatment in relation to primary diagnosis
SS24	Recovery and incidence rates, net rate changes, seven recovery markers - 'complete data only method'
SS25	Recovery and incidence rates, net rate changes, seven recovery markers - 'second unknown, no change method'
SS26	Employment / benefit status progress
SS27	Changes in symptom and W&SAS scores for patients having CBT in four main diagnostic groups.
SS28	Symptom score changes, effect sizes and 'remission' and 'recovery' rates for comparison with pilot work
SS29	Service level outcome and service characteristics used for correlation analysis

Table SS1

Data availability for simple comparison of patients proceeding from initial contact or referral to initial assessment.

Site	Site Code	Information system	Total records	In Study Group	Not Study Group	proportion in study group	Usable age group Study group	Usable age group Others	Usable gender group Study group	Usable gender group Others
	4	PC-MIS	2,453	1,746	707	71.2%	100.0%	99.9%	99.8%	100.0%
	23	IAPTus	6,551	3,687	2,864	56.3%	100.0%	100.0%	99.9%	99.8%
	20	PC-MIS	2,343	1,786	557	76.2%	100.0%	100.0%	98.2%	96.8%
	19	PC-MIS	2,402	1,196	1,206	49.8%	99.4%	99.7%	87.5%	81.4%
	14	PC-MIS	9,084	3,801	5,283	41.8%	99.8%	100.0%	96.6%	97.7%
	5	PC-MIS	6,541	2,891	3,650	44.2%	100.0%	99.9%	99.6%	99.5%
	8	PC-MIS	3,991	2,219	1,772	55.6%	99.9%	99.7%	97.0%	90.1%
	9	PC-MIS	3,601	1,870	1,731	51.9%	99.6%	99.5%	98.9%	97.2%
	24	PC-MIS	10,188	6,060	4,128	59.5%	100.0%	99.9%	98.3%	96.1%
	36	IAPTus	6,374	4,555	1,819	71.5%	100.0%	100.0%	99.8%	99.9%
	10	PC-MIS	2,265	1,793	472	79.2%	99.9%	100.0%	98.7%	89.6%
	30	SystemOne	2,111	570	1,541	27.0%	99.8%	100.0%	99.6%	99.9%
	21	PC-MIS	2,055	1,603	452	78.0%	99.9%	100.0%	98.4%	99.3%
	11	PC-MIS	3,394	2,023	1,371	59.6%	99.9%	99.9%	99.2%	97.7%
	25	PC-MIS	6,038	5,326	712	88.2%	98.3%	98.5%	99.9%	98.5%
	15	Manual	3,920	2,262	1,658	57.7%	100.0%	99.9%	99.9%	99.9%
	31	PC-MIS	13,354	5,912	7,442	44.3%	98.0%	98.0%	94.2%	92.0%
	32	SystemOne	1,516	1,516	0	100.0%	0.0%	-	82.7%	-
	26	PC-MIS	2,500	1,441	1,059	57.6%	99.9%	100.0%	99.5%	98.9%
	3	CORNET	1,828	1,618	210	88.5%	96.6%	92.9%	100.0%	100.0%
	16	PC-MIS	4,454	2,550	1,904	57.3%	98.9%	99.5%	97.3%	97.4%
	33	Manual	4,240	4,103	137	96.8%	0.0%	0.0%	100.0%	100.0%
	29	Manual	452	442	10	97.8%	0.0%	0.0%	97.3%	100.0%
	13	IAPTus	2,776	1,135	1,641	40.9%	99.9%	100.0%	100.0%	100.0%
	12	IAPTus	2,275	1,254	1,021	55.1%	99.9%	99.6%	100.0%	99.8%
	28	PC-MIS	3,751	1,650	2,101	44.0%	99.5%	99.7%	98.4%	96.7%
	6	PC-MIS	7,490	3,826	3,664	51.1%	99.9%	99.8%	97.9%	96.1%
	27	PC-MIS	4,249	3,743	506	88.1%	99.6%	100.0%	99.3%	98.2%
	18	Local PAS	628	626	2	99.7%	70.0%	100.0%	99.8%	100.0%
	7	PC-MIS	7,732	3,120	4,612	40.4%	99.9%	99.8%	96.9%	93.1%
	22	CORNET	348	346	2	99.4%	100.0%	100.0%	100.0%	100.0%
	17	PC-MIS	6,381	2,640	3,741	41.4%	99.4%	99.8%	83.4%	37.4%
Total	0		137,285	79,310	57,975	57.8%	91.7%	99.3%	97.5%	92.4%

Table SS1 (cont)

Data availability for simple comparison of patients proceeding from initial contact or referral to initial assessment.

Site	Site Code	Usable ethnic category Study group	Usable ethnic category Others
	4	97.7%	96.6%
	23	74.9%	35.8%
	20	75.0%	29.8%
	19	38.8%	3.9%
	14	49.8%	33.1%
	5	48.8%	33.9%
	8	74.0%	14.2%
	9	71.4%	14.9%
	24	83.9%	43.7%
	36	89.8%	61.4%
	10	89.7%	35.6%
	30	47.5%	4.2%
	21	84.2%	84.3%
	11	83.6%	10.9%
	25	90.6%	33.4%
	15	91.8%	78.3%
	31	47.5%	15.9%
	32	0.0%	-
	26	54.1%	54.7%
	3	72.3%	51.0%
	16	41.1%	26.6%
	33	58.0%	55.5%
	29	99.1%	90.0%
	13	34.4%	14.0%
	12	90.0%	10.3%
	28	47.2%	31.9%
	6	79.7%	33.4%
	27	86.3%	23.3%
	18	78.6%	100.0%
	7	64.6%	7.2%
	22	99.4%	100.0%
	17	56.6%	17.1%
Total	0	69.5%	28.3%

Table SS2

Completeness of usable data in Study Group patient records in datasets supplied by sites:

Site	Site Code	Records	Gender	Age	Ethnicity	Visual disability	Speech disability	Hearing disability	Mobility disability	Spoken English	Referral date	Assessment date	First treatment date	Ending data	Source of referral	Reason for ending
	4	1746	99.8%	100.0%	97.7%	0.0%	0.0%	0.0%	97.9%	0.0%	100.0%	97.7%	98.0%	69.9%	100.0%	68.4%
	23	3687	99.9%	100.0%	74.9%	75.6%	75.3%	75.8%	75.8%	97.7%	100.0%	100.0%	77.5%	69.8%	100.0%	69.8%
	20	1786	98.2%	100.0%	75.0%	0.0%	0.0%	0.0%	9.1%	0.0%	100.0%	82.8%	91.4%	71.9%	99.8%	69.9%
	19	1196	87.5%	99.4%	38.8%	0.0%	0.0%	0.0%	7.6%	0.0%	100.0%	96.5%	82.7%	40.6%	88.4%	37.1%
	14	3801	96.6%	99.8%	49.8%	0.0%	0.0%	0.0%	2.7%	0.0%	100.0%	97.1%	96.9%	61.8%	99.6%	57.1%
	5	2891	99.6%	100.0%	48.8%	0.0%	0.0%	0.0%	11.4%	0.0%	100.0%	0.0%	0.0%	0.0%	99.9%	65.4%
	8	2219	97.0%	99.9%	74.0%	0.0%	0.0%	0.0%	4.6%	0.0%	100.0%	96.3%	90.9%	57.4%	98.9%	52.9%
	9	1870	98.9%	99.6%	71.4%	0.0%	0.0%	0.0%	4.6%	0.0%	100.0%	97.8%	79.0%	44.9%	99.5%	41.3%
	24	6060	98.3%	100.0%	83.9%	0.0%	0.0%	0.0%	0.5%	0.3%	100.0%	98.8%	71.0%	3.8%	100.0%	3.8%
	36	4555	99.8%	100.0%	89.8%	64.2%	64.0%	64.1%	64.9%	95.6%	100.0%	100.0%	61.4%	40.3%	100.0%	40.3%
	10	1793	98.7%	99.9%	89.7%	0.0%	0.0%	0.0%	28.9%	0.0%	100.0%	96.5%	91.4%	69.2%	98.5%	68.3%
	30	570	99.6%	99.8%	47.5%	0.0%	0.0%	0.0%	0.0%	3.0%	99.8%	71.8%	35.1%	30.2%	100.0%	30.2%
	21	1603	98.4%	99.9%	84.2%	0.0%	0.0%	0.0%	6.3%	0.0%	100.0%	93.7%	98.4%	64.1%	98.6%	61.3%
	11	2023	99.2%	99.9%	83.6%	0.0%	0.0%	0.0%	43.2%	0.0%	100.0%	96.5%	85.3%	62.5%	94.7%	59.1%
	25	5326	99.9%	98.3%	90.6%	0.0%	0.0%	0.0%	2.6%	0.0%	100.0%	85.1%	98.2%	71.0%	100.0%	70.8%
	15	2262	99.9%	100.0%	91.8%	0.0%	0.0%	0.0%	0.0%	0.0%	100.0%	99.9%	78.2%	51.4%	100.0%	51.4%
	31	5912	94.2%	98.0%	47.5%	0.0%	0.0%	0.0%	0.5%	0.0%	100.0%	97.2%	75.6%	60.6%	94.2%	57.2%
	32	1516	82.7%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	82.7%	100.0%	0.0%	0.0%	82.7%	0.0%
	26	1441	99.5%	99.9%	54.1%	0.0%	0.0%	0.0%	0.1%	0.0%	100.0%	70.7%	74.9%	37.6%	100.0%	34.1%
	3	1618	100.0%	96.6%	72.2%	100.0%	100.0%	100.0%	100.0%	70.6%	0.0%	98.9%	34.5%	34.4%	100.0%	100.0%
	16	2550	97.3%	98.9%	41.1%	0.0%	0.0%	0.0%	6.4%	0.0%	100.0%	96.1%	89.2%	62.3%	98.6%	59.1%
	33	4103	100.0%	0.0%	58.0%	0.0%	0.0%	0.0%	0.0%	0.0%	100.0%	0.0%	0.0%	51.7%	100.0%	51.7%
	29	442	97.3%	0.0%	99.1%	0.0%	0.0%	0.0%	0.0%	0.0%	96.6%	92.3%	64.5%	32.6%	100.0%	33.0%
	13	1135	100.0%	99.9%	34.4%	0.6%	0.4%	0.4%	0.4%	12.9%	100.0%	100.0%	35.5%	31.5%	100.0%	31.5%
	12	1254	100.0%	99.9%	90.0%	72.6%	72.4%	72.2%	72.6%	89.4%	100.0%	100.0%	99.9%	45.4%	100.0%	45.4%
	28	1650	98.4%	99.5%	47.2%	0.0%	0.0%	0.0%	20.5%	0.0%	100.0%	96.7%	96.1%	58.6%	98.8%	55.7%
	6	3826	97.9%	99.9%	79.7%	0.0%	0.0%	0.0%	36.7%	0.0%	100.0%	98.2%	93.2%	63.1%	99.1%	55.8%
	27	3743	99.3%	99.6%	86.3%	0.0%	0.0%	0.0%	0.2%	0.0%	100.0%	80.3%	98.7%	72.1%	100.0%	72.0%
	18	626	99.8%	70.0%	78.6%	5.1%	4.8%	4.8%	5.0%	54.3%	99.7%	100.0%	99.7%	36.1%	99.7%	24.4%
	7	3120	96.9%	99.9%	64.6%	0.0%	0.0%	0.0%	10.2%	0.0%	100.0%	97.7%	86.0%	63.1%	99.0%	61.6%
	22	346	100.0%	100.0%	99.4%	100.0%	100.0%	100.0%	100.0%	92.5%	0.0%	100.0%	81.5%	44.2%	100.0%	100.0%
	17	2640	83.4%	99.4%	56.6%	0.0%	0.0%	0.0%	4.7%	0.0%	100.0%	95.6%	89.7%	41.2%	90.0%	39.2%
Total	0	79310	97.5%	91.7%	69.5%	10.9%	10.8%	10.9%	19.3%	14.0%	97.2%	86.6%	74.1%	50.1%	98.3%	52.2%

Table SS2 (cont)

Completeness of usable data in Study Group patient records in datasets supplied by sites

Site	Site Code	First employment status	First sick pay status	First benefit status	First psychotropic drug status	Last employment status	Last sick pay status	Last benefit status	Last psychotropic drug status	Primary diagnosis	First PHQ9 rating	First GAD7 rating	First phobia questions rating	First WASAS rating	Last PHQ9 rating	Last GAD7 rating
	4	99.8%	99.9%	99.9%	99.9%	78.2%	78.4%	78.3%	83.0%	96.3%	100.0%	100.0%	99.8%	99.7%	78.4%	78.3%
	23	100.0%	100.0%	100.0%	100.0%	69.7%	69.7%	69.7%	69.7%	53.8%	100.0%	100.0%	100.0%	100.0%	69.6%	69.6%
	20	98.4%	98.5%	98.4%	99.7%	73.5%	73.9%	73.7%	82.0%	93.1%	99.9%	99.8%	97.8%	97.2%	74.5%	74.4%
	19	99.0%	99.3%	99.3%	99.9%	62.3%	62.5%	62.5%	66.1%	43.6%	99.4%	99.7%	98.2%	97.8%	62.0%	62.0%
	14	99.1%	99.2%	99.3%	99.5%	65.5%	65.6%	65.6%	82.4%	63.7%	99.7%	99.6%	98.4%	97.7%	59.8%	59.9%
	5	97.8%	97.9%	97.9%	99.4%	52.6%	52.6%	52.6%	61.1%	70.3%	99.8%	99.4%	95.4%	97.3%	52.7%	52.7%
	8	99.0%	99.2%	99.2%	99.5%	63.0%	63.0%	63.0%	68.5%	75.5%	99.7%	99.4%	96.8%	96.2%	59.8%	59.8%
	9	98.0%	98.0%	97.9%	99.9%	56.1%	56.0%	56.0%	62.2%	49.3%	99.8%	99.5%	96.0%	95.6%	55.5%	55.5%
	24	97.1%	96.8%	96.9%	99.9%	56.0%	55.8%	55.9%	64.9%	0.3%	99.7%	99.0%	94.5%	93.5%	58.5%	58.3%
	36	100.0%	100.0%	100.0%	100.0%	57.4%	57.5%	57.4%	57.5%	21.7%	100.0%	100.0%	100.0%	100.0%	57.2%	57.2%
	10	97.0%	97.0%	97.2%	99.9%	43.9%	43.8%	43.8%	49.0%	84.4%	99.9%	99.1%	95.6%	94.6%	43.9%	43.8%
	30	84.7%	77.4%	77.9%	70.7%	48.4%	43.2%	44.2%	40.7%	45.4%	99.3%	99.1%	89.1%	98.2%	54.2%	57.2%
	21	98.0%	98.0%	98.1%	99.9%	69.6%	69.4%	69.3%	84.2%	94.4%	99.6%	99.5%	95.8%	93.6%	71.1%	71.0%
	11	98.9%	99.0%	99.0%	99.2%	51.7%	51.9%	51.8%	56.3%	66.5%	100.0%	99.7%	98.0%	98.6%	52.0%	51.8%
	25	99.2%	99.1%	99.2%	99.9%	38.4%	38.5%	38.5%	42.6%	74.9%	99.8%	99.4%	79.1%	97.8%	39.1%	38.5%
	15	91.0%	100.0%	91.0%	30.6%	21.0%	100.0%	21.0%	5.7%	97.5%	93.6%	93.0%	92.7%	38.4%	21.7%	21.4%
	31	98.6%	98.6%	98.6%	100.0%	50.1%	50.1%	50.1%	54.0%	46.1%	99.7%	99.5%	96.5%	97.3%	48.9%	48.9%
	32	99.8%	99.8%	99.8%	0.0%	99.9%	99.9%	99.9%	0.0%	81.7%	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%
	26	71.3%	71.3%	71.4%	79.0%	23.5%	23.3%	23.3%	65.3%	92.9%	99.9%	71.8%	70.3%	69.7%	49.2%	39.2%
	3	84.0%	100.0%	100.0%	100.0%	56.8%	100.0%	100.0%	100.0%	4.8%	97.7%	98.9%	81.6%	86.4%	54.9%	56.1%
	16	90.0%	91.0%	90.9%	99.9%	44.4%	44.6%	44.6%	80.6%	58.8%	99.6%	98.9%	76.5%	82.1%	53.6%	52.4%
	33	98.5%	98.0%	97.4%	100.0%	98.5%	97.9%	97.4%	99.8%	7.3%	100.0%	99.3%	98.2%	98.1%	100.0%	99.3%
	29	97.3%	100.0%	100.0%	100.0%	32.1%	33.3%	32.4%	27.6%	80.5%	99.8%	99.1%	71.0%	98.4%	32.8%	33.0%
	13	99.6%	99.8%	99.9%	99.8%	40.5%	40.7%	40.7%	40.5%	0.0%	100.0%	99.9%	99.8%	99.8%	39.7%	39.7%
	12	99.8%	99.8%	99.9%	99.8%	62.7%	62.8%	62.8%	62.8%	26.6%	100.0%	100.0%	99.7%	99.6%	61.7%	61.7%
	28	98.5%	98.5%	98.5%	99.5%	65.0%	65.0%	65.0%	69.7%	25.2%	99.9%	99.5%	95.9%	96.8%	67.5%	67.3%
	6	95.6%	95.5%	95.6%	99.8%	25.3%	25.1%	25.0%	75.0%	84.9%	99.9%	99.8%	84.8%	94.9%	65.4%	65.2%
	27	98.3%	98.2%	98.2%	99.9%	45.3%	45.2%	45.3%	49.5%	78.8%	99.7%	98.4%	92.2%	96.0%	45.2%	44.7%
	18	86.3%	90.1%	89.9%	92.2%	65.2%	66.5%	66.5%	67.4%	1.4%	100.0%	100.0%	99.4%	99.4%	83.1%	83.1%
	7	99.4%	99.4%	99.5%	99.9%	61.8%	61.8%	61.8%	64.4%	64.4%	99.9%	99.8%	99.0%	98.7%	61.9%	61.9%
	22	91.0%	100.0%	100.0%	100.0%	50.3%	100.0%	100.0%	100.0%	0.0%	98.6%	99.1%	98.0%	99.4%	53.5%	53.2%
	17	93.1%	93.0%	93.1%	99.5%	49.8%	49.6%	49.9%	62.0%	71.1%	99.6%	99.5%	92.3%	89.5%	52.3%	52.4%
Total	0	96.9%	97.5%	97.2%	95.3%	55.6%	58.9%	56.6%	63.0%	54.4%	99.6%	98.8%	93.5%	94.2%	58.4%	58.1%

Table SS2 (cont)

Completeness of usable data in Study Group patient records in datasets supplied by sites

Site	Site Code	Last phobia questions rating	Last WASAS rating	Contacts by intervention	Contacts by session purpose	Contacts by therapist grade	Information system
	4	78.1%	78.1%	99.6%	99.8%	41.1%	PC-MIS
	23	69.6%	69.6%	100.0%	100.0%	97.1%	IAPTus
	20	71.6%	70.4%	92.8%	99.4%	93.9%	PC-MIS
	19	61.0%	61.5%	85.5%	99.7%	6.8%	PC-MIS
	14	58.9%	58.2%	95.9%	99.3%	94.0%	PC-MIS
	5	51.4%	51.9%	92.7%	99.0%	11.1%	PC-MIS
	8	57.6%	57.6%	91.8%	99.3%	70.9%	PC-MIS
	9	52.6%	53.3%	85.8%	99.4%	98.1%	PC-MIS
	24	53.4%	53.7%	87.1%	100.0%	41.9%	PC-MIS
	36	57.1%	57.1%	100.0%	100.0%	73.5%	IAPTus
	10	43.2%	43.2%	95.4%	99.0%	98.1%	PC-MIS
	30	47.7%	54.0%	68.4%	22.1%	80.2%	SystemOne
	21	64.3%	62.6%	98.7%	99.6%	93.4%	PC-MIS
	11	51.0%	51.3%	84.9%	98.9%	95.9%	PC-MIS
	25	32.3%	36.0%	96.5%	94.8%	98.4%	PC-MIS
	15	19.1%	12.1%	91.9%	99.9%	98.7%	Manual
	31	47.3%	48.0%	77.7%	99.8%	40.5%	PC-MIS
	32	100.0%	100.0%	78.0%	97.1%	100.0%	SystemOne
	26	26.1%	20.4%	74.9%	77.7%	69.4%	PC-MIS
	3	41.9%	53.0%	92.0%	96.3%	99.6%	CORNET
	16	31.1%	35.7%	89.0%	99.2%	27.1%	PC-MIS
	33	98.2%	98.1%	100.0%	100.0%	100.0%	Manual
	29	26.7%	32.4%	0.0%	0.0%	0.0%	Manual
	13	39.5%	39.6%	99.6%	100.0%	76.7%	IAPTus
	12	61.6%	61.6%	99.9%	100.0%	77.8%	IAPTus
	28	61.8%	63.9%	98.0%	99.2%	0.0%	PC-MIS
	6	18.7%	19.5%	97.4%	99.3%	88.4%	PC-MIS
	27	41.5%	42.7%	98.8%	92.2%	97.4%	PC-MIS
	18	83.1%	83.1%	70.0%	70.0%	68.7%	Local PAS
	7	61.2%	61.3%	90.4%	99.7%	97.5%	PC-MIS
	22	52.6%	53.5%	100.0%	100.0%	100.0%	CORNET
	17	48.4%	47.7%	87.7%	99.3%	24.2%	PC-MIS
Total	0	52.6%	53.2%	91.5%	97.1%	71.9%	

SS3

Patient progress overview by site.

Site	Site Code	Total in study group	Not more than one attendance				More than one attendance			
			Not concluded	Concluded	% of sub-group concluded	<i>Sub-total</i>	Not concluded	Concluded	% of sub-group concluded	<i>Sub-total</i>
	4	1746	98 (5.6%)	213 (12.2%)	68.5%	311 (17.8%)	418 (23.9%)	1,017 (58.2%)	70.9%	1,435 (82.2%)
	23	3687	254 (6.9%)	860 (23.3%)	77.2%	1,114 (30.2%)	859 (23.3%)	1,714 (46.5%)	66.6%	2,573 (69.8%)
	20	1786	228 (12.8%)	131 (7.3%)	36.5%	359 (20.1%)	273 (15.3%)	1,154 (64.6%)	80.9%	1,427 (79.9%)
	19	1196	219 (18.3%)	204 (17.1%)	48.2%	423 (35.4%)	491 (41.1%)	282 (23.6%)	36.5%	773 (64.6%)
	14	3801	329 (8.7%)	386 (10.2%)	54.0%	715 (18.8%)	1,100 (28.9%)	1,986 (52.2%)	64.4%	3,086 (81.2%)
	5	2891	463 (16.0%)	786 (27.2%)	62.9%	1,249 (43.2%)	537 (18.6%)	1,105 (38.2%)	67.3%	1,642 (56.8%)
	8	2219	303 (13.7%)	424 (19.1%)	58.3%	727 (32.8%)	626 (28.2%)	866 (39.0%)	58.0%	1,492 (67.2%)
	9	1870	404 (21.6%)	251 (13.4%)	38.3%	655 (35.0%)	626 (33.5%)	589 (31.5%)	48.5%	1,215 (65.0%)
	24	6060	2,023 (33.4%)	88 (1.5%)	4.2%	2,111 (34.8%)	3,806 (62.8%)	143 (2.4%)	3.6%	3,949 (65.2%)
	36	4555	1,154 (25.3%)	765 (16.8%)	39.9%	1,919 (42.1%)	1,567 (34.4%)	1,069 (23.5%)	40.6%	2,636 (57.9%)
	10	1793	202 (11.3%)	733 (40.9%)	78.4%	935 (52.1%)	347 (19.4%)	511 (28.5%)	59.6%	858 (47.9%)
	30	570	169 (29.6%)	103 (18.1%)	37.9%	272 (47.7%)	229 (40.2%)	69 (12.1%)	23.2%	298 (52.3%)
	21	1603	216 (13.5%)	99 (6.2%)	31.4%	315 (19.7%)	345 (21.5%)	943 (58.8%)	73.2%	1,288 (80.3%)
	11	2023	395 (19.5%)	510 (25.2%)	56.4%	905 (44.7%)	363 (17.9%)	755 (37.3%)	67.5%	1,118 (55.3%)
	25	5326	629 (11.8%)	2,223 (41.7%)	77.9%	2,852 (53.5%)	915 (17.2%)	1,559 (29.3%)	63.0%	2,474 (46.5%)
	15	2262	470 (20.8%)	244 (10.8%)	34.2%	714 (31.6%)	629 (27.8%)	919 (40.6%)	59.4%	1,548 (68.4%)
	31	5912	1,101 (18.6%)	1,613 (27.3%)	59.4%	2,714 (45.9%)	1,224 (20.7%)	1,974 (33.4%)	61.7%	3,198 (54.1%)
	32	1516	515 (34.0%)	(0.0%)	0.0%	515 (34.0%)	1,001 (66.0%)	(0.0%)	0.0%	1,001 (66.0%)
	26	1441	427 (29.6%)	117 (8.1%)	21.5%	544 (37.8%)	468 (32.5%)	429 (29.8%)	47.8%	897 (62.2%)
	3	1618	279 (17.2%)	81 (5.0%)	22.5%	360 (22.2%)	776 (48.0%)	482 (29.8%)	38.3%	1,258 (77.8%)
	16	2550	392 (15.4%)	489 (19.2%)	55.5%	881 (34.5%)	564 (22.1%)	1,105 (43.3%)	66.2%	1,669 (65.5%)
	33	4103	730 (17.8%)	641 (15.6%)	46.8%	1,371 (33.4%)	1,252 (30.5%)	1,480 (36.1%)	54.2%	2,732 (66.6%)
	29	442	295 (66.7%)	147 (33.3%)	33.3%	442 (100.0%)	(0.0%)	(0.0%)	-	(0.0%)
	13	1135	452 (39.8%)	202 (17.8%)	30.9%	654 (57.6%)	325 (28.6%)	156 (13.7%)	32.4%	481 (42.4%)
	12	1254	260 (20.7%)	197 (15.7%)	43.1%	457 (36.4%)	425 (33.9%)	372 (29.7%)	46.7%	797 (63.6%)
	28	1650	220 (13.3%)	293 (17.8%)	57.1%	513 (31.1%)	461 (27.9%)	676 (41.0%)	59.5%	1,137 (68.9%)
	6	3826	432 (11.3%)	674 (17.6%)	60.9%	1,106 (28.9%)	973 (25.4%)	1,747 (45.7%)	64.2%	2,720 (71.1%)
	27	3743	397 (10.6%)	1,284 (34.3%)	76.4%	1,681 (44.9%)	646 (17.3%)	1,416 (37.8%)	68.7%	2,062 (55.1%)
	18	626	127 (20.3%)	165 (26.4%)	56.5%	292 (46.6%)	273 (43.6%)	61 (9.7%)	18.3%	334 (53.4%)
	7	3120	351 (11.3%)	781 (25.0%)	69.0%	1,132 (36.3%)	798 (25.6%)	1,190 (38.1%)	59.9%	1,988 (63.7%)
	22	346	110 (31.8%)	9 (2.6%)	7.6%	119 (34.4%)	81 (23.4%)	146 (42.2%)	64.3%	227 (65.6%)
	17	2640	811 (30.7%)	231 (8.8%)	22.2%	1,042 (39.5%)	733 (27.8%)	865 (32.8%)	54.1%	1,598 (60.5%)
Total	0	79310	14,455 (18.2%)	14,944 (18.8%)	50.8%	29,399 (37.1%)	23,131 (29.2%)	26,780 (33.8%)	53.7%	49,911 (62.9%)

SS4 Site	Age specific rates for engagement with the service: Study group patients per 1000 population by age group, women (95% confidence interval)
Site Code	Age 5 to 17 Age 18 to 24 Age 25 to 34 Age 35 to 44 Age 45 to 54
4	0.15 (0.05 to 0.36) 9.25 (7.82 to 10.87) 11.40 (10.16 to 12.76) 9.61 (8.59 to 10.72) 7.78 (6.78 to 8.89)
23	1.33 (0.88 to 1.93) 27.21 (24.62 to 30.00) 32.02 (29.51 to 34.68) 27.34 (25.16 to 29.66) 19.77 (17.82 to 21.88)
20	0.00 (0.00 to 0.23) 9.45 (8.01 to 11.09) 16.72 (14.99 to 18.59) 15.82 (14.17 to 17.62) 11.45 (9.80 to 13.30)
19	0.02 (0.00 to 0.13) 6.04 (4.94 to 7.30) 5.90 (5.06 to 6.84) 4.72 (4.09 to 5.44) 3.84 (3.23 to 4.54)
14	0.97 (0.67 to 1.36) 20.29 (18.18 to 22.57) 22.28 (20.43 to 24.25) 17.72 (16.38 to 19.14) 14.76 (13.45 to 16.16)
5	0.23 (0.12 to 0.39) 8.19 (7.29 to 9.17) 9.81 (8.96 to 10.72) 8.85 (8.11 to 9.64) 6.84 (6.13 to 7.61)
8	0.00 (0.00 to 0.28) 11.31 (9.69 to 13.13) 15.12 (13.79 to 16.55) 17.67 (15.80 to 19.70) 19.31 (16.86 to 22.03)
9	0.06 (0.00 to 0.34) 9.55 (7.82 to 11.54) 21.70 (19.89 to 23.63) 14.87 (13.17 to 16.72) 15.77 (13.62 to 18.16)
24	3.29 (2.74 to 3.91) 29.35 (27.00 to 31.86) 32.30 (30.16 to 34.56) 25.41 (23.83 to 27.06) 19.54 (18.14 to 21.03)
36	3.35 (2.73 to 4.07) 39.02 (35.50 to 42.79) 39.31 (36.33 to 42.47) 25.95 (24.09 to 27.92) 19.35 (17.76 to 21.04)
10	0.19 (0.05 to 0.49) 10.35 (8.73 to 12.18) 12.55 (11.28 to 13.93) 10.31 (9.08 to 11.66) 10.79 (9.37 to 12.36)
30	0.45 (0.22 to 0.80) 3.82 (2.77 to 5.13) 4.32 (3.34 to 5.50) 4.19 (3.42 to 5.08) 3.07 (2.40 to 3.87)
21	0.36 (0.16 to 0.69) 16.69 (14.38 to 19.27) 14.47 (12.62 to 16.52) 10.30 (9.05 to 11.68) 8.81 (7.64 to 10.10)
11	0.59 (0.27 to 1.12) 12.13 (10.14 to 14.39) 17.93 (16.24 to 19.74) 21.80 (19.80 to 23.96) 20.86 (18.49 to 23.46)
15	1.71 (1.07 to 2.58) 28.19 (24.57 to 32.19) 36.88 (32.98 to 41.11) 28.11 (25.25 to 31.21) 28.62 (25.55 to 31.95)
31	0.58 (0.39 to 0.82) 11.88 (10.98 to 12.83) 17.76 (16.67 to 18.90) 15.27 (14.24 to 16.35) 14.66 (13.56 to 15.82)
26	0.40 (0.15 to 0.87) 22.33 (18.97 to 26.13) 20.53 (17.89 to 23.45) 14.62 (12.77 to 16.66) 12.86 (11.04 to 14.89)
3	0.26 (0.09 to 0.62) 6.33 (5.44 to 7.33) 14.55 (13.03 to 16.21) 12.56 (11.00 to 14.29) 11.68 (10.00 to 13.56)
16	1.38 (0.86 to 2.09) 23.39 (20.80 to 26.22) 28.18 (25.57 to 30.98) 24.24 (21.82 to 26.87) 22.84 (20.32 to 25.59)
13	0.89 (0.42 to 1.63) 18.94 (15.84 to 22.46) 19.92 (17.06 to 23.13) 14.62 (12.47 to 17.02) 13.35 (11.26 to 15.71)
12	0.18 (0.04 to 0.52) 7.91 (6.53 to 9.50) 7.70 (6.77 to 8.74) 10.19 (8.93 to 11.58) 7.89 (6.54 to 9.44)
28	0.60 (0.30 to 1.08) 12.14 (10.30 to 14.21) 14.96 (13.10 to 17.01) 16.19 (14.38 to 18.16) 12.66 (10.97 to 14.53)
6	0.55 (0.36 to 0.81) 17.45 (15.74 to 19.30) 17.62 (16.23 to 19.09) 15.70 (14.55 to 16.91) 11.71 (10.66 to 12.84)
27	1.86 (1.24 to 2.69) 45.39 (40.82 to 50.33) 47.26 (43.68 to 51.06) 44.29 (41.08 to 47.69) 32.65 (29.61 to 35.92)
18	0.08 (0.02 to 0.25) 2.37 (1.76 to 3.12) 3.40 (2.79 to 4.12) 2.50 (2.01 to 3.07) 1.34 (0.95 to 1.84)
7	0.07 (0.01 to 0.20) 16.76 (14.97 to 18.72) 14.72 (13.48 to 16.03) 11.19 (10.23 to 12.22) 10.79 (9.76 to 11.91)
22	0.00 (0.00 to 0.07) 1.25 (0.85 to 1.79) 1.58 (1.22 to 2.03) 1.22 (0.95 to 1.55) 0.99 (0.72 to 1.32)
17	1.04 (0.62 to 1.65) 21.70 (19.02 to 24.65) 25.33 (22.62 to 28.28) 20.23 (18.20 to 22.43) 17.34 (15.38 to 19.50)
Total	0 0.69 (0.64 to 0.76) 13.83 (13.50 to 14.17) 16.33 (16.03 to 16.63) 13.98 (13.72 to 14.24) 11.82 (11.56 to 12.09)

SS4 (cont)

Age specific rates for engagement with the service: Study group patients per 1000 population by age group, women (95% confidence intervals in parentheses)

Site	Site Code	Age 55 to 64	Age 65 to 74	Age 75 to 84	Age 85 and over	All ages
	4	5.39 (4.51 to 6.39)	2.93 (2.16 to 3.89)	0.88 (0.42 to 1.61)	0.40 (0.05 to 1.46)	5.77 (5.44 to 6.10)
	23	13.69 (12.05 to 15.49)	4.70 (3.65 to 5.96)	3.40 (2.49 to 4.54)	1.68 (0.87 to 2.93)	15.22 (14.61 to 15.84)
	20	6.66 (5.27 to 8.30)	2.34 (1.45 to 3.58)	0.37 (0.08 to 1.09)	0.00 (0.00 to 0.82)	8.54 (8.04 to 9.06)
	19	2.00 (1.53 to 2.55)	1.08 (0.69 to 1.63)	0.79 (0.41 to 1.39)	0.56 (0.15 to 1.42)	2.79 (2.59 to 3.01)
	14	9.91 (8.83 to 11.09)	4.73 (3.85 to 5.74)	1.83 (1.23 to 2.63)	0.42 (0.09 to 1.22)	10.63 (10.21 to 11.05)
	5	4.43 (3.84 to 5.08)	0.20 (0.07 to 0.43)	0.04 (0.00 to 0.25)	0.00 (0.00 to 0.36)	4.89 (4.67 to 5.11)
	8	13.25 (11.05 to 15.77)	5.98 (4.16 to 8.32)	3.60 (2.01 to 5.94)	1.76 (0.36 to 5.14)	11.70 (11.09 to 12.34)
	9	8.78 (6.84 to 11.09)	4.18 (2.62 to 6.34)	1.14 (0.31 to 2.91)	1.76 (0.36 to 5.13)	10.93 (10.32 to 11.56)
	24	12.07 (11.03 to 13.17)	5.53 (4.69 to 6.46)	2.66 (2.02 to 3.45)	0.37 (0.10 to 0.96)	14.43 (13.98 to 14.88)
	36	11.52 (10.38 to 12.76)	6.38 (5.43 to 7.46)	2.67 (2.01 to 3.49)	0.42 (0.11 to 1.08)	14.51 (14.00 to 15.04)
	10	8.16 (6.73 to 9.81)	3.79 (2.65 to 5.24)	1.46 (0.70 to 2.69)	0.34 (0.01 to 1.92)	7.46 (7.03 to 7.91)
	30	1.81 (1.33 to 2.41)	0.89 (0.51 to 1.44)	0.32 (0.09 to 0.81)	0.18 (0.00 to 0.98)	2.15 (1.93 to 2.38)
	21	5.37 (4.48 to 6.37)	1.34 (0.87 to 1.98)	0.19 (0.04 to 0.55)	0.00 (0.00 to 0.43)	5.88 (5.53 to 6.26)
	11	11.73 (9.60 to 14.19)	3.84 (2.46 to 5.71)	1.76 (0.71 to 3.63)	0.61 (0.02 to 3.39)	12.55 (11.90 to 13.22)
	15	19.32 (16.43 to 22.57)	6.62 (4.83 to 8.86)	2.59 (1.38 to 4.44)	3.28 (1.06 to 7.66)	18.40 (17.46 to 19.37)
	31	7.21 (6.40 to 8.10)	3.89 (3.21 to 4.67)	1.31 (0.88 to 1.87)	0.58 (0.21 to 1.25)	9.31 (9.00 to 9.61)
	26	7.49 (6.16 to 9.03)	4.30 (3.12 to 5.77)	1.76 (0.96 to 2.96)	1.44 (0.53 to 3.13)	9.16 (8.59 to 9.76)
	3	7.46 (5.96 to 9.22)	2.17 (1.32 to 3.35)	0.77 (0.28 to 1.68)	0.00 (0.00 to 1.12)	7.20 (6.77 to 7.66)
	16	12.96 (10.98 to 15.20)	4.06 (2.86 to 5.60)	1.60 (0.80 to 2.86)	0.62 (0.07 to 2.23)	14.72 (14.01 to 15.46)
	13	6.92 (5.30 to 8.87)	3.45 (2.23 to 5.10)	1.32 (0.57 to 2.61)	0.00 (0.00 to 1.60)	9.29 (8.62 to 9.99)
	12	4.43 (3.19 to 5.99)	3.62 (2.34 to 5.34)	3.08 (1.76 to 5.01)	1.77 (0.48 to 4.53)	5.95 (5.55 to 6.38)
	28	5.68 (4.53 to 7.04)	2.27 (1.47 to 3.36)	0.93 (0.40 to 1.82)	0.00 (0.00 to 1.06)	8.00 (7.51 to 8.51)
	6	6.83 (6.05 to 7.69)	3.96 (3.26 to 4.77)	1.74 (1.22 to 2.39)	0.30 (0.06 to 0.87)	8.58 (8.25 to 8.92)
	27	23.05 (20.22 to 26.15)	11.42 (9.13 to 14.13)	5.94 (4.09 to 8.35)	1.81 (0.49 to 4.62)	25.91 (24.91 to 26.94)
	18	0.91 (0.58 to 1.37)	0.37 (0.13 to 0.80)	0.09 (0.00 to 0.49)	0.18 (0.00 to 0.99)	1.42 (1.27 to 1.58)
	7	6.45 (5.58 to 7.42)	3.01 (2.31 to 3.85)	0.86 (0.48 to 1.42)	0.25 (0.03 to 0.90)	7.37 (7.05 to 7.70)
	22	0.63 (0.42 to 0.92)	0.34 (0.16 to 0.62)	0.19 (0.05 to 0.47)	0.00 (0.00 to 0.37)	0.72 (0.63 to 0.81)
	17	9.70 (8.22 to 11.37)	5.63 (4.38 to 7.14)	3.25 (2.16 to 4.70)	2.43 (1.11 to 4.62)	12.19 (11.58 to 12.83)
Total	0	7.19 (6.98 to 7.41)	3.27 (3.10 to 3.44)	1.45 (1.32 to 1.58)	0.52 (0.41 to 0.65)	8.37 (8.29 to 8.45)

SS5 Site	Age specific rates for engagement with the service: Study group patients per 1000 population by age group, men (95% confidence int					
Code	Age 5 to 17	Age 18 to 24	Age 25 to 34	Age 35 to 44	Age 45 to 54	
4	0.09 (0.02 to 0.25)	4.07 (3.18 to 5.13)	5.29 (4.42 to 6.29)	4.45 (3.77 to 5.23)	4.21 (3.49 to 5.04)	
23	0.42 (0.19 to 0.80)	12.25 (10.57 to 14.12)	17.46 (15.61 to 19.47)	16.42 (14.73 to 18.24)	14.16 (12.48 to 15.99)	
20	0.00 (0.00 to 0.23)	4.43 (3.40 to 5.67)	8.13 (6.98 to 9.41)	8.61 (7.45 to 9.90)	9.65 (8.14 to 11.35)	
19	0.02 (0.00 to 0.13)	1.81 (1.27 to 2.51)	2.41 (1.87 to 3.06)	2.06 (1.63 to 2.57)	1.91 (1.48 to 2.42)	
14	0.30 (0.15 to 0.53)	7.82 (6.56 to 9.24)	10.12 (8.88 to 11.48)	9.66 (8.66 to 10.75)	8.52 (7.53 to 9.60)	
5	0.08 (0.03 to 0.19)	3.28 (2.74 to 3.89)	4.65 (4.09 to 5.27)	4.48 (3.95 to 5.05)	4.59 (4.01 to 5.23)	
8	0.00 (0.00 to 0.28)	6.13 (4.86 to 7.63)	7.95 (6.99 to 9.01)	9.18 (7.93 to 10.56)	11.30 (9.48 to 13.38)	
9	0.06 (0.00 to 0.33)	4.34 (3.16 to 5.80)	9.95 (8.69 to 11.33)	10.40 (9.03 to 11.93)	8.82 (7.21 to 10.68)	
24	1.08 (0.78 to 1.44)	12.61 (11.17 to 14.18)	16.65 (15.11 to 18.31)	15.03 (13.78 to 16.36)	11.57 (10.45 to 12.78)	
36	0.93 (0.63 to 1.32)	14.12 (12.28 to 16.17)	16.72 (14.79 to 18.84)	13.96 (12.54 to 15.49)	12.91 (11.58 to 14.34)	
10	0.14 (0.03 to 0.40)	3.90 (2.96 to 5.05)	6.15 (5.32 to 7.08)	6.76 (5.84 to 7.80)	6.05 (4.98 to 7.29)	
30	0.19 (0.06 to 0.45)	2.02 (1.35 to 2.90)	2.74 (1.97 to 3.70)	2.11 (1.57 to 2.79)	1.72 (1.23 to 2.34)	
21	0.15 (0.04 to 0.39)	6.06 (4.74 to 7.64)	8.94 (7.42 to 10.68)	6.49 (5.47 to 7.64)	6.08 (5.09 to 7.21)	
11	0.13 (0.02 to 0.46)	5.61 (4.30 to 7.19)	6.31 (5.38 to 7.36)	8.32 (7.16 to 9.62)	9.39 (7.76 to 11.25)	
15	0.83 (0.41 to 1.48)	14.78 (12.23 to 17.70)	22.04 (18.90 to 25.56)	18.68 (16.19 to 21.44)	17.36 (14.85 to 20.16)	
31	0.26 (0.15 to 0.44)	4.63 (4.08 to 5.24)	8.17 (7.46 to 8.92)	9.65 (8.82 to 10.53)	8.48 (7.64 to 9.39)	
26	0.06 (0.00 to 0.35)	7.32 (5.58 to 9.42)	9.61 (7.84 to 11.67)	8.03 (6.67 to 9.58)	8.23 (6.77 to 9.91)	
3	0.10 (0.01 to 0.37)	2.06 (1.57 to 2.66)	5.80 (4.90 to 6.82)	7.34 (6.21 to 8.61)	6.72 (5.46 to 8.17)	
16	0.30 (0.10 to 0.69)	8.45 (6.98 to 10.13)	12.62 (10.95 to 14.47)	13.68 (11.95 to 15.58)	13.48 (11.61 to 15.57)	
13	0.49 (0.18 to 1.07)	7.06 (5.27 to 9.26)	10.48 (8.46 to 12.84)	10.02 (8.20 to 12.11)	8.46 (6.79 to 10.43)	
12	0.11 (0.01 to 0.41)	3.06 (2.27 to 4.03)	3.97 (3.32 to 4.71)	4.52 (3.75 to 5.39)	5.66 (4.53 to 6.98)	
28	0.10 (0.01 to 0.38)	6.34 (5.04 to 7.86)	10.03 (8.51 to 11.75)	9.48 (8.10 to 11.03)	8.09 (6.75 to 9.62)	
6	0.27 (0.15 to 0.47)	5.54 (4.64 to 6.57)	7.05 (6.20 to 7.99)	7.97 (7.15 to 8.85)	6.81 (6.01 to 7.69)	
27	0.38 (0.14 to 0.83)	15.49 (12.96 to 18.37)	19.37 (17.15 to 21.79)	19.85 (17.77 to 22.10)	20.64 (18.26 to 23.24)	
18	0.03 (0.00 to 0.15)	0.92 (0.56 to 1.42)	0.86 (0.58 to 1.23)	1.08 (0.77 to 1.47)	0.57 (0.33 to 0.91)	
7	0.04 (0.01 to 0.16)	6.15 (5.10 to 7.34)	7.28 (6.40 to 8.25)	6.53 (5.79 to 7.34)	5.53 (4.80 to 6.35)	
22	0.00 (0.00 to 0.06)	0.39 (0.19 to 0.72)	0.74 (0.49 to 1.06)	0.49 (0.31 to 0.72)	0.51 (0.32 to 0.76)	
17	0.38 (0.15 to 0.78)	8.01 (6.39 to 9.91)	12.46 (10.58 to 14.59)	10.50 (9.02 to 12.15)	10.29 (8.77 to 11.99)	
Total	0.24 (0.21 to 0.28)	5.54 (5.33 to 5.75)	7.69 (7.48 to 7.90)	7.66 (7.47 to 7.86)	7.10 (6.89 to 7.30)	

SS5 (cont)

Age specific rates for engagement with the service: Study group patients per 1000 population by age group, men (95% confidence intervals in parentheses)

Site	Site Code	Age 55 to 64	Age 65 to 74	Age 75 to 84	Age 85 and over	All ages
	4	2.39 (1.81 to 3.09)	1.38 (0.86 to 2.11)	0.79 (0.32 to 1.63)	0.00 (0.00 to 1.59)	2.77 (2.54 to 3.01)
	23	7.07 (5.89 to 8.41)	3.40 (2.46 to 4.58)	2.00 (1.20 to 3.12)	0.90 (0.18 to 2.62)	9.04 (8.55 to 9.54)
	20	5.19 (3.97 to 6.66)	0.37 (0.08 to 1.08)	0.38 (0.05 to 1.38)	0.51 (0.01 to 2.85)	5.24 (4.84 to 5.66)
	19	1.68 (1.25 to 2.21)	0.80 (0.46 to 1.31)	0.27 (0.05 to 0.78)	0.30 (0.01 to 1.70)	1.30 (1.17 to 1.46)
	14	5.05 (4.28 to 5.92)	2.30 (1.68 to 3.08)	0.96 (0.48 to 1.71)	1.56 (0.50 to 3.64)	5.44 (5.14 to 5.76)
	5	2.99 (2.50 to 3.55)	0.14 (0.04 to 0.36)	0.18 (0.04 to 0.51)	0.00 (0.00 to 0.76)	2.66 (2.50 to 2.83)
	8	9.81 (7.80 to 12.17)	5.50 (3.63 to 8.01)	2.88 (1.31 to 5.47)	3.09 (0.64 to 9.04)	6.79 (6.32 to 7.28)
	9	5.68 (4.09 to 7.68)	1.61 (0.69 to 3.17)	1.02 (0.21 to 2.99)	1.26 (0.03 to 7.02)	5.93 (5.48 to 6.41)
	24	6.31 (5.55 to 7.14)	2.52 (1.96 to 3.19)	1.55 (1.01 to 2.29)	0.20 (0.01 to 1.14)	7.80 (7.46 to 8.15)
	36	7.36 (6.41 to 8.41)	2.19 (1.62 to 2.89)	1.55 (0.99 to 2.31)	1.00 (0.32 to 2.32)	7.62 (7.24 to 8.01)
	10	4.83 (3.71 to 6.17)	2.02 (1.19 to 3.19)	1.22 (0.45 to 2.67)	0.00 (0.00 to 2.23)	4.17 (3.85 to 4.50)
	30	1.08 (0.70 to 1.58)	0.41 (0.16 to 0.85)	0.42 (0.12 to 1.08)	0.00 (0.00 to 1.48)	1.24 (1.08 to 1.42)
	21	3.05 (2.36 to 3.88)	0.55 (0.25 to 1.05)	0.44 (0.14 to 1.03)	0.00 (0.00 to 0.92)	3.52 (3.23 to 3.82)
	11	6.29 (4.65 to 8.31)	3.60 (2.20 to 5.55)	1.43 (0.39 to 3.65)	1.39 (0.04 to 7.75)	5.32 (4.90 to 5.76)
	15	13.52 (11.00 to 16.44)	3.08 (1.83 to 4.87)	2.43 (1.05 to 4.80)	1.64 (0.04 to 9.13)	11.21 (10.45 to 12.01)
	31	4.66 (4.00 to 5.40)	1.41 (0.99 to 1.94)	0.64 (0.31 to 1.17)	0.00 (0.00 to 0.76)	4.97 (4.75 to 5.20)
	26	3.93 (2.96 to 5.12)	2.15 (1.31 to 3.32)	0.84 (0.27 to 1.95)	0.00 (0.00 to 1.90)	4.75 (4.33 to 5.19)
	3	4.81 (3.65 to 6.24)	1.49 (0.77 to 2.60)	0.18 (0.00 to 1.02)	0.00 (0.00 to 2.43)	3.65 (3.34 to 3.97)
	16	7.60 (6.10 to 9.35)	1.68 (0.92 to 2.83)	1.29 (0.47 to 2.80)	0.77 (0.02 to 4.29)	7.70 (7.19 to 8.24)
	13	6.06 (4.54 to 7.93)	1.71 (0.85 to 3.05)	1.01 (0.28 to 2.59)	1.85 (0.22 to 6.70)	5.64 (5.11 to 6.21)
	12	4.61 (3.31 to 6.25)	1.82 (0.91 to 3.25)	1.08 (0.30 to 2.77)	1.78 (0.22 to 6.42)	3.23 (2.94 to 3.54)
	28	4.10 (3.14 to 5.25)	0.84 (0.36 to 1.65)	0.51 (0.11 to 1.50)	0.00 (0.00 to 2.43)	5.02 (4.63 to 5.44)
	6	3.07 (2.54 to 3.68)	1.46 (1.04 to 1.99)	0.61 (0.29 to 1.12)	0.21 (0.01 to 1.14)	4.00 (3.77 to 4.23)
	27	12.28 (10.23 to 14.62)	3.98 (2.62 to 5.80)	2.87 (1.48 to 5.02)	0.00 (0.00 to 3.54)	12.17 (11.49 to 12.88)
	18	0.28 (0.11 to 0.59)	0.00 (0.00 to 0.24)	0.11 (0.00 to 0.62)	0.81 (0.10 to 2.93)	0.52 (0.43 to 0.63)
	7	3.48 (2.84 to 4.22)	2.05 (1.45 to 2.81)	0.73 (0.33 to 1.38)	0.00 (0.00 to 1.00)	3.87 (3.63 to 4.11)
	22	0.19 (0.08 to 0.38)	0.15 (0.04 to 0.38)	0.19 (0.04 to 0.55)	0.00 (0.00 to 0.81)	0.31 (0.25 to 0.38)
	17	5.54 (4.42 to 6.86)	2.90 (1.97 to 4.11)	1.74 (0.87 to 3.11)	0.00 (0.00 to 2.13)	6.23 (5.78 to 6.70)
Total		4.20 (4.03 to 4.37)	1.54 (1.42 to 1.66)	0.88 (0.76 to 1.00)	0.42 (0.28 to 0.60)	4.42 (4.37 to 4.48)

SS6

Age specific gender ratios, all study group patients, by site

Site	Site Code	05 to 17	18 to 24	25 to 34	35 to 44	45 to 54	55 to 64
	4	1.78 (0.43 to 7.45)	2.27 (1.71 to 3.01)	2.16 (1.76 to 2.65)	2.16 (1.78 to 2.62)	1.85 (1.48 to 2.31)	2.26 (1.66 to 3.07)
	23	3.14 (1.48 to 6.67)	2.22 (1.87 to 2.63)	1.83 (1.60 to 2.10)	1.67 (1.46 to 1.90)	1.40 (1.19 to 1.63)	1.94 (1.57 to 2.40)
	20	-	2.13 (1.59 to 2.86)	2.06 (1.72 to 2.46)	1.84 (1.54 to 2.19)	1.19 (0.95 to 1.48)	1.28 (0.92 to 1.79)
	19	1.05 (0.07 to 16.83)	3.33 (2.28 to 4.86)	2.44 (1.85 to 3.24)	2.30 (1.77 to 2.98)	2.01 (1.51 to 2.69)	1.19 (0.82 to 1.72)
	14	3.28 (1.66 to 6.47)	2.60 (2.13 to 3.16)	2.20 (1.89 to 2.56)	1.83 (1.61 to 2.09)	1.73 (1.49 to 2.01)	1.96 (1.62 to 2.38)
	5	2.71 (0.97 to 7.61)	2.50 (2.03 to 3.07)	2.11 (1.81 to 2.46)	1.98 (1.71 to 2.29)	1.49 (1.26 to 1.76)	1.48 (1.19 to 1.84)
	8	-	1.85 (1.42 to 2.40)	1.90 (1.63 to 2.22)	1.93 (1.61 to 2.30)	1.71 (1.38 to 2.11)	1.35 (1.03 to 1.78)
	9	1.03 (0.06 to 16.42)	2.20 (1.56 to 3.12)	2.18 (1.87 to 2.55)	1.43 (1.19 to 1.71)	1.79 (1.41 to 2.26)	1.55 (1.06 to 2.26)
	24	3.06 (2.17 to 4.31)	2.33 (2.02 to 2.68)	1.94 (1.73 to 2.18)	1.69 (1.52 to 1.88)	1.69 (1.49 to 1.91)	1.91 (1.64 to 2.23)
	36	3.61 (2.40 to 5.42)	2.76 (2.35 to 3.25)	2.35 (2.04 to 2.70)	1.86 (1.64 to 2.11)	1.50 (1.31 to 1.71)	1.57 (1.33 to 1.85)
	10	1.38 (0.31 to 6.18)	2.65 (1.96 to 3.59)	2.04 (1.71 to 2.43)	1.52 (1.26 to 1.84)	1.78 (1.42 to 2.24)	1.69 (1.24 to 2.30)
	30	2.30 (0.80 to 6.62)	1.89 (1.18 to 3.02)	1.58 (1.07 to 2.32)	1.98 (1.42 to 2.78)	1.79 (1.21 to 2.63)	1.68 (1.04 to 2.72)
	21	2.38 (0.73 to 7.72)	2.75 (2.10 to 3.61)	1.62 (1.30 to 2.02)	1.59 (1.29 to 1.95)	1.45 (1.16 to 1.80)	1.76 (1.31 to 2.36)
	11	4.63 (1.00 to 21.41)	2.16 (1.60 to 2.92)	2.84 (2.37 to 3.40)	2.62 (2.21 to 3.11)	2.22 (1.79 to 2.75)	1.87 (1.33 to 2.61)
	15	2.06 (1.00 to 4.24)	1.91 (1.53 to 2.38)	1.67 (1.40 to 2.01)	1.51 (1.27 to 1.79)	1.65 (1.37 to 1.98)	1.43 (1.12 to 1.83)
	31	2.18 (1.18 to 4.04)	2.56 (2.22 to 2.96)	2.17 (1.95 to 2.42)	1.58 (1.42 to 1.77)	1.73 (1.52 to 1.96)	1.55 (1.28 to 1.87)
	26	6.29 (0.76 to 52.28)	3.05 (2.27 to 4.10)	2.14 (1.69 to 2.70)	1.82 (1.46 to 2.27)	1.56 (1.23 to 1.98)	1.90 (1.38 to 2.63)
	3	2.61 (0.51 to 13.43)	3.07 (2.29 to 4.11)	2.51 (2.07 to 3.04)	1.71 (1.40 to 2.10)	1.74 (1.36 to 2.22)	1.55 (1.11 to 2.17)
	16	4.65 (1.76 to 12.27)	2.77 (2.24 to 3.43)	2.23 (1.89 to 2.63)	1.77 (1.50 to 2.09)	1.69 (1.41 to 2.03)	1.71 (1.31 to 2.21)
	13	1.81 (0.66 to 4.97)	2.68 (1.95 to 3.69)	1.90 (1.48 to 2.44)	1.46 (1.14 to 1.86)	1.58 (1.21 to 2.05)	1.14 (0.79 to 1.64)
	12	1.57 (0.26 to 9.40)	2.59 (1.86 to 3.61)	1.94 (1.57 to 2.40)	2.26 (1.81 to 2.81)	1.39 (1.06 to 1.84)	0.96 (0.63 to 1.48)
	28	5.78 (1.28 to 26.05)	1.92 (1.47 to 2.50)	1.49 (1.22 to 1.83)	1.71 (1.41 to 2.06)	1.56 (1.26 to 1.95)	1.39 (1.00 to 1.92)
	6	2.02 (1.04 to 3.96)	3.15 (2.59 to 3.83)	2.50 (2.16 to 2.89)	1.97 (1.73 to 2.24)	1.72 (1.48 to 2.00)	2.22 (1.79 to 2.76)
	27	4.87 (2.02 to 11.76)	2.93 (2.41 to 3.57)	2.44 (2.12 to 2.80)	2.23 (1.96 to 2.54)	1.58 (1.36 to 1.84)	1.88 (1.52 to 2.32)
	18	3.13 (0.33 to 30.09)	2.57 (1.53 to 4.32)	3.95 (2.63 to 5.92)	2.31 (1.59 to 3.35)	2.36 (1.33 to 4.17)	3.22 (1.38 to 7.50)
	7	1.53 (0.26 to 9.16)	2.73 (2.21 to 3.36)	2.02 (1.74 to 2.35)	1.71 (1.48 to 1.98)	1.95 (1.65 to 2.31)	1.85 (1.46 to 2.35)
	22	-	3.19 (1.56 to 6.52)	2.15 (1.38 to 3.35)	2.52 (1.59 to 3.98)	1.94 (1.17 to 3.20)	3.25 (1.48 to 7.15)
	17	2.77 (1.16 to 6.63)	2.71 (2.12 to 3.47)	2.03 (1.68 to 2.46)	1.93 (1.61 to 2.30)	1.69 (1.39 to 2.04)	1.75 (1.34 to 2.28)
Total		2.91 (2.46 to 3.43)	2.51 (2.40 to 2.63)	2.13 (2.06 to 2.20)	1.82 (1.77 to 1.88)	1.67 (1.61 to 1.73)	1.72 (1.63 to 1.80)

SS6 (cont)		Age specific gender ratios, all study group patients, by site		
Site	Site Code	65 to 74	75 and over	All ages
	4	2.12 (1.27 to 3.54)	1.17 (0.46 to 2.98)	2.08 (1.89 to 2.30)
	23	1.38 (0.95 to 2.03)	1.64 (1.00 to 2.67)	1.68 (1.57 to 1.80)
	20	6.32 (1.89 to 21.18)	0.57 (0.12 to 2.83)	1.63 (1.48 to 1.80)
	19	1.35 (0.71 to 2.55)	2.61 (0.87 to 7.81)	2.14 (1.88 to 2.44)
	14	2.05 (1.45 to 2.92)	1.28 (0.70 to 2.33)	1.95 (1.82 to 2.09)
	5	1.39 (0.39 to 4.94)	0.22 (0.02 to 2.16)	1.84 (1.70 to 1.98)
	8	1.09 (0.66 to 1.79)	1.05 (0.50 to 2.17)	1.72 (1.58 to 1.88)
	9	2.60 (1.16 to 5.84)	1.25 (0.37 to 4.26)	1.84 (1.67 to 2.03)
	24	2.19 (1.65 to 2.92)	1.53 (0.97 to 2.42)	1.85 (1.75 to 1.95)
	36	2.92 (2.12 to 4.02)	1.38 (0.88 to 2.15)	1.90 (1.79 to 2.03)
	10	1.88 (1.07 to 3.30)	1.23 (0.46 to 3.33)	1.79 (1.63 to 1.97)
	30	2.16 (0.89 to 5.24)	0.82 (0.22 to 3.04)	1.73 (1.46 to 2.06)
	21	2.43 (1.13 to 5.20)	0.38 (0.09 to 1.58)	1.67 (1.51 to 1.86)
	11	1.07 (0.59 to 1.93)	1.00 (0.33 to 3.07)	2.36 (2.14 to 2.59)
	15	2.15 (1.25 to 3.71)	1.19 (0.54 to 2.65)	1.64 (1.51 to 1.79)
	31	2.76 (1.91 to 4.00)	2.22 (1.10 to 4.47)	1.87 (1.77 to 1.98)
	26	2.00 (1.18 to 3.38)	2.61 (0.98 to 6.96)	1.93 (1.73 to 2.15)
	3	1.45 (0.71 to 2.97)	3.77 (0.45 to 31.27)	1.97 (1.78 to 2.19)
	16	2.41 (1.30 to 4.46)	1.09 (0.44 to 2.74)	1.91 (1.76 to 2.08)
	13	2.02 (1.00 to 4.11)	0.80 (0.28 to 2.32)	1.65 (1.46 to 1.86)
	12	1.99 (0.98 to 4.04)	2.15 (0.87 to 5.36)	1.84 (1.64 to 2.07)
	28	2.72 (1.23 to 6.03)	1.62 (0.43 to 6.10)	1.59 (1.44 to 1.76)
	6	2.72 (1.89 to 3.92)	2.45 (1.26 to 4.78)	2.15 (2.00 to 2.30)
	27	2.87 (1.86 to 4.42)	2.07 (1.08 to 3.97)	2.13 (1.99 to 2.28)
	18	-	0.45 (0.07 to 2.68)	2.71 (2.20 to 3.35)
	7	1.47 (0.98 to 2.20)	1.19 (0.53 to 2.68)	1.91 (1.77 to 2.06)
	22	2.25 (0.71 to 7.19)	0.86 (0.19 to 3.85)	2.31 (1.84 to 2.92)
	17	1.94 (1.27 to 2.97)	2.20 (1.12 to 4.32)	1.96 (1.79 to 2.14)
Total		2.13 (1.93 to 2.34)	1.49 (1.28 to 1.74)	1.89 (1.86 to 1.93)

SS7
Site

Numbers of Study group patients by ethnic group and site; proportions of those with usable ethnic codes in parentheses.

Site code	Total	% Usable ethnic category	White British	White Irish	White Other	Mixed White and Black Caribbean	Mixed White and Black African	Mixed White and Asian	
4	1746	98%	1,591 (93.3%)	9 (0.5%)	41 (2.4%)	4 (0.2%)	3 (0.2%)	5 (0.3%)	
23	3687	75%	2,567 (92.9%)	10 (0.4%)	93 (3.4%)	11 (0.4%)	1 (0.0%)	2 (0.1%)	
20	1786	75%	1,184 (88.4%)	22 (1.6%)	83 (6.2%)	5 (0.4%)	4 (0.3%)	4 (0.3%)	
19	1196	39%	412 (88.8%)	8 (1.7%)	12 (2.6%)	6 (1.3%)	2 (0.4%)	3 (0.6%)	
14	3801	50%	1,833 (96.9%)	5 (0.3%)	23 (1.2%)	(0.0%)	1 (0.1%)	3 (0.2%)	
5	2891	49%	1,323 (93.8%)	9 (0.6%)	44 (3.1%)	2 (0.1%)	2 (0.1%)	1 (0.1%)	
8	2219	74%	904 (55.1%)	65 (4.0%)	333 (20.3%)	10 (0.6%)	8 (0.5%)	18 (1.1%)	
9	1870	71%	666 (49.9%)	43 (3.2%)	254 (19.0%)	14 (1.0%)	10 (0.7%)	11 (0.8%)	
24	6060	84%	4,937 (97.1%)	17 (0.3%)	86 (1.7%)	5 (0.1%)	4 (0.1%)	2 (0.0%)	
36	4555	90%	3,977 (97.3%)	10 (0.2%)	44 (1.1%)	26 (0.6%)	(0.0%)	(0.0%)	
10	1793	90%	718 (44.7%)	61 (3.8%)	188 (11.7%)	24 (1.5%)	13 (0.8%)	23 (1.4%)	
30	570	48%	264 (97.4%)	3 (1.1%)	3 (1.1%)	(0.0%)	(0.0%)	(0.0%)	
21	1603	84%	1,301 (96.4%)	3 (0.2%)	23 (1.7%)	2 (0.1%)	2 (0.1%)	2 (0.1%)	
11	2023	84%	632 (37.4%)	66 (3.9%)	510 (30.2%)	30 (1.8%)	10 (0.6%)	9 (0.5%)	
25	5326	91%	4,637 (96.1%)	17 (0.4%)	88 (1.8%)	8 (0.2%)	6 (0.1%)	3 (0.1%)	
15	2262	92%	2,036 (98.0%)	4 (0.2%)	4 (0.2%)	4 (0.2%)	1 (0.0%)	2 (0.1%)	
31	5912	48%	2,450 (87.2%)	31 (1.1%)	65 (2.3%)	20 (0.7%)	4 (0.1%)	12 (0.4%)	
32	1516	0%	-	-	-	-	-	-	
26	1441	54%	725 (93.1%)	1 (0.1%)	21 (2.7%)	1 (0.1%)	1 (0.1%)	(0.0%)	
3	1618	72%	947 (81.0%)	16 (1.4%)	32 (2.7%)	25 (2.1%)	8 (0.7%)	5 (0.4%)	
16	2550	41%	969 (92.6%)	8 (0.8%)	23 (2.2%)	3 (0.3%)	1 (0.1%)	3 (0.3%)	
33	4103	58%	2,130 (89.5%)	9 (0.4%)	33 (1.4%)	11 (0.5%)	2 (0.1%)	10 (0.4%)	
29	442	99%	432 (98.6%)	1 (0.2%)	2 (0.5%)	(0.0%)	(0.0%)	(0.0%)	
13	1135	34%	382 (97.9%)	(0.0%)	1 (0.3%)	(0.0%)	(0.0%)	(0.0%)	
12	1254	90%	530 (47.0%)	28 (2.5%)	296 (26.2%)	14 (1.2%)	5 (0.4%)	8 (0.7%)	
28	1650	47%	737 (94.6%)	(0.0%)	6 (0.8%)	2 (0.3%)	(0.0%)	1 (0.1%)	
6	3826	80%	2,836 (93.0%)	12 (0.4%)	100 (3.3%)	14 (0.5%)	6 (0.2%)	3 (0.1%)	
27	3743	86%	2,959 (91.6%)	31 (1.0%)	84 (2.6%)	13 (0.4%)	9 (0.3%)	9 (0.3%)	
18	626	79%	421 (85.6%)	4 (0.8%)	20 (4.1%)	2 (0.4%)	3 (0.6%)	3 (0.6%)	
7	3120	65%	1,766 (87.6%)	37 (1.8%)	77 (3.8%)	12 (0.6%)	2 (0.1%)	7 (0.3%)	
22	346	99%	330 (95.9%)	2 (0.6%)	7 (2.0%)	(0.0%)	1 (0.3%)	1 (0.3%)	
17	2640	57%	1,456 (97.5%)	9 (0.6%)	17 (1.1%)	(0.0%)	2 (0.1%)	2 (0.1%)	
Total	0	79310	69%	48,052 (87.2%)	541 (1.0%)	2,613 (4.7%)	268 (0.5%)	111 (0.2%)	152 (0.3%)

SS7 (cont) Numbers of Study group patients by ethnic group and site; proportions of those with usable ethnic codes in parentheses.

Site	Site code	Any other mixed background	Indian	Pakistani	Bangla-deshi	Any other Asian	Black Caribbean	Black African	Any other Black	Chinese	Other
	4	7 (0.4%)	17 (1.0%)	2 (0.1%)	2 (0.1%)	3 (0.2%)	6 (0.4%)	2 (0.1%)	3 (0.2%)	1 (0.1%)	9 (0.5%)
	23	10 (0.4%)	15 (0.5%)	(0.0%)	1 (0.0%)	10 (0.4%)	9 (0.3%)	4 (0.1%)	1 (0.0%)	5 (0.2%)	23 (0.8%)
	20	9 (0.7%)	3 (0.2%)	2 (0.1%)	(0.0%)	6 (0.4%)	2 (0.1%)	4 (0.3%)	3 (0.2%)	2 (0.1%)	6 (0.4%)
	19	2 (0.4%)	2 (0.4%)	9 (1.9%)	(0.0%)	5 (1.1%)	1 (0.2%)	1 (0.2%)	1 (0.2%)	(0.0%)	(0.0%)
	14	2 (0.1%)	4 (0.2%)	1 (0.1%)	(0.0%)	1 (0.1%)	(0.0%)	1 (0.1%)	(0.0%)	2 (0.1%)	15 (0.8%)
	5	7 (0.5%)	5 (0.4%)	(0.0%)	(0.0%)	1 (0.1%)	2 (0.1%)	3 (0.2%)	1 (0.1%)	3 (0.2%)	7 (0.5%)
	8	34 (2.1%)	36 (2.2%)	8 (0.5%)	49 (3.0%)	20 (1.2%)	22 (1.3%)	36 (2.2%)	20 (1.2%)	18 (1.1%)	61 (3.7%)
	9	18 (1.3%)	28 (2.1%)	9 (0.7%)	18 (1.3%)	19 (1.4%)	100 (7.5%)	50 (3.7%)	23 (1.7%)	6 (0.4%)	66 (4.9%)
	24	4 (0.1%)	5 (0.1%)	1 (0.0%)	1 (0.0%)	4 (0.1%)	1 (0.0%)	2 (0.0%)	1 (0.0%)	3 (0.1%)	9 (0.2%)
	36	7 (0.2%)	5 (0.1%)	(0.0%)	2 (0.0%)	6 (0.1%)	2 (0.0%)	(0.0%)	1 (0.0%)	2 (0.0%)	7 (0.2%)
	10	38 (2.4%)	189 (11.8%)	74 (4.6%)	7 (0.4%)	74 (4.6%)	65 (4.0%)	44 (2.7%)	18 (1.1%)	2 (0.1%)	70 (4.4%)
	30	(0.0%)	(0.0%)	1 (0.4%)	(0.0%)	(0.0%)	(0.0%)	(0.0%)	(0.0%)	(0.0%)	(0.0%)
	21	1 (0.1%)	2 (0.1%)	(0.0%)	(0.0%)	1 (0.1%)	(0.0%)	2 (0.1%)	1 (0.1%)	2 (0.1%)	7 (0.5%)
	11	17 (1.0%)	48 (2.8%)	8 (0.5%)	12 (0.7%)	45 (2.7%)	132 (7.8%)	88 (5.2%)	27 (1.6%)	8 (0.5%)	49 (2.9%)
	25	14 (0.3%)	9 (0.2%)	(0.0%)	(0.0%)	2 (0.0%)	13 (0.3%)	9 (0.2%)	5 (0.1%)	2 (0.0%)	12 (0.2%)
	15	14 (0.7%)	2 (0.1%)	1 (0.0%)	(0.0%)	(0.0%)	(0.0%)	4 (0.2%)	(0.0%)	1 (0.0%)	4 (0.2%)
	31	6 (0.2%)	36 (1.3%)	38 (1.4%)	6 (0.2%)	23 (0.8%)	33 (1.2%)	16 (0.6%)	9 (0.3%)	5 (0.2%)	57 (2.0%)
	32	-	-	-	-	-	-	-	-	-	-
	26	15 (1.9%)	2 (0.3%)	(0.0%)	1 (0.1%)	3 (0.4%)	(0.0%)	1 (0.1%)	2 (0.3%)	1 (0.1%)	5 (0.6%)
	3	10 (0.9%)	23 (2.0%)	22 (1.9%)	2 (0.2%)	5 (0.4%)	35 (3.0%)	13 (1.1%)	8 (0.7%)	4 (0.3%)	14 (1.2%)
	16	3 (0.3%)	4 (0.4%)	1 (0.1%)	1 (0.1%)	3 (0.3%)	1 (0.1%)	9 (0.9%)	1 (0.1%)	2 (0.2%)	15 (1.4%)
	33	12 (0.5%)	13 (0.5%)	48 (2.0%)	11 (0.5%)	17 (0.7%)	22 (0.9%)	14 (0.6%)	6 (0.3%)	8 (0.3%)	35 (1.5%)
	29	1 (0.2%)	2 (0.5%)	(0.0%)	(0.0%)	(0.0%)	(0.0%)	(0.0%)	(0.0%)	(0.0%)	(0.0%)
	13	2 (0.5%)	1 (0.3%)	(0.0%)	1 (0.3%)	2 (0.5%)	(0.0%)	1 (0.3%)	(0.0%)	(0.0%)	(0.0%)
	12	16 (1.4%)	15 (1.3%)	4 (0.4%)	4 (0.4%)	6 (0.5%)	71 (6.3%)	51 (4.5%)	26 (2.3%)	10 (0.9%)	44 (3.9%)
	28	4 (0.5%)	1 (0.1%)	16 (2.1%)	1 (0.1%)	3 (0.4%)	2 (0.3%)	3 (0.4%)	(0.0%)	(0.0%)	3 (0.4%)
	6	11 (0.4%)	7 (0.2%)	(0.0%)	2 (0.1%)	7 (0.2%)	12 (0.4%)	7 (0.2%)	3 (0.1%)	2 (0.1%)	26 (0.9%)
	27	15 (0.5%)	36 (1.1%)	10 (0.3%)	2 (0.1%)	5 (0.2%)	15 (0.5%)	7 (0.2%)	7 (0.2%)	10 (0.3%)	19 (0.6%)
	18	7 (1.4%)	11 (2.2%)	5 (1.0%)	3 (0.6%)	1 (0.2%)	8 (1.6%)	2 (0.4%)	1 (0.2%)	(0.0%)	1 (0.2%)
	7	5 (0.2%)	34 (1.7%)	15 (0.7%)	3 (0.1%)	18 (0.9%)	10 (0.5%)	7 (0.3%)	3 (0.1%)	5 (0.2%)	15 (0.7%)
	22	(0.0%)	(0.0%)	(0.0%)	(0.0%)	1 (0.3%)	(0.0%)	(0.0%)	(0.0%)	(0.0%)	2 (0.6%)
	17	1 (0.1%)	(0.0%)	(0.0%)	(0.0%)	2 (0.1%)	1 (0.1%)	(0.0%)	1 (0.1%)	(0.0%)	3 (0.2%)
Total	0	292 (0.5%)	555 (1.0%)	275 (0.5%)	129 (0.2%)	293 (0.5%)	565 (1.0%)	381 (0.7%)	172 (0.3%)	104 (0.2%)	584 (1.1%)

SS8

Females

Indirectly age-standardised ratios (and 95% confidence intervals) for entry to study group for ethnic groups by gender.

Site	White British	White Irish	White Other	Mixed White and Black Caribbean
	112.9% (106.3% to 119.8%)	40.9% (14.9% to 89.0%)	42.7% (27.4% to 63.6%)	39.8% (4.8% to 143.7%)
	105.5% (100.5% to 110.7%)	20.5% (4.2% to 59.8%)	73.4% (56.0% to 94.4%)	167.4% (72.1% to 330.0%)
	107.3% (99.6% to 115.4%)	109.5% (59.8% to 183.8%)	108.9% (84.2% to 138.6%)	117.9% (32.1% to 301.8%)
	110.1% (97.6% to 123.6%)	127.0% (40.9% to 296.3%)	36.5% (14.6% to 75.2%)	232.5% (47.9% to 679.4%)
	105.0% (99.2% to 111.0%)	30.3% (6.2% to 88.4%)	52.5% (31.1% to 83.0%)	0.0% (0.0% to 107.9%)
	113.7% (106.1% to 121.7%)	112.7% (51.4% to 213.9%)	46.7% (30.8% to 68.0%)	33.5% (0.8% to 186.6%)
	101.9% (93.5% to 110.9%)	122.3% (86.5% to 167.8%)	133.4% (117.1% to 151.3%)	79.6% (25.6% to 185.7%)
	92.8% (83.8% to 102.5%)	124.7% (81.5% to 182.8%)	169.3% (145.9% to 195.3%)	115.4% (55.2% to 212.2%)
	104.9% (101.3% to 108.6%)	47.5% (21.7% to 90.2%)	55.6% (42.1% to 72.1%)	59.0% (16.1% to 151.1%)
	106.2% (102.2% to 110.3%)	32.7% (11.9% to 71.2%)	35.3% (24.0% to 50.1%)	277.3% (161.4% to 444.0%)
	101.5% (92.3% to 111.3%)	102.3% (72.4% to 140.4%)	113.7% (95.4% to 134.6%)	254.4% (148.1% to 407.3%)
	104.1% (88.9% to 121.2%)	272.8% (33.0% to 985.3%)	30.8% (0.8% to 171.7%)	0.0% (0.0% to 1314.0%)
	108.9% (101.6% to 116.6%)	40.7% (8.4% to 118.8%)	40.6% (22.7% to 66.9%)	85.2% (10.3% to 307.9%)
	72.1% (65.3% to 79.5%)	116.3% (85.4% to 154.6%)	219.9% (198.4% to 243.0%)	248.2% (160.6% to 366.4%)
	102.8% (97.3% to 108.5%)	28.5% (3.5% to 103.0%)	21.4% (4.4% to 62.6%)	82.6% (17.0% to 241.4%)
	106.1% (100.9% to 111.5%)	98.9% (57.6% to 158.3%)	74.5% (53.9% to 100.4%)	158.4% (88.6% to 261.3%)
	100.2% (91.5% to 109.4%)	29.7% (0.8% to 165.4%)	89.7% (49.0% to 150.6%)	72.7% (1.8% to 404.9%)
	108.8% (100.3% to 117.8%)	149.9% (77.3% to 261.8%)	67.2% (43.0% to 100.0%)	221.8% (131.4% to 350.5%)
	107.9% (99.7% to 116.7%)	46.1% (12.6% to 118.0%)	69.5% (40.5% to 111.3%)	70.0% (8.5% to 252.8%)
	105.6% (92.8% to 119.7%)	0.0% (0.0% to 546.2%)	32.3% (0.8% to 180.0%)	0.0% (0.0% to 1227.5%)
	85.6% (76.5% to 95.5%)	117.3% (71.6% to 181.2%)	225.6% (194.5% to 260.4%)	158.7% (72.4% to 301.3%)
	105.7% (96.4% to 115.7%)	0.0% (0.0% to 193.4%)	50.6% (13.8% to 129.6%)	106.7% (12.9% to 385.5%)
	107.1% (102.3% to 111.9%)	39.6% (14.4% to 86.1%)	72.2% (57.2% to 89.8%)	117.9% (56.4% to 216.8%)
	106.3% (101.7% to 111.1%)	70.1% (39.2% to 115.6%)	60.9% (46.6% to 78.3%)	88.1% (35.3% to 181.6%)
	102.1% (88.6% to 117.0%)	107.0% (22.1% to 312.8%)	66.5% (33.1% to 118.9%)	0.0% (0.0% to 305.7%)
	111.2% (104.9% to 117.7%)	111.1% (73.2% to 161.7%)	60.6% (45.1% to 79.7%)	128.1% (51.3% to 263.9%)
	111.7% (97.8% to 127.0%)	87.7% (10.6% to 317.0%)	26.6% (5.5% to 77.8%)	0.0% (0.0% to 518.9%)
	105.1% (98.5% to 111.9%)	78.1% (31.3% to 160.9%)	49.4% (25.5% to 86.4%)	0.0% (0.0% to 183.5%)
Combined	105.1% (103.9% to 106.4%)	86.1% (77.0% to 95.9%)	103.0% (98.2% to 107.9%)	135.2% (115.7% to 156.9%)

SS8 (cont)

Indirectly age-standardised ratios (and 95% confidence intervals) for entry to study group for ethnic groups by gender.

Females

Site	Mixed White and Black African	Mixed White and Asian	Any Other Mixed Background	Indian
	164.6% (33.9% to 480.9%)	98.6% (26.9% to 252.4%)	87.8% (23.9% to 224.9%)	33.4% (16.6% to 59.8%)
	0.0% (0.0% to 109.2%)	14.6% (0.4% to 81.5%)	98.6% (39.5% to 203.2%)	55.8% (26.7% to 102.6%)
	109.6% (22.6% to 320.2%)	34.2% (4.1% to 123.6%)	137.5% (55.1% to 283.4%)	0.0% (0.0% to 23.4%)
	205.1% (5.2% to 1142.8%)	228.0% (47.0% to 666.3%)	170.1% (20.6% to 614.5%)	27.9% (3.4% to 100.6%)
	76.5% (1.9% to 426.5%)	35.7% (0.9% to 199.1%)	77.9% (9.4% to 281.4%)	19.1% (2.3% to 69.1%)
	126.6% (15.3% to 457.4%)	0.0% (0.0% to 91.6%)	105.9% (28.8% to 271.0%)	11.0% (1.3% to 39.9%)
	94.7% (30.5% to 220.9%)	94.3% (45.1% to 173.4%)	220.2% (142.4% to 325.0%)	50.5% (32.3% to 75.1%)
	145.7% (58.4% to 300.2%)	151.6% (69.2% to 287.8%)	146.4% (77.9% to 250.3%)	34.5% (17.8% to 60.3%)
	46.7% (5.7% to 168.8%)	12.0% (0.3% to 66.6%)	13.8% (0.3% to 76.9%)	9.4% (1.1% to 33.9%)
	0.0% (0.0% to 128.1%)	0.0% (0.0% to 48.2%)	61.8% (16.8% to 158.3%)	29.9% (9.6% to 69.8%)
	248.3% (118.9% to 456.7%)	136.4% (72.6% to 233.3%)	319.9% (212.5% to 462.4%)	77.9% (64.5% to 93.2%)
	0.0% (0.0% to 2158.6%)	0.0% (0.0% to 924.8%)	0.0% (0.0% to 1171.6%)	0.0% (0.0% to 276.1%)
	126.0% (15.3% to 455.2%)	27.6% (0.7% to 153.8%)	31.7% (0.8% to 176.6%)	11.2% (0.3% to 62.5%)
	117.2% (50.5% to 231.0%)	46.2% (14.9% to 107.9%)	106.1% (56.4% to 181.4%)	86.8% (59.7% to 121.9%)
	30.4% (0.8% to 169.6%)	0.0% (0.0% to 133.1%)	225.9% (97.3% to 445.1%)	17.9% (0.5% to 99.5%)
	57.1% (6.9% to 206.2%)	86.8% (34.8% to 178.8%)	70.2% (19.1% to 179.7%)	38.6% (23.2% to 60.2%)
	181.5% (4.6% to 1011.3%)	0.0% (0.0% to 265.1%)	871.5% (434.5% to 1559.5%)	49.5% (6.0% to 178.9%)
	282.3% (91.0% to 658.9%)	51.5% (6.2% to 186.1%)	103.5% (28.2% to 265.0%)	42.8% (22.1% to 74.8%)
	72.6% (1.8% to 404.6%)	91.0% (11.0% to 328.8%)	88.7% (10.7% to 320.3%)	21.2% (2.6% to 76.7%)
	0.0% (0.0% to 1247.5%)	0.0% (0.0% to 610.3%)	291.2% (35.3% to 1051.9%)	16.0% (0.4% to 89.2%)
	46.5% (5.6% to 168.0%)	165.2% (71.1% to 325.6%)	129.9% (59.3% to 246.6%)	42.7% (21.3% to 76.4%)
	0.0% (0.0% to 556.8%)	0.0% (0.0% to 304.6%)	299.1% (61.7% to 874.1%)	0.0% (0.0% to 73.3%)
	61.4% (12.7% to 179.5%)	12.5% (0.3% to 69.5%)	77.7% (31.1% to 160.0%)	11.8% (3.2% to 30.2%)
	234.1% (100.8% to 461.3%)	40.4% (11.0% to 103.4%)	201.4% (104.0% to 351.8%)	48.2% (30.9% to 71.7%)
	414.8% (50.2% to 1498.5%)	255.5% (52.7% to 746.7%)	460.0% (148.2% to 1073.5%)	97.6% (39.1% to 201.0%)
	76.4% (9.2% to 275.9%)	60.9% (16.6% to 155.9%)	49.3% (10.2% to 144.2%)	44.0% (26.8% to 67.9%)
	0.0% (0.0% to 1255.3%)	101.5% (2.6% to 565.7%)	0.0% (0.0% to 416.7%)	0.0% (0.0% to 63.3%)
	87.5% (2.2% to 487.6%)	40.0% (1.0% to 223.0%)	0.0% (0.0% to 184.8%)	0.0% (0.0% to 46.6%)
Combined	103.2% (80.8% to 130.0%)	61.1% (48.6% to 75.7%)	136.1% (117.0% to 157.5%)	46.1% (41.2% to 51.4%)

SS8 (cont)
Females

Indirectly age-standardised ratios (and 95% confidence intervals) for entry to study group for ethnic groups by gender.

Site	Pakistani	Bangladeshi	Any Other Asian	Black Caribbean	Black African
	6.8% (0.2% to 38.1%)	11.0% (0.3% to 61.5%)	49.4% (10.2% to 144.4%)	27.8% (7.6% to 71.1%)	8.6% (0.2% to 47.9%)
	0.0% (0.0% to 71.4%)	22.8% (0.6% to 127.3%)	158.5% (75.9% to 291.5%)	44.0% (9.1% to 128.6%)	29.2% (8.0% to 74.7%)
	17.8% (0.4% to 99.0%)	0.0% (0.0% to 81.2%)	57.0% (11.8% to 166.7%)	26.6% (3.2% to 96.1%)	10.6% (0.3% to 59.1%)
	59.4% (21.7% to 129.2%)	0.0% (0.0% to 538.7%)	211.7% (57.7% to 542.1%)	24.2% (0.6% to 135.0%)	29.0% (0.7% to 161.3%)
	16.2% (0.4% to 90.2%)	0.0% (0.0% to 173.7%)	36.0% (0.9% to 200.8%)	0.0% (0.0% to 105.0%)	20.7% (0.5% to 115.2%)
	0.0% (0.0% to 29.1%)	0.0% (0.0% to 125.3%)	21.4% (0.5% to 119.4%)	16.7% (0.4% to 93.1%)	32.3% (6.7% to 94.5%)
	37.0% (10.1% to 94.8%)	62.0% (41.2% to 89.7%)	101.3% (53.9% to 173.2%)	74.9% (40.9% to 125.7%)	59.3% (39.4% to 85.8%)
	58.1% (25.0% to 114.5%)	45.2% (20.6% to 85.8%)	127.5% (61.0% to 234.4%)	106.1% (83.6% to 132.8%)	43.2% (30.1% to 60.0%)
	12.6% (0.3% to 70.4%)	0.0% (0.0% to 87.6%)	0.0% (0.0% to 62.6%)	10.7% (0.3% to 59.5%)	13.6% (1.6% to 49.0%)
	0.0% (0.0% to 58.1%)	27.8% (0.7% to 154.9%)	72.5% (23.4% to 169.3%)	0.0% (0.0% to 43.5%)	0.0% (0.0% to 25.6%)
	97.8% (69.6% to 133.8%)	59.4% (16.2% to 152.1%)	106.6% (75.8% to 145.8%)	104.5% (76.2% to 139.8%)	67.5% (44.1% to 98.9%)
	113.2% (2.9% to 630.7%)	0.0% (0.0% to 2063.1%)	0.0% (0.0% to 969.0%)	0.0% (0.0% to 1164.9%)	0.0% (0.0% to 520.9%)
	0.0% (0.0% to 137.6%)	0.0% (0.0% to 132.1%)	26.6% (0.7% to 148.2%)	0.0% (0.0% to 89.9%)	26.7% (3.2% to 96.3%)
	36.0% (11.6% to 84.1%)	51.2% (23.4% to 97.2%)	169.5% (114.4% to 242.0%)	92.6% (75.1% to 113.0%)	57.8% (43.7% to 75.0%)
	0.0% (0.0% to 198.5%)	0.0% (0.0% to 659.2%)	0.0% (0.0% to 210.9%)	0.0% (0.0% to 234.8%)	104.1% (28.4% to 266.5%)
	56.2% (35.6% to 84.3%)	62.5% (22.8% to 135.9%)	99.1% (49.4% to 177.3%)	113.9% (69.5% to 175.9%)	31.4% (12.6% to 64.7%)
	0.0% (0.0% to 219.3%)	111.1% (2.8% to 618.8%)	92.4% (2.3% to 515.1%)	0.0% (0.0% to 243.1%)	43.6% (1.1% to 243.1%)
	46.4% (23.9% to 81.0%)	32.9% (0.8% to 183.2%)	37.4% (4.5% to 135.0%)	106.3% (69.4% to 155.7%)	74.8% (34.2% to 142.1%)
	0.0% (0.0% to 43.8%)	46.4% (1.2% to 258.6%)	54.2% (6.6% to 195.7%)	29.6% (0.7% to 164.8%)	63.4% (20.4% to 148.0%)
	0.0% (0.0% to 292.8%)	47.6% (1.2% to 264.9%)	95.2% (2.4% to 530.3%)	0.0% (0.0% to 1709.8%)	0.0% (0.0% to 420.0%)
	43.8% (5.3% to 158.1%)	28.1% (5.8% to 82.2%)	45.7% (9.4% to 133.6%)	110.2% (83.5% to 142.8%)	42.8% (30.0% to 59.3%)
	71.6% (34.3% to 131.6%)	0.0% (0.0% to 232.9%)	0.0% (0.0% to 240.0%)	0.0% (0.0% to 194.7%)	36.5% (0.9% to 203.6%)
	0.0% (0.0% to 53.6%)	29.1% (3.5% to 105.0%)	86.0% (27.7% to 200.6%)	75.7% (34.5% to 143.7%)	51.7% (20.7% to 106.5%)
	43.7% (16.0% to 95.1%)	13.1% (0.3% to 73.0%)	36.9% (7.6% to 107.7%)	73.4% (31.6% to 144.6%)	31.4% (8.6% to 80.3%)
	25.5% (0.6% to 141.9%)	442.4% (91.2% to 1293.0%)	0.0% (0.0% to 229.5%)	268.7% (115.7% to 529.6%)	49.4% (6.0% to 178.3%)
	32.7% (13.1% to 67.3%)	37.6% (7.8% to 109.9%)	110.5% (58.8% to 188.9%)	52.5% (22.6% to 103.5%)	18.5% (5.0% to 47.3%)
	0.0% (0.0% to 405.0%)	0.0% (0.0% to 540.0%)	81.1% (2.1% to 451.9%)	0.0% (0.0% to 237.5%)	0.0% (0.0% to 129.5%)
	0.0% (0.0% to 128.0%)	0.0% (0.0% to 145.7%)	49.3% (1.2% to 274.6%)	61.3% (1.6% to 341.8%)	0.0% (0.0% to 110.7%)
Combined	42.8% (35.7% to 50.9%)	41.5% (32.6% to 52.0%)	89.8% (76.5% to 104.7%)	85.0% (76.7% to 94.0%)	43.8% (38.5% to 49.7%)

SS8 (cont)

Indirectly age-standardised ratios (and 95% confidence intervals) for entry to study group for ethnic

Females

Site	Any Other Black	Chinese	Other
	167.2% (34.5% to 488.5%)	0.0% (0.0% to 32.4%)	63.9% (23.3% to 139.0%)
	62.6% (1.6% to 349.0%)	23.3% (6.3% to 59.6%)	69.3% (37.9% to 116.3%)
	202.0% (41.7% to 590.3%)	18.1% (2.2% to 65.4%)	45.9% (14.8% to 107.2%)
	0.0% (0.0% to 679.1%)	0.0% (0.0% to 148.9%)	0.0% (0.0% to 118.9%)
	0.0% (0.0% to 561.3%)	27.2% (3.3% to 98.2%)	116.6% (46.7% to 240.2%)
	0.0% (0.0% to 170.7%)	24.7% (5.1% to 72.2%)	43.5% (14.0% to 101.5%)
	307.7% (175.8% to 499.8%)	35.3% (18.2% to 61.7%)	82.6% (57.2% to 115.5%)
	112.9% (64.5% to 183.4%)	34.3% (11.0% to 80.0%)	244.3% (175.3% to 331.5%)
	29.4% (0.7% to 163.9%)	13.7% (1.7% to 49.6%)	56.2% (24.2% to 110.8%)
	0.0% (0.0% to 238.8%)	8.7% (1.1% to 31.4%)	23.2% (7.5% to 54.2%)
	206.8% (106.7% to 361.2%)	5.6% (0.1% to 31.2%)	85.8% (61.3% to 116.9%)
	0.0% (0.0% to 6267.3%)	0.0% (0.0% to 445.3%)	0.0% (0.0% to 543.5%)
	150.8% (3.8% to 840.2%)	22.8% (2.8% to 82.3%)	48.0% (13.1% to 122.8%)
	147.0% (87.1% to 232.4%)	30.6% (11.2% to 66.5%)	87.4% (56.5% to 129.0%)
	0.0% (0.0% to 367.8%)	16.2% (0.4% to 90.4%)	33.5% (0.8% to 186.8%)
	199.4% (79.9% to 410.8%)	13.8% (3.8% to 35.5%)	149.8% (102.5% to 211.5%)
	641.3% (77.7% to 2316.6%)	29.3% (0.7% to 163.4%)	163.2% (52.6% to 381.0%)
	163.8% (52.8% to 382.2%)	16.1% (3.3% to 47.0%)	76.7% (30.7% to 158.1%)
	118.2% (3.0% to 658.7%)	8.9% (0.2% to 49.5%)	116.2% (50.0% to 228.9%)
	0.0% (0.0% to 2840.2%)	0.0% (0.0% to 505.3%)	0.0% (0.0% to 428.9%)
	206.5% (122.3% to 326.4%)	35.2% (15.2% to 69.4%)	222.3% (151.0% to 315.5%)
	0.0% (0.0% to 800.9%)	0.0% (0.0% to 155.0%)	62.2% (7.5% to 224.6%)
	21.2% (2.6% to 76.6%)	13.1% (1.6% to 47.3%)	74.3% (41.6% to 122.6%)
	214.0% (69.0% to 499.4%)	38.9% (14.2% to 84.6%)	43.8% (20.9% to 80.5%)
	179.6% (4.5% to 1000.4%)	0.0% (0.0% to 106.1%)	29.7% (0.8% to 165.5%)
	108.6% (22.4% to 317.5%)	35.4% (11.4% to 82.6%)	68.2% (34.0% to 122.0%)
	0.0% (0.0% to 1268.6%)	0.0% (0.0% to 190.2%)	111.0% (13.4% to 400.9%)
	0.0% (0.0% to 911.9%)	0.0% (0.0% to 76.3%)	40.6% (4.9% to 146.8%)
Combined	135.1% (111.5% to 162.1%)	20.9% (16.4% to 26.4%)	86.8% (77.6% to 96.9%)

SS8 (cont)

Indirectly age-standardised ratios (and 95% confidence intervals) for entry to study group for ethnic groups by gender.

Males

Site	White British	White Irish	White Other	Mixed White and Black Caribbean
	109.8% (100.4% to 119.8%)	46.7% (9.6% to 136.4%)	73.8% (43.0% to 118.2%)	98.3% (11.9% to 355.1%)
	105.3% (98.6% to 112.4%)	89.7% (35.9% to 184.8%)	78.2% (53.5% to 110.4%)	129.7% (26.7% to 379.0%)
	111.5% (101.5% to 122.2%)	103.1% (44.4% to 203.1%)	54.5% (31.7% to 87.3%)	0.0% (0.0% to 244.9%)
	104.4% (96.1% to 113.2%)	43.5% (5.3% to 157.0%)	33.1% (10.7% to 77.3%)	0.0% (0.0% to 307.5%)
	113.5% (103.7% to 124.0%)	0.0% (0.0% to 75.9%)	54.4% (31.7% to 87.2%)	67.0% (1.7% to 373.1%)
	111.7% (100.4% to 124.1%)	125.4% (80.3% to 186.6%)	93.5% (75.1% to 115.1%)	169.7% (54.7% to 396.0%)
	110.6% (97.8% to 124.5%)	131.5% (75.1% to 213.6%)	113.4% (87.3% to 144.8%)	106.7% (29.1% to 273.2%)
	103.9% (98.9% to 109.0%)	82.7% (35.6% to 162.9%)	63.0% (41.9% to 91.1%)	30.9% (0.8% to 172.1%)
	105.7% (100.0% to 111.5%)	44.1% (12.0% to 113.0%)	37.3% (19.8% to 63.8%)	293.8% (134.1% to 557.8%)
	98.6% (87.1% to 111.2%)	106.7% (66.8% to 161.5%)	86.1% (64.5% to 112.6%)	211.7% (84.8% to 436.3%)
	103.4% (83.9% to 126.0%)	229.1% (5.8% to 1276.7%)	116.5% (14.1% to 421.0%)	0.0% (0.0% to 2191.1%)
	108.8% (99.2% to 119.2%)	0.0% (0.0% to 95.2%)	47.5% (20.5% to 93.6%)	0.0% (0.0% to 323.9%)
	83.6% (73.0% to 95.3%)	103.4% (62.2% to 161.4%)	170.7% (142.2% to 203.3%)	134.8% (43.4% to 314.6%)
	102.7% (95.4% to 110.4%)	52.5% (6.4% to 189.5%)	12.8% (0.3% to 71.3%)	49.0% (1.2% to 273.0%)
	105.8% (98.7% to 113.3%)	136.3% (72.5% to 233.0%)	57.3% (35.0% to 88.5%)	116.5% (37.5% to 271.8%)
	102.6% (89.7% to 116.8%)	0.0% (0.0% to 235.7%)	105.3% (42.2% to 217.0%)	0.0% (0.0% to 693.1%)
	107.4% (95.7% to 120.1%)	63.2% (13.0% to 184.6%)	40.0% (16.0% to 82.4%)	209.9% (76.6% to 456.8%)
	107.7% (96.2% to 120.3%)	83.5% (22.7% to 213.8%)	47.4% (17.3% to 103.1%)	77.5% (2.0% to 431.8%)
	108.9% (91.4% to 128.8%)	0.0% (0.0% to 895.8%)	0.0% (0.0% to 217.0%)	0.0% (0.0% to 1817.2%)
	95.4% (82.9% to 109.1%)	76.4% (32.9% to 150.6%)	241.5% (198.3% to 291.3%)	204.7% (66.0% to 477.7%)
	103.4% (91.1% to 116.8%)	0.0% (0.0% to 354.6%)	43.1% (5.2% to 155.5%)	0.0% (0.0% to 367.5%)
	109.3% (102.2% to 116.7%)	89.0% (32.5% to 193.8%)	34.7% (21.2% to 53.5%)	106.4% (29.0% to 272.5%)
	105.3% (98.7% to 112.3%)	144.9% (82.8% to 235.3%)	51.9% (32.9% to 77.9%)	189.0% (69.0% to 411.3%)
	109.3% (86.9% to 135.7%)	0.0% (0.0% to 359.6%)	39.4% (4.8% to 142.2%)	0.0% (0.0% to 867.2%)
	109.3% (100.7% to 118.5%)	80.5% (36.7% to 152.8%)	74.9% (48.9% to 109.7%)	190.1% (61.3% to 443.7%)
	108.8% (88.2% to 132.9%)	0.0% (0.0% to 422.8%)	102.8% (28.0% to 263.2%)	0.0% (0.0% to 1458.6%)
	105.5% (96.3% to 115.4%)	44.4% (5.4% to 160.2%)	31.7% (8.6% to 81.1%)	0.0% (0.0% to 421.5%)
Combined	105.8% (104.0% to 107.6%)	90.8% (78.0% to 105.1%)	86.0% (79.8% to 92.6%)	126.4% (98.7% to 159.4%)

SS8 (cont)

Indirectly age-standardised ratios (and 95% confidence intervals) for entry to study group for ethnic groups by gender.

Males

Site	Mixed White and Black African	Mixed White and Asian	Any Other Mixed Background	Indian
	0.0% (0.0% to 453.1%)	53.0% (1.3% to 295.1%)	158.5% (32.7% to 463.2%)	39.9% (14.6% to 86.9%)
	57.5% (1.5% to 320.2%)	24.8% (0.6% to 138.2%)	81.1% (16.7% to 237.0%)	49.3% (15.9% to 115.0%)
	64.5% (1.6% to 359.6%)	64.4% (7.8% to 232.8%)	75.1% (9.1% to 271.5%)	23.3% (2.8% to 84.1%)
	0.0% (0.0% to 593.6%)	158.2% (19.2% to 571.6%)	0.0% (0.0% to 339.8%)	42.8% (5.2% to 154.5%)
	0.0% (0.0% to 392.5%)	46.6% (1.2% to 259.6%)	158.1% (32.6% to 461.9%)	29.7% (6.1% to 86.9%)
	121.0% (25.0% to 353.7%)	136.2% (58.7% to 268.5%)	163.0% (74.4% to 309.5%)	44.2% (22.8% to 77.2%)
	119.9% (24.7% to 350.5%)	56.6% (6.9% to 204.6%)	109.4% (35.2% to 255.2%)	78.5% (43.9% to 129.5%)
	88.5% (10.7% to 319.7%)	25.5% (0.6% to 142.3%)	92.4% (19.0% to 269.9%)	28.0% (5.8% to 81.7%)
	0.0% (0.0% to 219.1%)	0.0% (0.0% to 103.4%)	75.3% (9.1% to 272.0%)	0.0% (0.0% to 50.8%)
	130.5% (26.9% to 381.4%)	173.8% (83.2% to 319.7%)	195.9% (89.4% to 371.9%)	79.6% (61.9% to 100.8%)
	0.0% (0.0% to 3523.4%)	0.0% (0.0% to 1393.2%)	0.0% (0.0% to 2027.1%)	0.0% (0.0% to 437.3%)
	0.0% (0.0% to 462.7%)	58.2% (1.5% to 324.1%)	0.0% (0.0% to 230.2%)	22.4% (0.6% to 124.9%)
	69.4% (8.4% to 250.8%)	77.7% (21.2% to 199.0%)	79.3% (21.6% to 203.0%)	87.2% (48.8% to 143.8%)
	0.0% (0.0% to 216.6%)	147.0% (17.8% to 531.2%)	323.2% (118.0% to 703.5%)	25.5% (0.6% to 142.2%)
	89.7% (10.9% to 323.9%)	111.0% (35.8% to 259.0%)	64.2% (7.8% to 231.8%)	55.1% (31.5% to 89.5%)
	0.0% (0.0% to 1625.4%)	0.0% (0.0% to 621.8%)	716.1% (195.1% to 1833.5%)	0.0% (0.0% to 196.1%)
	114.2% (2.9% to 636.2%)	160.2% (33.0% to 468.2%)	289.6% (93.3% to 675.8%)	81.7% (40.7% to 146.2%)
	0.0% (0.0% to 512.1%)	87.5% (2.2% to 487.3%)	83.0% (2.1% to 462.5%)	42.8% (5.2% to 154.5%)
	0.0% (0.0% to 1878.3%)	0.0% (0.0% to 1009.6%)	0.0% (0.0% to 1004.4%)	0.0% (0.0% to 77.1%)
	138.8% (28.6% to 405.8%)	0.0% (0.0% to 140.7%)	193.4% (77.5% to 398.5%)	27.6% (7.5% to 70.7%)
	0.0% (0.0% to 882.5%)	131.3% (3.3% to 731.7%)	171.8% (4.3% to 957.1%)	33.8% (0.9% to 188.1%)
	129.2% (26.6% to 377.6%)	60.2% (7.3% to 217.4%)	103.8% (28.3% to 265.8%)	14.1% (1.7% to 50.9%)
	58.8% (1.5% to 327.5%)	89.6% (24.4% to 229.5%)	116.9% (24.1% to 341.7%)	39.1% (18.7% to 71.8%)
	559.3% (14.1% to 3116.1%)	0.0% (0.0% to 893.1%)	566.4% (68.6% to 2046.1%)	123.8% (25.5% to 361.8%)
	0.0% (0.0% to 305.0%)	92.4% (19.1% to 270.0%)	74.6% (9.0% to 269.4%)	66.5% (36.3% to 111.6%)
	720.3% (18.2% to 4013.5%)	0.0% (0.0% to 893.6%)	0.0% (0.0% to 1113.8%)	0.0% (0.0% to 152.3%)
	202.6% (5.1% to 1129.0%)	87.6% (2.2% to 488.1%)	110.8% (2.8% to 617.1%)	0.0% (0.0% to 83.5%)
Combined	81.8% (54.8% to 117.5%)	79.8% (60.1% to 103.8%)	129.0% (102.4% to 160.3%)	53.2% (46.1% to 61.2%)

SS8 (cont)

Indirectly age-standardised ratios (and 95% confidence intervals) for entry to study group for ethnic groups by gender.

Males Site	Pakistani	Bangladeshi	Any Other Asian	Black Caribbean	Black African
	15.4% (0.4% to 85.7%)	26.1% (0.7% to 145.4%)	0.0% (0.0% to 111.8%)	31.3% (3.8% to 113.2%)	18.9% (0.5% to 105.6%)
	0.0% (0.0% to 105.7%)	0.0% (0.0% to 125.3%)	0.0% (0.0% to 78.3%)	149.0% (54.4% to 324.4%)	0.0% (0.0% to 44.9%)
	29.4% (0.7% to 164.0%)	0.0% (0.0% to 142.0%)	79.8% (16.5% to 233.3%)	0.0% (0.0% to 106.1%)	56.1% (11.6% to 164.0%)
	0.0% (0.0% to 139.7%)	0.0% (0.0% to 488.5%)	0.0% (0.0% to 257.3%)	0.0% (0.0% to 212.1%)	0.0% (0.0% to 158.1%)
	0.0% (0.0% to 53.6%)	0.0% (0.0% to 228.1%)	0.0% (0.0% to 121.7%)	29.5% (0.7% to 164.3%)	0.0% (0.0% to 69.0%)
	59.9% (16.3% to 153.3%)	85.6% (53.0% to 130.9%)	86.2% (34.5% to 177.6%)	89.8% (36.0% to 184.9%)	34.9% (15.0% to 68.7%)
	13.2% (0.3% to 73.5%)	84.5% (38.6% to 160.4%)	149.6% (64.4% to 294.8%)	72.9% (46.2% to 109.5%)	34.7% (19.4% to 57.3%)
	0.0% (0.0% to 81.1%)	32.1% (0.8% to 178.9%)	111.1% (30.3% to 284.3%)	0.0% (0.0% to 82.9%)	0.0% (0.0% to 46.0%)
	0.0% (0.0% to 116.4%)	42.0% (1.1% to 234.0%)	20.9% (0.5% to 116.3%)	34.3% (4.2% to 123.9%)	0.0% (0.0% to 52.8%)
	152.1% (106.0% to 211.6%)	84.7% (17.5% to 247.4%)	137.9% (96.0% to 191.8%)	98.5% (59.3% to 153.8%)	82.6% (48.9% to 130.5%)
	0.0% (0.0% to 646.9%)	0.0% (0.0% to 3148.2%)	0.0% (0.0% to 1304.0%)	0.0% (0.0% to 1599.0%)	0.0% (0.0% to 790.6%)
	0.0% (0.0% to 237.6%)	0.0% (0.0% to 226.0%)	0.0% (0.0% to 150.3%)	0.0% (0.0% to 190.0%)	0.0% (0.0% to 88.9%)
	41.6% (8.6% to 121.5%)	38.6% (8.0% to 112.9%)	159.5% (89.2% to 263.1%)	101.2% (70.1% to 141.4%)	74.8% (51.2% to 105.6%)
	75.4% (1.9% to 420.0%)	0.0% (0.0% to 847.4%)	0.0% (0.0% to 243.1%)	0.0% (0.0% to 321.5%)	0.0% (0.0% to 131.3%)
	61.4% (33.5% to 103.0%)	0.0% (0.0% to 67.3%)	136.2% (67.9% to 243.8%)	149.4% (79.5% to 255.5%)	52.8% (22.8% to 104.1%)
	0.0% (0.0% to 419.7%)	0.0% (0.0% to 744.3%)	309.7% (37.5% to 1118.9%)	0.0% (0.0% to 449.1%)	0.0% (0.0% to 304.6%)
	81.3% (38.9% to 149.6%)	70.8% (1.8% to 394.6%)	68.1% (8.2% to 246.0%)	75.2% (32.4% to 148.3%)	60.4% (16.4% to 154.5%)
	21.8% (0.6% to 121.6%)	0.0% (0.0% to 337.5%)	41.2% (1.0% to 229.7%)	0.0% (0.0% to 222.6%)	81.4% (22.2% to 208.4%)
	0.0% (0.0% to 390.7%)	0.0% (0.0% to 280.6%)	104.1% (2.6% to 580.1%)	0.0% (0.0% to 2382.6%)	137.8% (3.5% to 767.8%)
	69.2% (8.4% to 249.8%)	17.0% (0.4% to 94.7%)	65.4% (13.5% to 191.1%)	66.8% (36.5% to 112.1%)	33.4% (18.7% to 55.0%)
	77.0% (28.1% to 167.6%)	109.9% (2.8% to 612.1%)	244.3% (50.4% to 714.0%)	174.1% (21.1% to 629.0%)	95.7% (11.6% to 345.6%)
	0.0% (0.0% to 96.8%)	0.0% (0.0% to 114.6%)	61.7% (7.5% to 222.9%)	47.3% (9.8% to 138.2%)	0.0% (0.0% to 57.2%)
	61.9% (16.9% to 158.5%)	26.8% (0.7% to 149.5%)	38.9% (4.7% to 140.6%)	93.9% (34.3% to 204.3%)	38.1% (7.9% to 111.4%)
	71.0% (1.8% to 395.6%)	0.0% (0.0% to 1488.1%)	154.0% (3.9% to 857.9%)	0.0% (0.0% to 381.4%)	0.0% (0.0% to 253.0%)
	74.6% (32.1% to 147.0%)	0.0% (0.0% to 96.1%)	58.0% (15.8% to 148.4%)	13.5% (0.3% to 75.2%)	29.1% (6.0% to 85.1%)
	0.0% (0.0% to 944.7%)	0.0% (0.0% to 1188.0%)	0.0% (0.0% to 584.5%)	0.0% (0.0% to 643.7%)	0.0% (0.0% to 325.5%)
	0.0% (0.0% to 210.4%)	0.0% (0.0% to 215.2%)	65.6% (1.7% to 365.3%)	0.0% (0.0% to 464.6%)	0.0% (0.0% to 187.5%)
Combined	58.9% (47.6% to 72.1%)	44.9% (32.5% to 60.4%)	91.4% (74.9% to 110.5%)	73.1% (61.5% to 86.2%)	40.9% (33.8% to 49.1%)

SS8 (cont)

Indirectly age-standardised ratios (and 95% confidence intervals) for entry to study group for ethnic groups by gender.

Males

Site	Any Other Black	Chinese	Other
	0.0% (0.0% to 408.4%)	21.2% (0.5% to 118.4%)	84.0% (17.3% to 245.5%)
	0.0% (0.0% to 315.5%)	10.8% (0.3% to 59.9%)	90.1% (41.1% to 171.0%)
	0.0% (0.0% to 505.5%)	0.0% (0.0% to 62.2%)	18.5% (0.5% to 103.1%)
	0.0% (0.0% to 1171.0%)	0.0% (0.0% to 115.3%)	333.2% (143.5% to 656.7%)
	70.9% (1.8% to 395.3%)	0.0% (0.0% to 57.6%)	17.8% (0.5% to 99.3%)
	171.8% (46.8% to 439.9%)	32.3% (11.8% to 70.4%)	126.4% (81.8% to 186.6%)
	117.9% (47.3% to 243.0%)	12.6% (0.3% to 70.4%)	272.7% (174.6% to 405.7%)
	0.0% (0.0% to 246.9%)	14.9% (0.4% to 83.1%)	18.8% (0.5% to 105.0%)
	102.4% (2.6% to 570.3%)	0.0% (0.0% to 36.0%)	23.8% (2.9% to 85.9%)
	226.6% (82.7% to 493.2%)	10.6% (0.3% to 59.1%)	114.3% (77.1% to 163.2%)
	0.0% (0.0% to 7232.0%)	0.0% (0.0% to 820.9%)	0.0% (0.0% to 1126.8%)
	0.0% (0.0% to 925.4%)	0.0% (0.0% to 84.3%)	78.3% (16.2% to 228.9%)
	211.4% (96.5% to 401.4%)	21.4% (2.6% to 77.4%)	189.7% (121.5% to 282.2%)
	0.0% (0.0% to 462.1%)	0.0% (0.0% to 104.3%)	143.2% (29.5% to 418.4%)
	63.8% (1.6% to 355.4%)	5.3% (0.1% to 29.8%)	183.5% (118.7% to 270.8%)
	0.0% (0.0% to 2302.7%)	0.0% (0.0% to 256.4%)	0.0% (0.0% to 312.9%)
	218.6% (45.1% to 638.9%)	10.7% (0.3% to 59.6%)	137.7% (50.3% to 299.7%)
	0.0% (0.0% to 1014.8%)	15.9% (0.4% to 88.5%)	180.1% (72.2% to 371.2%)
	0.0% (0.0% to 4658.9%)	0.0% (0.0% to 987.4%)	0.0% (0.0% to 672.3%)
	215.7% (92.9% to 425.0%)	16.2% (2.0% to 58.5%)	173.1% (92.1% to 296.1%)
	0.0% (0.0% to 1317.2%)	0.0% (0.0% to 244.2%)	51.2% (1.3% to 285.3%)
	19.3% (0.5% to 107.5%)	0.0% (0.0% to 61.4%)	150.0% (74.8% to 268.5%)
	190.7% (23.1% to 688.7%)	43.8% (9.0% to 127.9%)	85.7% (39.1% to 162.7%)
	0.0% (0.0% to 2135.6%)	0.0% (0.0% to 312.9%)	0.0% (0.0% to 367.1%)
	0.0% (0.0% to 284.2%)	0.0% (0.0% to 63.5%)	63.9% (17.4% to 163.5%)
	0.0% (0.0% to 3078.3%)	0.0% (0.0% to 505.3%)	0.0% (0.0% to 620.3%)
	584.9% (14.8% to 3258.7%)	0.0% (0.0% to 161.0%)	45.3% (1.1% to 252.2%)
Combined	115.0% (83.9% to 153.9%)	12.1% (7.5% to 18.5%)	119.6% (104.0% to 136.9%)

SS9

Disabilities and spoken English status of study group members by site.

Site	Site code	Total records	Usable visual disability data	% usable visual dis data	% visually disabled where known	Usable speech disability data	% usable speech disability data	% speech disabled where known
	4	1,746	0	-	-	0	-	-
	23	3,687	2,788	75.6%	3.4%	2,777	75.3%	1.6%
	20	1,786	0	-	-	0	-	-
	19	1,196	0	-	-	0	-	-
	14	3,801	0	-	-	0	-	-
	5	2,891	0	-	-	0	-	-
	8	2,219	0	-	-	0	-	-
	9	1,870	0	-	-	0	-	-
	24	6,060	0	-	-	0	-	-
	36	4,555	2,924	64.2%	2.9%	2,915	64.0%	1.0%
	10	1,793	0	-	-	0	-	-
	30	570	0	-	-	0	-	-
	21	1,603	0	-	-	0	-	-
	11	2,023	0	-	-	0	-	-
	25	5,326	0	-	-	0	-	-
	15	2,262	0	-	-	0	-	-
	31	5,912	0	-	-	0	-	-
	32	1,516	0	-	-	0	-	-
	26	1,441	0	-	-	0	-	-
	3	1,618	1,618	100.0%	0.2%	1,618	100.0%	0.1%
	16	2,550	0	-	-	0	-	-
	33	4,103	0	-	-	0	-	-
	29	442	0	-	-	0	-	-
	13	1,135	7	0.6%	42.9%	4	0.4%	0.0%
	12	1,254	910	72.6%	2.7%	908	72.4%	0.7%
	28	1,650	0	-	-	0	-	-
	6	3,826	0	-	-	0	-	-
	27	3,743	0	-	-	0	-	-
	18	626	32	5.1%	9.4%	30	4.8%	0.0%
	7	3,120	0	-	-	0	-	-
	22	346	346	100.0%	2.0%	346	100.0%	0.6%
	17	2,640	0	-	-	0	-	-
Total	0	79,310	8,625	10.9%	2.6%	8,598	10.8%	1.0%

SS9 (cont)

Disabilities and spoken English status of study group members by site.

Site	Site code	Usable hearing disability data	% usable hearing disability data	% hearing disabled where known	Usable mobility disability data	% usable mobility disability data	% mobility disabled where known
	4	0	-	-	1,710	97.9%	3.5%
	23	2,796	75.8%	4.3%	2,793	75.8%	8.2%
	20	0	-	-	163	9.1%	8.6%
	19	0	-	-	91	7.6%	7.7%
	14	0	-	-	102	2.7%	9.8%
	5	0	-	-	330	11.4%	3.9%
	8	0	-	-	103	4.6%	9.7%
	9	0	-	-	86	4.6%	14.0%
	24	1	0.0%	100.0%	29	0.5%	10.3%
	36	2,920	64.1%	3.3%	2,955	64.9%	7.1%
	10	0	-	-	519	28.9%	6.4%
	30	0	-	-	0	-	-
	21	0	-	-	101	6.3%	7.9%
	11	0	-	-	874	43.2%	8.1%
	25	0	-	-	141	2.6%	3.5%
	15	0	-	-	0	-	-
	31	0	-	-	27	0.5%	11.1%
	32	0	-	-	0	-	-
	26	0	-	-	2	0.1%	50.0%
	3	1,618	100.0%	0.6%	1,618	100.0%	2.6%
	16	0	-	-	163	6.4%	11.0%
	33	0	-	-	0	-	-
	29	0	-	-	0	-	-
	13	4	0.4%	50.0%	4	0.4%	0.0%
	12	905	72.2%	2.2%	911	72.6%	5.2%
	28	0	-	-	339	20.5%	3.5%
	6	0	-	-	1,403	36.7%	7.1%
	27	0	-	-	8	0.2%	50.0%
	18	30	4.8%	0.0%	31	5.0%	9.7%
	7	0	-	-	318	10.2%	7.2%
	22	346	100.0%	2.0%	346	100.0%	3.2%
	17	0	-	-	125	4.7%	10.4%
Total	0	8,620	10.9%	2.9%	15,292	19.3%	6.3%

SS9 (cont)	Disabilities and spoken English status of study group members by site.			
Site	Site code	Usable spoken english data	% usable spoken english data	% no spoken english where known
	4	0	-	-
	23	3,604	97.7%	0.1%
	20	0	-	-
	19	0	-	-
	14	0	-	-
	5	0	-	-
	8	0	-	-
	9	0	-	-
	24	21	0.3%	4.8%
	36	4,355	95.6%	0.0%
	10	0	-	-
	30	17	3.0%	0.0%
	21	0	-	-
	11	0	-	-
	25	0	-	-
	15	0	-	-
	31	0	-	-
	32	0	-	-
	26	0	-	-
	3	1,143	70.6%	0.8%
	16	0	-	-
	33	0	-	-
	29	0	-	-
	13	146	12.9%	1.4%
	12	1,121	89.4%	1.3%
	28	0	-	-
	6	0	-	-
	27	0	-	-
	18	340	54.3%	0.6%
	7	0	-	-
	22	320	92.5%	0.3%
	17	0	-	-
Total	0	11,067	14.0%	0.3%

SS10 Sources of referral of study group members by site. Table presents total episodes, proportion with usably coded data and then numbers and proportions for each specific source. Figures in parentheses show proportions by row.

Site	Site code	Total	% Usable referral source code	General Medical Practitioner	Self	Other clinical specialty	Community/ practice nurse/ health visitor	Local Authority Social Services	Police
	4	1746	100%	1,337 (76.6%)	23 (1.3%)	277 (15.9%)	60 (3.4%)	1 (0.1%)	-
	23	3687	100%	2,302 (62.4%)	1,167 (31.7%)	170 (4.6%)	15 (0.4%)	25 (0.7%)	-
	20	1786	100%	1,642 (91.9%)	3 (0.2%)	121 (6.8%)	-	6 (0.3%)	-
	19	1196	88%	857 (71.7%)	26 (2.2%)	157 (13.1%)	2 (0.2%)	-	1 (0.1%)
	14	3801	100%	3,050 (80.2%)	471 (12.4%)	48 (1.3%)	27 (0.7%)	7 (0.2%)	-
	5	2891	100%	2,694 (93.2%)	5 (0.2%)	96 (3.3%)	17 (0.6%)	6 (0.2%)	-
	8	2219	99%	1,933 (87.1%)	59 (2.7%)	55 (2.5%)	23 (1.0%)	2 (0.1%)	-
	9	1870	100%	1,824 (97.5%)	4 (0.2%)	25 (1.3%)	3 (0.2%)	2 (0.1%)	-
	24	6060	100%	6,052 (99.9%)	2 (0.0%)	3 (0.1%)	2 (0.0%)	-	-
	36	4555	100%	3,978 (87.3%)	100 (2.2%)	185 (4.1%)	205 (4.5%)	3 (0.1%)	2 (0.0%)
	10	1793	98%	1,004 (56.0%)	656 (36.6%)	77 (4.3%)	9 (0.5%)	2 (0.1%)	-
	30	570	100%	-	569 (99.8%)	-	1 (0.2%)	-	-
	21	1603	99%	1,418 (88.5%)	123 (7.7%)	24 (1.5%)	2 (0.1%)	-	-
	11	2023	95%	1,188 (58.7%)	558 (27.6%)	105 (5.2%)	17 (0.8%)	6 (0.3%)	1 (0.0%)
	25	5326	100%	3,866 (72.6%)	1,196 (22.5%)	106 (2.0%)	46 (0.9%)	4 (0.1%)	-
	15	2262	100%	1,997 (88.3%)	-	20 (0.9%)	239 (10.6%)	-	-
	31	5912	94%	4,253 (71.9%)	1,147 (19.4%)	9 (0.2%)	75 (1.3%)	1 (0.0%)	-
	32	1516	83%	1,215 (80.1%)	2 (0.1%)	1 (0.1%)	-	2 (0.1%)	14 (0.9%)
	26	1441	100%	1,307 (90.7%)	128 (8.9%)	-	3 (0.2%)	-	-
	3	1618	100%	1,468 (90.7%)	16 (1.0%)	48 (3.0%)	10 (0.6%)	2 (0.1%)	-
	16	2550	99%	2,454 (96.2%)	31 (1.2%)	1 (0.0%)	19 (0.7%)	-	-
	33	4103	100%	4,002 (97.5%)	42 (1.0%)	-	-	-	-
	29	442	100%	272 (61.5%)	9 (2.0%)	95 (21.5%)	32 (7.2%)	3 (0.7%)	1 (0.2%)
	13	1135	100%	1,026 (90.4%)	3 (0.3%)	78 (6.9%)	14 (1.2%)	1 (0.1%)	-
	12	1254	100%	957 (76.3%)	105 (8.4%)	33 (2.6%)	15 (1.2%)	3 (0.2%)	-
	28	1650	99%	1,494 (90.5%)	4 (0.2%)	1 (0.1%)	-	-	-
	6	3826	99%	3,329 (87.0%)	212 (5.5%)	51 (1.3%)	83 (2.2%)	3 (0.1%)	-
	27	3743	100%	3,451 (92.2%)	112 (3.0%)	61 (1.6%)	25 (0.7%)	4 (0.1%)	18 (0.5%)
	18	626	100%	299 (47.8%)	13 (2.1%)	295 (47.1%)	4 (0.6%)	-	1 (0.2%)
	7	3120	99%	3,029 (97.1%)	8 (0.3%)	31 (1.0%)	3 (0.1%)	3 (0.1%)	-
	22	346	100%	341 (98.6%)	-	-	5 (1.4%)	-	-
	17	2640	90%	2,258 (85.5%)	17 (0.6%)	44 (1.7%)	35 (1.3%)	2 (0.1%)	-
Total	0	79310	98%	66,297 (83.6%)	6,811 (8.6%)	2,217 (2.8%)	991 (1.3%)	88 (0.1%)	38 (0.0%)

SS10

Sources of referral of study group members by site. Table presents total episodes, proportion with usably coded data and then numbers and proportions for each specific source. Figures in parentheses show proportions by row.

Site	Site code	A&E Department	Voluntary sector organisation	Carer	Employer	Job centre plus	Education Service	Courts	Probation Service	Other
	4	-	1 (0.1%)	-	-	-	-	-	-	47 (2.7%)
	23	-	-	1 (0.0%)	1 (0.0%)	-	-	-	-	6 (0.2%)
	20	3 (0.2%)	1 (0.1%)	-	1 (0.1%)	-	-	1 (0.1%)	-	4 (0.2%)
	19	-	-	-	2 (0.2%)	1 (0.1%)	1 (0.1%)	1 (0.1%)	-	9 (0.8%)
	14	4 (0.1%)	2 (0.1%)	1 (0.0%)	-	-	-	-	1 (0.0%)	175 (4.6%)
	5	3 (0.1%)	-	-	-	1 (0.0%)	-	-	-	66 (2.3%)
	8	1 (0.0%)	-	-	1 (0.0%)	-	-	-	-	120 (5.4%)
	9	1 (0.1%)	-	-	-	-	-	-	-	2 (0.1%)
	24	-	-	-	-	-	-	-	-	1 (0.0%)
	36	-	1 (0.0%)	-	-	1 (0.0%)	-	-	-	80 (1.8%)
	10	-	-	-	-	-	-	-	-	18 (1.0%)
	30	-	-	-	-	-	-	-	-	-
	21	-	2 (0.1%)	1 (0.1%)	2 (0.1%)	-	1 (0.1%)	1 (0.1%)	-	7 (0.4%)
	11	2 (0.1%)	-	-	-	-	-	1 (0.0%)	-	38 (1.9%)
	25	1 (0.0%)	2 (0.0%)	10 (0.2%)	1 (0.0%)	-	-	-	1 (0.0%)	92 (1.7%)
	15	-	-	-	-	-	-	-	-	6 (0.3%)
	31	1 (0.0%)	2 (0.0%)	3 (0.1%)	2 (0.0%)	-	1 (0.0%)	-	-	78 (1.3%)
	32	-	-	-	-	-	-	-	-	19 (1.3%)
	26	-	-	-	1 (0.1%)	-	-	-	-	2 (0.1%)
	3	1 (0.1%)	-	1 (0.1%)	-	-	-	-	-	72 (4.5%)
	16	-	-	-	1 (0.0%)	-	-	-	-	9 (0.4%)
	33	-	-	-	-	-	-	-	-	59 (1.4%)
	29	1 (0.2%)	-	-	-	-	-	-	-	29 (6.6%)
	13	1 (0.1%)	-	-	-	3 (0.3%)	-	-	1 (0.1%)	8 (0.7%)
	12	1 (0.1%)	2 (0.2%)	-	-	-	-	-	-	138 (11.0%)
	28	-	-	-	-	-	-	-	-	131 (7.9%)
	6	1 (0.0%)	15 (0.4%)	-	-	-	-	-	-	97 (2.5%)
	27	2 (0.1%)	8 (0.2%)	1 (0.0%)	2 (0.1%)	-	3 (0.1%)	-	-	56 (1.5%)
	18	-	-	-	-	-	-	-	-	12 (1.9%)
	7	2 (0.1%)	-	-	2 (0.1%)	-	-	-	-	12 (0.4%)
	22	-	-	-	-	-	-	-	-	-
	17	12 (0.5%)	-	-	-	2 (0.1%)	-	-	-	6 (0.2%)
Total	0	37 (0.0%)	36 (0.0%)	18 (0.0%)	16 (0.0%)	8 (0.0%)	6 (0.0%)	4 (0.0%)	3 (0.0%)	1,399 (1.8%)

SS11 Initial employment and social security benefit status of study group members.								
Site	Site code	Total cases	Employed full-time	Employed part-time	Any employment	Unemployed	Economically active	Unemployed as proportion of EA
	4	1746	42.9%	17.4%	60.3%	18.2%	78.4%	23.2%
	23	3687	37.3%	14.5%	51.8%	26.3%	78.1%	33.7%
	20	1786	41.5%	15.8%	57.3%	27.5%	84.8%	32.5%
	19	1196	44.1%	17.6%	61.6%	17.5%	79.1%	22.1%
	14	3801	39.6%	15.4%	55.0%	23.1%	78.1%	29.6%
	5	2891	44.0%	16.8%	60.9%	20.8%	81.6%	25.4%
	8	2219	38.2%	11.1%	49.3%	29.8%	79.2%	37.7%
	9	1870	43.5%	10.0%	53.5%	31.8%	85.3%	37.3%
	24	6060	35.7%	16.1%	51.8%	21.4%	73.2%	29.3%
	36	4555	37.4%	18.1%	55.5%	19.7%	75.2%	26.2%
	10	1793	39.0%	11.5%	50.6%	30.5%	81.0%	37.6%
	30	570	30.5%	15.4%	46.0%	17.9%	63.9%	28.0%
	21	1603	31.6%	15.3%	47.0%	29.8%	76.7%	38.8%
	11	2023	34.4%	13.2%	47.6%	32.1%	79.7%	40.3%
	25	5326	43.8%	18.1%	61.8%	16.7%	78.5%	21.2%
	15	2262	31.7%	5.8%	37.5%	45.9%	83.4%	55.0%
	31	5912	44.3%	13.7%	57.9%	21.7%	79.6%	27.2%
	32	1516	38.7%	16.5%	55.1%	24.8%	79.9%	31.0%
	26	1441	24.6%	12.8%	37.5%	19.2%	56.6%	33.8%
	3	1618	33.7%	10.8%	44.4%	23.3%	67.7%	34.4%
	16	2550	35.5%	10.2%	45.7%	29.8%	75.5%	39.4%
	33	4103	36.2%	15.5%	51.7%	24.7%	76.3%	32.3%
	29	442	32.4%	19.0%	51.4%	21.7%	73.1%	29.7%
	13	1135	37.0%	10.0%	47.0%	34.3%	81.3%	42.1%
	12	1254	39.4%	12.3%	51.7%	30.1%	81.7%	36.8%
	28	1650	37.6%	12.0%	49.6%	34.6%	84.2%	41.1%
	6	3826	37.5%	17.6%	55.1%	19.9%	75.0%	26.5%
	27	3743	48.3%	14.1%	62.4%	17.7%	80.1%	22.1%
	18	626	42.3%	11.3%	53.7%	19.0%	72.7%	26.2%
	7	3120	43.0%	17.0%	60.0%	19.6%	79.6%	24.7%
	22	346	36.1%	18.2%	54.3%	15.0%	69.4%	21.7%
	17	2640	37.3%	14.5%	51.9%	20.2%	72.0%	28.0%
Total	0	79310	39.0%	14.7%	53.7%	23.8%	77.5%	30.7%

SS11 (cont)

Initial employment and social security benefit status of study group members.

Site	Site code	Full-time student	Full-time homemaker or carer	Retired	Economically inactive	Economic activity data missing	Receiving benefits	No benefits	Benefit status not known
	4	3.9%	10.3%	7.2%	21.4%	0.2%	20.7%	78.8%	0.5%
	23	3.1%	10.5%	8.3%	21.9%	0.0%	33.4%	65.1%	1.5%
	20	4.0%	6.8%	2.8%	13.5%	1.6%	29.8%	67.5%	2.6%
	19	3.2%	9.4%	7.3%	19.9%	1.0%	20.4%	77.8%	1.8%
	14	3.9%	7.6%	9.5%	21.0%	0.9%	27.7%	69.8%	2.6%
	5	3.7%	9.2%	3.2%	16.2%	2.2%	29.1%	67.6%	3.3%
	8	8.8%	5.6%	5.4%	19.8%	1.0%	30.6%	66.9%	2.5%
	9	4.8%	4.7%	3.2%	12.7%	2.0%	29.2%	60.9%	9.9%
	24	5.1%	9.5%	9.3%	23.9%	2.9%	29.5%	59.7%	10.8%
	36	3.8%	10.8%	10.1%	24.7%	0.0%	27.9%	64.9%	7.2%
	10	5.1%	6.5%	4.5%	16.0%	3.0%	31.6%	63.7%	4.6%
	30	3.9%	8.1%	8.9%	20.9%	15.3%	21.1%	57.2%	21.8%
	21	4.6%	11.2%	5.5%	21.3%	2.0%	37.6%	58.0%	4.5%
	11	5.1%	10.1%	3.9%	19.1%	1.1%	37.6%	60.3%	2.1%
	25	3.5%	9.0%	8.1%	20.7%	0.8%	23.9%	71.5%	4.6%
	15	2.8%	0.0%	4.9%	7.6%	9.0%	51.0%	40.2%	8.8%
	31	6.6%	5.9%	6.5%	19.0%	1.4%	28.6%	69.0%	2.5%
	32	3.7%	9.2%	6.9%	19.9%	0.2%	27.3%	63.7%	9.0%
	26	1.9%	6.4%	6.4%	14.6%	28.7%	24.2%	46.6%	29.2%
	3	6.1%	5.7%	4.4%	16.3%	16.0%	30.8%	56.9%	12.2%
	16	4.1%	5.8%	4.6%	14.5%	10.0%	37.5%	51.6%	10.9%
	33	7.3%	6.9%	7.9%	22.2%	1.5%	32.6%	64.9%	2.5%
	29	4.1%	10.2%	10.0%	24.2%	2.7%	28.7%	64.3%	7.0%
	13	3.3%	7.8%	7.1%	18.3%	0.4%	46.8%	49.3%	3.9%
	12	5.1%	6.3%	6.7%	18.1%	0.2%	31.8%	62.7%	5.5%
	28	3.3%	6.7%	4.3%	14.3%	1.5%	43.2%	54.2%	2.5%
	6	3.3%	9.8%	7.4%	20.6%	4.4%	25.7%	68.5%	5.8%
	27	2.5%	9.8%	5.9%	18.2%	1.7%	26.7%	63.6%	9.6%
	18	3.2%	6.7%	3.7%	13.6%	13.7%	20.4%	58.6%	20.9%
	7	3.7%	10.2%	5.9%	19.8%	0.6%	22.5%	76.5%	0.9%
	22	2.3%	9.5%	9.8%	21.7%	9.0%	24.6%	75.1%	0.3%
	17	4.3%	8.3%	8.5%	21.1%	6.9%	29.8%	61.1%	9.1%
Total	0	4.4%	8.1%	6.8%	19.3%	3.1%	29.9%	64.1%	6.0%

SS12		Primary diagnoses: completeness and pattern by site.					
Site	Site code	Total records	Records with usable diagnosis	% with usable diagnosis	Ment/behav due to alcohol	Bipolar affective disorder	Depressive episode
	4	1746	1681	96.30%	2 (0.1%)	0.00%	267 (15.9%)
	23	3687	1985	53.80%	15 (0.8%)	2 (0.1%)	433 (21.8%)
	20	1786	1662	93.10%	6 (0.4%)	4 (0.2%)	529 (31.8%)
	19	1196	521	43.60%	1 (0.2%)	2 (0.4%)	201 (38.6%)
	14	3801	2420	63.70%	15 (0.6%)	7 (0.3%)	773 (31.9%)
	5	2891	2031	70.30%	11 (0.5%)	8 (0.4%)	573 (28.2%)
	8	2219	1675	75.50%	12 (0.7%)	14 (0.8%)	580 (34.6%)
	9	1870	922	49.30%	4 (0.4%)	3 (0.3%)	279 (30.3%)
	24	6060	19	0.30%	0.00%	0.00%	4 (21.1%)
	36	4555	990	21.70%	5 (0.5%)	3 (0.3%)	238 (24.0%)
	10	1793	1514	84.40%	11 (0.7%)	9 (0.6%)	493 (32.6%)
	30	570	259	45.40%	2 (0.8%)	0.00%	85 (32.8%)
	21	1603	1513	94.40%	7 (0.5%)	4 (0.3%)	298 (19.7%)
	11	2023	1345	66.50%	8 (0.6%)	2 (0.1%)	257 (19.1%)
	25	5326	3990	74.90%	16 (0.4%)	17 (0.4%)	1,233 (30.9%)
	15	2262	2206	97.50%	5 (0.2%)	2 (0.1%)	606 (27.5%)
	31	5912	2726	46.10%	10 (0.4%)	4 (0.1%)	947 (34.7%)
	32	1516	1238	81.70%	2 (0.2%)	4 (0.3%)	647 (52.3%)
	26	1441	1338	92.90%	6 (0.4%)	7 (0.5%)	656 (49.0%)
	3	1618	77	4.80%	0.00%	0.00%	14 (18.2%)
	16	2550	1500	58.80%	13 (0.9%)	4 (0.3%)	662 (44.1%)
	33	4103	300	7.30%	0.00%	0.00%	40 (13.3%)
	29	442	356	80.50%	5 (1.4%)	6 (1.7%)	50 (14.0%)
	13	1135	0	0.00%	-	-	-
	12	1254	333	26.60%	3 (0.9%)	2 (0.6%)	71 (21.3%)
	28	1650	416	25.20%	1 (0.2%)	0.00%	112 (26.9%)
	6	3826	3248	84.90%	6 (0.2%)	3 (0.1%)	880 (27.1%)
	27	3743	2950	78.80%	19 (0.6%)	4 (0.1%)	808 (27.4%)
	18	626	9	1.40%	0.00%	0.00%	1 (11.1%)
	7	3120	2010	64.40%	11 (0.5%)	2 (0.1%)	504 (25.1%)
	22	346	0	0.00%	-	-	-
	17	2640	1877	71.10%	11 (0.6%)	3 (0.2%)	443 (23.6%)
Total		79310	43111	54.40%	207 (0.5%)	116 (0.3%)	12,684 (29.4%)

Table shows numbers and proportions of study group records with usable diagnoses by site; records in each diagnostic category as numbers and percentage of those with usable diagnosis for the site.

SS12 (cont)

Site	Primary diagnoses: completeness and pattern by site.					
	Site code	Recurrent depressive disorder	Generalized anxiety disorder	Mixed anxiety and depressive disorder	Agora-phobia	Social phobias
4	189 (11.2%)	577 (34.3%)	527 (31.4%)	7 (0.4%)	17 (1.0%)	26 (1.5%)
23	216 (10.9%)	316 (15.9%)	700 (35.3%)	24 (1.2%)	37 (1.9%)	31 (1.6%)
20	146 (8.8%)	393 (23.6%)	338 (20.3%)	42 (2.5%)	39 (2.3%)	23 (1.4%)
19	23 (4.4%)	113 (21.7%)	111 (21.3%)	10 (1.9%)	15 (2.9%)	17 (3.3%)
14	171 (7.1%)	480 (19.8%)	560 (23.1%)	62 (2.6%)	50 (2.1%)	39 (1.6%)
5	222 (10.9%)	452 (22.3%)	468 (23.0%)	36 (1.8%)	29 (1.4%)	49 (2.4%)
8	123 (7.3%)	250 (14.9%)	392 (23.4%)	29 (1.7%)	39 (2.3%)	24 (1.4%)
9	106 (11.5%)	191 (20.7%)	148 (16.1%)	20 (2.2%)	30 (3.3%)	11 (1.2%)
24	0.00%	7 (36.8%)	5 (26.3%)	1 (5.3%)	0.00%	0.00%
36	90 (9.1%)	120 (12.1%)	373 (37.7%)	26 (2.6%)	19 (1.9%)	19 (1.9%)
10	146 (9.6%)	157 (10.4%)	328 (21.7%)	78 (5.2%)	66 (4.4%)	30 (2.0%)
30	10 (3.9%)	66 (25.5%)	79 (30.5%)	2 (0.8%)	1 (0.4%)	2 (0.8%)
21	97 (6.4%)	322 (21.3%)	567 (37.5%)	36 (2.4%)	16 (1.1%)	30 (2.0%)
11	124 (9.2%)	137 (10.2%)	585 (43.5%)	25 (1.9%)	36 (2.7%)	21 (1.6%)
25	145 (3.6%)	713 (17.9%)	1,548 (38.8%)	15 (0.4%)	34 (0.9%)	21 (0.5%)
15	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
31	249 (9.1%)	534 (19.6%)	635 (23.3%)	31 (1.1%)	45 (1.7%)	22 (0.8%)
32	4 (0.3%)	128 (10.3%)	300 (24.2%)	0.00%	2 (0.2%)	2 (0.2%)
26	69 (5.2%)	201 (15.0%)	312 (23.3%)	16 (1.2%)	7 (0.5%)	8 (0.6%)
3	6 (7.8%)	0.00%	0.00%	0.00%	0.00%	0.00%
16	102 (6.8%)	178 (11.9%)	441 (29.4%)	11 (0.7%)	6 (0.4%)	7 (0.5%)
33	40 (13.3%)	19 (6.3%)	149 (49.7%)	8 (2.7%)	1 (0.3%)	3 (1.0%)
29	40 (11.2%)	60 (16.9%)	107 (30.1%)	15 (4.2%)	20 (5.6%)	11 (3.1%)
13	-	-	-	-	-	-
12	27 (8.1%)	24 (7.2%)	54 (16.2%)	51 (15.3%)	33 (9.9%)	5 (1.5%)
28	34 (8.2%)	37 (8.9%)	187 (45.0%)	4 (1.0%)	5 (1.2%)	3 (0.7%)
6	260 (8.0%)	650 (20.0%)	1,156 (35.6%)	38 (1.2%)	33 (1.0%)	43 (1.3%)
27	109 (3.7%)	636 (21.6%)	1,173 (39.8%)	11 (0.4%)	14 (0.5%)	11 (0.4%)
18	1 (11.1%)	1 (11.1%)	3 (33.3%)	0.00%	1 (11.1%)	2 (22.2%)
7	123 (6.1%)	397 (19.8%)	683 (34.0%)	41 (2.0%)	46 (2.3%)	40 (2.0%)
22	-	-	-	-	-	-
17	96 (5.1%)	395 (21.0%)	698 (37.2%)	9 (0.5%)	24 (1.3%)	30 (1.6%)
Total	2,968 (6.9%)	7,554 (17.5%)	12,627 (29.3%)	648 (1.5%)	665 (1.5%)	530 (1.2%)

Table shows numbers and proportions of study group records with usable diagnoses by site; records in each diagnostic category as numbers and percentage of those with usable diagnosis for the site.

SS12 (cont)

Site	Primary diagnoses: completeness and pattern by site.							
	Site code	Obsessive-compulsive disorder	Post-traumatic stress disorder	Somatoform disorders	Eating disorders	Disappearance / death of family member	Other specified mental disorder	Other diagnosis
4	23 (1.4%)	17 (1.0%)	3 (0.2%)	3 (0.2%)	1 (0.1%)	22 (1.3%)	0.00%	
23	65 (3.3%)	58 (2.9%)	7 (0.4%)	21 (1.1%)	60 (3.0%)	0.00%	0.00%	
20	63 (3.8%)	22 (1.3%)	9 (0.5%)	7 (0.4%)	4 (0.2%)	37 (2.2%)	0.00%	
19	7 (1.3%)	3 (0.6%)	1 (0.2%)	2 (0.4%)	4 (0.8%)	11 (2.1%)	0.00%	
14	52 (2.1%)	68 (2.8%)	15 (0.6%)	6 (0.2%)	94 (3.9%)	28 (1.2%)	0.00%	
5	77 (3.8%)	34 (1.7%)	19 (0.9%)	11 (0.5%)	15 (0.7%)	27 (1.3%)	0.00%	
8	60 (3.6%)	30 (1.8%)	8 (0.5%)	10 (0.6%)	8 (0.5%)	96 (5.7%)	0.00%	
9	21 (2.3%)	40 (4.3%)	10 (1.1%)	17 (1.8%)	11 (1.2%)	31 (3.4%)	0.00%	
24	0.00%	1 (5.3%)	0.00%	0.00%	0.00%	0.00%	1 (5.3%)	
36	20 (2.0%)	21 (2.1%)	1 (0.1%)	8 (0.8%)	47 (4.7%)	0.00%	0.00%	
10	55 (3.6%)	52 (3.4%)	9 (0.6%)	8 (0.5%)	23 (1.5%)	49 (3.2%)	0.00%	
30	2 (0.8%)	2 (0.8%)	0.00%	0.00%	8 (3.1%)	0.00%	0.00%	
21	56 (3.7%)	15 (1.0%)	1 (0.1%)	19 (1.3%)	21 (1.4%)	24 (1.6%)	0.00%	
11	29 (2.2%)	61 (4.5%)	14 (1.0%)	6 (0.4%)	15 (1.1%)	25 (1.9%)	0.00%	
25	54 (1.4%)	31 (0.8%)	8 (0.2%)	29 (0.7%)	102 (2.6%)	24 (0.6%)	0.00%	
15	0.00%	169 (7.7%)	3 (0.1%)	8 (0.4%)	182 (8.3%)	1,067 (48.4%)	164 (7.4%)	
31	57 (2.1%)	37 (1.4%)	7 (0.3%)	27 (1.0%)	82 (3.0%)	39 (1.4%)	0.00%	
32	7 (0.6%)	13 (1.1%)	1 (0.1%)	0.00%	2 (0.2%)	126 (10.2%)	0.00%	
26	16 (1.2%)	21 (1.6%)	0.00%	4 (0.3%)	3 (0.2%)	12 (0.9%)	0.00%	
3	5 (6.5%)	0.00%	3 (3.9%)	0.00%	0.00%	49 (63.6%)	0.00%	
16	10 (0.7%)	21 (1.4%)	2 (0.1%)	3 (0.2%)	18 (1.2%)	22 (1.5%)	0.00%	
33	9 (3.0%)	7 (2.3%)	2 (0.7%)	2 (0.7%)	7 (2.3%)	13 (4.3%)	0.00%	
29	26 (7.3%)	11 (3.1%)	3 (0.8%)	1 (0.3%)	1 (0.3%)	0.00%	0.00%	
13	-	-	-	-	-	-	-	
12	27 (8.1%)	26 (7.8%)	9 (2.7%)	1 (0.3%)	0.00%	0.00%	0.00%	
28	13 (3.1%)	2 (0.5%)	3 (0.7%)	1 (0.2%)	5 (1.2%)	9 (2.2%)	0.00%	
6	60 (1.8%)	44 (1.4%)	14 (0.4%)	14 (0.4%)	17 (0.5%)	30 (0.9%)	0.00%	
27	32 (1.1%)	33 (1.1%)	4 (0.1%)	19 (0.6%)	61 (2.1%)	16 (0.5%)	0.00%	
18	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	
7	62 (3.1%)	24 (1.2%)	9 (0.4%)	19 (0.9%)	5 (0.2%)	44 (2.2%)	0.00%	
22	-	-	-	-	-	-	-	
17	36 (1.9%)	31 (1.7%)	11 (0.6%)	9 (0.5%)	61 (3.2%)	20 (1.1%)	0.00%	
Total	944 (2.2%)	894 (2.1%)	176 (0.4%)	255 (0.6%)	857 (2.0%)	1,821 (4.2%)	165 (0.4%)	

Table shows numbers and proportions of study group records with usable diagnoses by site; records in each diagnostic category as numbers and percentage of those with usable diagnosis for the site.

SS12a

Mean initial PHQ9 and GAD7 scores for study group patients with diagnoses indicated as either primary or secondary diagnosis.

Site	Site Code	Anxiety alone			Depression alone			Anxiety and depression			MADD alone (see text)			None of these diagnoses		
		Mean first	Mean first	Patients	Mean first	Mean first	Patients	Mean first	Mean first	Patients	Mean first	Mean first	Patients	Mean first	Mean first	Patients
		PHQ9	GAD7		PHQ9	GAD7		PHQ9	GAD7		PHQ9	GAD7		PHQ9	GAD7	
	4	11.47	12.13	578	14.78	12.01	424	14.09	12.52	54	13.88	12.82	529	11.19	11.40	161
	23	10.87	12.44	315	16.71	12.53	655				16.23	14.72	700	13.88	12.08	2,016
	20	11.41	12.33	394	14.57	11.57	693				15.03	13.26	341	12.51	12.09	356
	19	9.06	11.58	113	14.51	11.26	218	16.13	13.93	15	14.96	13.68	111	12.54	11.68	739
	14	11.23	11.64	483	15.00	12.37	946	17.10	13.80	20	15.07	13.17	567	13.07	11.64	1,785
	5	11.21	11.84	458	14.87	11.68	801				14.66	13.22	472	12.51	11.38	1,157
	8	10.39	12.21	249	14.96	12.10	719	12.20	10.20	5	15.12	13.65	402	12.78	11.79	844
	9	10.85	11.57	191	15.54	12.49	390				15.50	13.17	149	12.77	11.48	1,136
	24	9.14	7.71	7							14.00	11.80	5	13.74	12.00	6,044
	36	10.98	11.46	119	15.27	12.26	330				14.65	13.60	374	13.71	12.44	3,731
	10	10.87	12.67	157	16.08	12.32	656	16.28	14.26	47	15.65	14.07	348	12.32	11.46	585
	30	9.52	8.93	67	9.81	7.74	95				9.10	7.69	80	11.51	10.89	328
	21	12.01	12.30	325	15.92	12.23	399				14.63	12.66	568	12.40	11.49	310
	11	10.23	11.58	141	15.44	11.85	387				15.42	13.65	592	14.45	12.58	899
	25	11.56	11.84	716	14.93	11.93	1,382				14.79	12.68	1,551	12.49	11.16	1,677
	15	11.52	13.14	21	16.55	13.77	1,110							13.63	12.86	1,131
	31	12.12	12.36	546	15.49	12.66	1,206				15.65	13.87	643	13.77	12.12	3,514
	32	11.41	12.27	128	14.68	12.13	651				14.64	12.90	300	10.74	10.06	437
	26	11.40	7.88	202	15.32	8.70	729				14.82	8.89	314	12.38	8.78	195
	3				14.76	12.71	21							13.96	12.50	1,597
	16	12.43	12.42	179	15.74	13.00	770	17.83	12.17	6	15.08	13.28	443	14.66	12.41	1,152
	33	8.68	10.89	19	16.40	12.49	80				15.28	13.34	149	14.06	12.34	3,855
	29	10.42	11.83	60	14.74	11.91	90				15.07	13.06	107	12.91	11.97	185
	13													15.11	13.30	1,135
	12	8.35	11.16	31	15.67	11.53	129				14.24	12.24	54	12.33	10.74	1,038
	28	13.32	13.08	38	16.52	13.17	151				17.74	15.38	189	15.32	13.54	1,271
	6	11.63	12.34	657	15.50	12.44	1,147	16.89	14.44	9	15.68	13.88	1,158	12.70	11.93	855
	27	12.32	11.70	640	15.07	11.87	919				15.35	12.93	1,174	12.55	11.09	1,009
	18										12.44	11.47	620			
	7	9.70	11.35	398	15.00	11.61	636	12.79	12.07	14	14.87	13.21	694	12.82	11.77	1,378
	22													12.95	11.98	346
	17	12.34	12.59	394	16.14	12.97	551	13.40	11.80	5	15.35	13.22	695	13.70	12.26	995
Sites combined		11.38	11.9	7627	15.37	12.129	16291	15.171	13.181	199	15.141	13.211	12712	13.482	12.022	42481

Data dependent on less than 5 cases suppressed

SS13

Site	Completeness and caseness levels, initial symptom and W&SAS scores				
	Site code	Total records	GAD7	PHQ9	Phobia Qs
4	1746	100.0% (99.8% to 100.0%)	100.0% (99.8% to 100.0%)	99.8% (99.5% to 99.9%)	99.7% (99.3% to 99.9%)
23	3687	100.0% (99.9% to 100.0%)	100.0% (99.9% to 100.0%)	100.0% (99.9% to 100.0%)	100.0% (99.9% to 100.0%)
20	1786	99.8% (99.4% to 99.9%)	99.9% (99.6% to 100.0%)	97.8% (97.0% to 98.4%)	97.2% (96.3% to 97.9%)
19	1196	99.7% (99.1% to 99.9%)	99.4% (98.8% to 99.7%)	98.2% (97.3% to 98.8%)	97.8% (96.8% to 98.5%)
14	3801	99.6% (99.4% to 99.8%)	99.7% (99.5% to 99.9%)	98.4% (97.9% to 98.7%)	97.7% (97.2% to 98.1%)
5	2891	99.4% (99.1% to 99.7%)	99.8% (99.5% to 99.9%)	95.4% (94.6% to 96.1%)	97.3% (96.6% to 97.8%)
8	2219	99.4% (99.0% to 99.7%)	99.7% (99.4% to 99.8%)	96.8% (95.9% to 97.4%)	96.2% (95.3% to 96.9%)
9	1870	99.5% (99.1% to 99.7%)	99.8% (99.5% to 99.9%)	96.0% (95.0% to 96.8%)	95.6% (94.6% to 96.5%)
24	6060	99.0% (98.7% to 99.2%)	99.7% (99.5% to 99.8%)	94.5% (93.9% to 95.1%)	93.5% (92.9% to 94.1%)
36	4555	100.0% (99.9% to 100.0%)	100.0% (99.9% to 100.0%)	100.0% (99.8% to 100.0%)	100.0% (99.9% to 100.0%)
10	1793	99.1% (98.6% to 99.4%)	99.9% (99.6% to 100.0%)	95.6% (94.5% to 96.5%)	94.6% (93.5% to 95.6%)
30	570	99.1% (98.0% to 99.6%)	99.3% (98.2% to 99.7%)	89.1% (86.3% to 91.4%)	98.2% (96.8% to 99.0%)
21	1603	99.5% (99.0% to 99.7%)	99.6% (99.1% to 99.8%)	95.8% (94.7% to 96.7%)	93.6% (92.3% to 94.7%)
11	2023	99.7% (99.3% to 99.8%)	100.0% (99.7% to 100.0%)	98.0% (97.3% to 98.5%)	98.6% (98.0% to 99.0%)
25	5326	99.4% (99.2% to 99.6%)	99.8% (99.7% to 99.9%)	79.1% (78.0% to 80.2%)	97.8% (97.4% to 98.2%)
15	2262	93.0% (91.9% to 94.0%)	93.6% (92.5% to 94.5%)	92.7% (91.5% to 93.7%)	38.4% (36.4% to 40.4%)
31	5912	99.5% (99.3% to 99.7%)	99.7% (99.5% to 99.8%)	96.5% (96.0% to 97.0%)	97.3% (96.8% to 97.6%)
32	1516	100.0% (99.7% to 100.0%)	100.0% (99.7% to 100.0%)	100.0% (99.7% to 100.0%)	100.0% (99.7% to 100.0%)
26	1441	71.8% (69.4% to 74.0%)	99.9% (99.5% to 100.0%)	70.3% (67.9% to 72.6%)	69.7% (67.3% to 72.1%)
3	1618	98.9% (98.3% to 99.3%)	97.7% (96.8% to 98.3%)	81.6% (79.6% to 83.4%)	86.4% (84.6% to 88.0%)
16	2550	98.9% (98.5% to 99.3%)	99.6% (99.3% to 99.8%)	76.5% (74.8% to 78.1%)	82.1% (80.6% to 83.6%)
33	4103	99.3% (99.0% to 99.5%)	100.0% (99.9% to 100.0%)	98.2% (97.7% to 98.5%)	98.1% (97.7% to 98.5%)
29	442	99.1% (97.7% to 99.6%)	99.8% (98.7% to 100.0%)	71.0% (66.6% to 75.1%)	98.4% (96.8% to 99.2%)
13	1135	99.9% (99.5% to 100.0%)	100.0% (99.7% to 100.0%)	99.8% (99.4% to 100.0%)	99.8% (99.4% to 100.0%)
12	1254	100.0% (99.7% to 100.0%)	100.0% (99.7% to 100.0%)	99.7% (99.2% to 99.9%)	99.6% (99.1% to 99.8%)
28	1650	99.5% (99.0% to 99.8%)	99.9% (99.6% to 100.0%)	95.9% (94.8% to 96.7%)	96.8% (95.8% to 97.5%)
6	3826	99.8% (99.6% to 99.9%)	99.9% (99.8% to 100.0%)	84.8% (83.6% to 85.9%)	94.9% (94.1% to 95.5%)
27	3743	98.4% (98.0% to 98.8%)	99.7% (99.5% to 99.9%)	92.2% (91.3% to 93.0%)	96.0% (95.3% to 96.6%)
18	626	100.0% (99.4% to 100.0%)	100.0% (99.4% to 100.0%)	99.4% (98.4% to 99.8%)	99.4% (98.4% to 99.8%)
7	3120	99.8% (99.5% to 99.9%)	99.9% (99.7% to 100.0%)	99.0% (98.6% to 99.3%)	98.7% (98.2% to 99.0%)
22	346	99.1% (97.5% to 99.7%)	98.6% (96.7% to 99.4%)	98.0% (95.9% to 99.0%)	99.4% (97.9% to 99.8%)
17	2640	99.5% (99.2% to 99.7%)	99.6% (99.3% to 99.8%)	92.3% (91.2% to 93.3%)	89.5% (88.2% to 90.6%)
Total	79310	98.8% (98.7% to 98.9%)	99.6% (99.5% to 99.6%)	93.5% (93.3% to 93.6%)	94.2% (94.0% to 94.3%)

SS13 (cont)

Site

Completeness and caseness levels, initial symptom and W&SAS scores

Site code	Availability of intital ratings	
	GAD7 and PHQ	GAD7, PHQ and Phobia Qs
4	100.0% (99.8% to 100.0%)	99.8% (99.5% to 99.9%)
23	100.0% (99.9% to 100.0%)	100.0% (99.9% to 100.0%)
20	99.7% (99.3% to 99.9%)	97.6% (96.8% to 98.3%)
19	99.2% (98.5% to 99.5%)	97.6% (96.5% to 98.3%)
14	99.5% (99.2% to 99.7%)	98.1% (97.6% to 98.5%)
5	99.3% (98.9% to 99.6%)	95.2% (94.4% to 95.9%)
8	99.1% (98.7% to 99.5%)	96.3% (95.4% to 97.0%)
9	99.4% (98.9% to 99.6%)	95.8% (94.8% to 96.6%)
24	98.7% (98.4% to 99.0%)	94.1% (93.5% to 94.7%)
36	100.0% (99.9% to 100.0%)	99.9% (99.8% to 100.0%)
10	99.1% (98.5% to 99.4%)	95.5% (94.4% to 96.4%)
30	98.8% (97.5% to 99.4%)	88.8% (85.9% to 91.1%)
21	99.3% (98.7% to 99.6%)	95.4% (94.2% to 96.3%)
11	99.6% (99.2% to 99.8%)	98.0% (97.3% to 98.5%)
25	99.2% (99.0% to 99.4%)	78.9% (77.8% to 80.0%)
15	92.9% (91.8% to 93.9%)	85.7% (84.2% to 87.1%)
31	99.3% (99.1% to 99.5%)	96.2% (95.7% to 96.7%)
32	100.0% (99.7% to 100.0%)	100.0% (99.7% to 100.0%)
26	71.6% (69.2% to 73.9%)	70.2% (67.7% to 72.5%)
3	96.9% (95.9% to 97.6%)	79.0% (77.0% to 81.0%)
16	98.7% (98.1% to 99.0%)	76.2% (74.5% to 77.8%)
33	99.3% (99.0% to 99.5%)	98.1% (97.7% to 98.5%)
29	99.1% (97.7% to 99.6%)	70.1% (65.7% to 74.2%)
13	99.9% (99.5% to 100.0%)	99.8% (99.4% to 100.0%)
12	100.0% (99.7% to 100.0%)	99.7% (99.2% to 99.9%)
28	99.4% (98.9% to 99.7%)	95.9% (94.8% to 96.7%)
6	99.7% (99.5% to 99.9%)	84.6% (83.5% to 85.7%)
27	98.2% (97.7% to 98.5%)	91.7% (90.7% to 92.5%)
18	100.0% (99.4% to 100.0%)	99.4% (98.4% to 99.8%)
7	99.7% (99.5% to 99.8%)	98.9% (98.5% to 99.2%)
22	98.0% (95.9% to 99.0%)	96.0% (93.3% to 97.6%)
17	99.2% (98.8% to 99.5%)	92.0% (90.9% to 92.9%)
Total	98.6% (98.5% to 98.7%)	93.0% (92.8% to 93.2%)

SS13 (cont)

Completeness and caseness levels, initial symptom and W&SAS scores

Site	Site code	Caseness where rateable				
		First GAD7 8+	First PHQ9 10+	First phobia Qs Positive	MTR2 (any of GAD7, PHQ or Phobia Qs)	MTR1 (either of GAD7 or PHQ)
	4	78.3% (76.3% to 80.2%)	68.6% (66.3% to 70.7%)	54.5% (52.2% to 56.8%)	89.0% (87.5% to 90.4%)	83.6% (81.8% to 85.2%)
	23	78.7% (77.3% to 80.0%)	75.0% (73.6% to 76.4%)	55.6% (54.0% to 57.2%)	89.1% (88.0% to 90.0%)	84.9% (83.7% to 86.0%)
	20	77.0% (75.0% to 78.9%)	70.5% (68.4% to 72.6%)	54.4% (52.1% to 56.7%)	88.6% (87.0% to 90.0%)	84.6% (82.8% to 86.2%)
	19	74.2% (71.7% to 76.6%)	66.2% (63.5% to 68.8%)	50.5% (47.6% to 53.3%)	86.1% (84.0% to 88.0%)	79.6% (77.2% to 81.8%)
	14	75.2% (73.8% to 76.6%)	70.0% (68.6% to 71.5%)	52.2% (50.6% to 53.8%)	86.3% (85.1% to 87.3%)	81.4% (80.1% to 82.6%)
	5	74.0% (72.3% to 75.6%)	68.6% (66.9% to 70.3%)	56.0% (54.1% to 57.8%)	87.8% (86.5% to 88.9%)	80.3% (78.8% to 81.7%)
	8	77.1% (75.3% to 78.8%)	70.4% (68.5% to 72.3%)	50.3% (48.2% to 52.4%)	87.6% (86.2% to 89.0%)	83.5% (81.8% to 84.9%)
	9	74.9% (72.8% to 76.8%)	68.2% (66.0% to 70.2%)	51.1% (48.8% to 53.4%)	85.7% (84.0% to 87.3%)	80.6% (78.7% to 82.3%)
	24	76.7% (75.6% to 77.7%)	71.6% (70.4% to 72.7%)	49.2% (47.9% to 50.5%)	87.6% (86.8% to 88.5%)	83.7% (82.8% to 84.6%)
	36	78.6% (77.4% to 79.8%)	71.7% (70.4% to 73.0%)	52.2% (50.7% to 53.6%)	88.1% (87.1% to 89.0%)	84.2% (83.1% to 85.2%)
	10	79.3% (77.4% to 81.2%)	74.9% (72.9% to 76.9%)	61.9% (59.6% to 64.2%)	91.2% (89.8% to 92.5%)	85.8% (84.1% to 87.4%)
	30	58.6% (54.5% to 62.6%)	54.6% (50.5% to 58.7%)	39.4% (35.2% to 43.7%)	68.4% (64.2% to 72.3%)	63.8% (59.7% to 67.6%)
	21	77.4% (75.2% to 79.4%)	73.7% (71.5% to 75.8%)	61.8% (59.4% to 64.2%)	90.9% (89.4% to 92.2%)	84.0% (82.2% to 85.8%)
	11	79.6% (77.7% to 81.3%)	76.4% (74.5% to 78.2%)	65.2% (63.0% to 67.2%)	91.5% (90.2% to 92.6%)	86.6% (85.0% to 88.0%)
	25	74.1% (72.9% to 75.2%)	70.4% (69.2% to 71.7%)	50.4% (48.9% to 51.9%)	86.4% (85.4% to 87.4%)	82.0% (80.9% to 83.0%)
	15	89.5% (88.2% to 90.8%)	84.6% (83.0% to 86.0%)	70.5% (68.5% to 72.4%)	96.1% (95.1% to 96.9%)	93.2% (92.0% to 94.2%)
	31	78.2% (77.1% to 79.2%)	73.4% (72.3% to 74.5%)	51.8% (50.5% to 53.1%)	88.1% (87.2% to 88.9%)	84.3% (83.3% to 85.2%)
	32	73.6% (71.3% to 75.8%)	69.0% (66.6% to 71.3%)	42.0% (39.6% to 44.5%)	84.2% (82.2% to 85.9%)	80.9% (78.9% to 82.8%)
	26	78.2% (75.6% to 80.6%)	77.3% (75.1% to 79.4%)	53.7% (50.6% to 56.8%)	89.8% (87.8% to 91.5%)	85.8% (83.5% to 87.8%)
	3	78.6% (76.6% to 80.6%)	73.8% (71.6% to 75.9%)	53.2% (50.5% to 55.9%)	89.2% (87.4% to 90.8%)	85.0% (83.2% to 86.7%)
	16	80.1% (78.5% to 81.6%)	78.3% (76.6% to 79.8%)	54.5% (52.2% to 56.7%)	90.7% (89.4% to 91.9%)	86.5% (85.1% to 87.8%)
	33	77.8% (76.5% to 79.0%)	73.2% (71.8% to 74.5%)	50.9% (49.3% to 52.4%)	87.8% (86.7% to 88.7%)	84.0% (82.8% to 85.1%)
	29	77.4% (73.3% to 81.1%)	72.1% (67.7% to 76.1%)	63.1% (57.6% to 68.2%)	89.4% (85.4% to 92.3%)	83.6% (79.8% to 86.7%)
	13	79.2% (76.7% to 81.5%)	76.8% (74.3% to 79.2%)	56.8% (53.9% to 59.7%)	88.5% (86.5% to 90.3%)	84.6% (82.3% to 86.6%)
	12	65.6% (62.9% to 68.1%)	62.4% (59.7% to 65.1%)	48.3% (45.6% to 51.1%)	81.8% (79.6% to 83.9%)	74.7% (72.2% to 77.0%)
	28	85.2% (83.4% to 86.8%)	81.6% (79.7% to 83.4%)	62.0% (59.6% to 64.4%)	92.9% (91.5% to 94.0%)	89.6% (88.1% to 91.0%)
	6	79.4% (78.1% to 80.7%)	73.5% (72.1% to 74.9%)	57.9% (56.2% to 59.6%)	90.3% (89.2% to 91.2%)	85.2% (84.1% to 86.3%)
	27	75.9% (74.5% to 77.2%)	71.9% (70.5% to 73.3%)	48.2% (46.5% to 49.8%)	86.9% (85.7% to 88.0%)	82.9% (81.6% to 84.1%)
	18	73.8% (70.2% to 77.1%)	65.8% (62.0% to 69.4%)	54.7% (50.7% to 58.5%)	84.4% (81.3% to 87.0%)	78.8% (75.4% to 81.8%)
	7	75.1% (73.6% to 76.6%)	68.4% (66.8% to 70.0%)	51.5% (49.7% to 53.2%)	86.5% (85.2% to 87.6%)	81.5% (80.1% to 82.8%)
	22	78.7% (74.1% to 82.7%)	68.9% (63.8% to 73.6%)	47.8% (42.5% to 53.1%)	88.0% (84.0% to 91.0%)	84.1% (79.8% to 87.6%)
	17	78.4% (76.8% to 79.9%)	73.7% (71.9% to 75.3%)	48.2% (46.2% to 50.2%)	87.1% (85.7% to 88.3%)	83.9% (82.4% to 85.3%)
Total		77.3% (77.0% to 77.6%)	72.3% (72.0% to 72.7%)	53.3% (53.0% to 53.7%)	88.1% (87.8% to 88.3%)	83.6% (83.3% to 83.9%)

SS13 (cont)

Completeness and caseness levels, initial symptom and W&SAS scores

Site code	Rating of W&SAS where available		
	Any problems sub-clinical	Moderate problems	Severe problems
4	24.9% (23.0% to 27.0%)	45.0% (42.7% to 47.3%)	30.1% (28.0% to 32.3%)
23	20.0% (18.8% to 21.3%)	38.2% (36.7% to 39.8%)	41.7% (40.2% to 43.3%)
20	17.1% (15.4% to 19.0%)	42.6% (40.3% to 44.9%)	40.3% (38.0% to 42.6%)
19	23.6% (21.2% to 26.1%)	44.8% (42.0% to 47.6%)	31.6% (29.0% to 34.3%)
14	27.3% (25.9% to 28.8%)	37.1% (35.6% to 38.7%)	35.6% (34.0% to 37.1%)
5	23.6% (22.1% to 25.2%)	38.4% (36.6% to 40.2%)	38.0% (36.2% to 39.8%)
8	22.2% (20.5% to 24.0%)	43.8% (41.7% to 45.9%)	34.0% (32.0% to 36.1%)
9	23.8% (21.9% to 25.8%)	40.3% (38.0% to 42.6%)	36.0% (33.8% to 38.2%)
24	25.6% (24.5% to 26.8%)	43.0% (41.7% to 44.3%)	31.4% (30.2% to 32.6%)
36	28.1% (26.8% to 29.4%)	42.3% (40.9% to 43.8%)	29.5% (28.2% to 30.9%)
10	15.6% (13.9% to 17.4%)	34.6% (32.4% to 36.9%)	49.8% (47.4% to 52.2%)
30	41.8% (37.8% to 45.9%)	37.9% (33.9% to 41.9%)	20.4% (17.2% to 23.9%)
21	22.9% (20.8% to 25.0%)	37.8% (35.4% to 40.3%)	39.3% (36.9% to 41.8%)
11	15.0% (13.5% to 16.6%)	31.1% (29.1% to 33.2%)	53.9% (51.7% to 56.1%)
25	25.5% (24.3% to 26.7%)	45.0% (43.7% to 46.4%)	29.5% (28.3% to 30.8%)
15	16.9% (14.6% to 19.6%)	33.6% (30.6% to 36.8%)	49.4% (46.1% to 52.7%)
31	19.3% (18.3% to 20.3%)	42.5% (41.2% to 43.8%)	38.2% (37.0% to 39.5%)
32	32.7% (30.4% to 35.1%)	39.6% (37.1% to 42.1%)	27.7% (25.5% to 30.0%)
26	19.9% (17.5% to 22.5%)	42.0% (39.0% to 45.1%)	38.1% (35.2% to 41.2%)
3	20.6% (18.6% to 22.8%)	41.1% (38.6% to 43.7%)	38.3% (35.8% to 40.8%)
16	22.3% (20.5% to 24.1%)	39.6% (37.6% to 41.7%)	38.1% (36.1% to 40.2%)
33	24.6% (23.3% to 26.0%)	43.2% (41.6% to 44.7%)	32.2% (30.8% to 33.7%)
29	20.5% (16.9% to 24.5%)	45.3% (40.7% to 50.0%)	34.3% (29.9% to 38.8%)
13	27.9% (25.4% to 30.6%)	40.2% (37.3% to 43.0%)	32.0% (29.3% to 34.7%)
12	26.5% (24.1% to 29.0%)	42.6% (39.9% to 45.4%)	30.9% (28.4% to 33.5%)
28	15.2% (13.5% to 17.0%)	26.2% (24.1% to 28.4%)	58.7% (56.2% to 61.1%)
6	23.4% (22.1% to 24.8%)	40.4% (38.8% to 42.0%)	36.2% (34.6% to 37.7%)
27	24.7% (23.3% to 26.1%)	43.4% (41.8% to 45.0%)	31.9% (30.4% to 33.5%)
18	40.2% (36.4% to 44.1%)	32.0% (28.4% to 35.8%)	27.8% (24.4% to 31.5%)
7	24.4% (22.9% to 25.9%)	43.3% (41.5% to 45.0%)	32.4% (30.8% to 34.1%)
22	27.3% (22.9% to 32.3%)	41.9% (36.8% to 47.1%)	30.8% (26.2% to 35.9%)
17	27.1% (25.3% to 28.9%)	39.1% (37.1% to 41.1%)	33.8% (31.9% to 35.8%)
Total	23.7% (23.4% to 24.0%)	40.7% (40.4% to 41.1%)	35.6% (35.3% to 36.0%)

SS14

Initial symptom and W&SAS scores: medians and inter quartile ranges for sites

Site	Site code	Records	PHQ	GAD7	Phobia scores	W&SAS
	4	1746	13 (8 to 18)	13 (8 to 17)	6 (3 to 11)	15 (10 to 22)
	23	3687	15 (10 to 20)	13 (8 to 17)	7 (3 to 13)	18 (11 to 25)
	20	1786	14 (9 to 19)	12 (8 to 17)	6 (3 to 12)	18 (12 to 25)
	19	1196	13 (8 to 18)	12 (7 to 16)	6 (2 to 11)	16 (10 to 22)
	8	3801	14 (8 to 19)	13 (8 to 17)	6 (2 to 11)	16 (8 to 24)
	14	2891	13 (8 to 19)	12 (7 to 17)	6 (2 to 12)	17 (10 to 25)
	5	2219	14 (9 to 19)	13 (8 to 17)	6 (2 to 11)	16 (10 to 24)
	9	1870	13 (8 to 19)	12 (7 to 17)	6 (2 to 11)	17 (10 to 25)
	24	6060	14 (9 to 19)	13 (8 to 17)	6 (2 to 10)	16 (9 to 23)
	36	4555	14 (9 to 19)	13 (8 to 17)	6 (2 to 11)	15 (8 to 22)
	10	1793	15 (9 to 20)	13 (9 to 17)	7 (3 to 13)	20 (13 to 28)
	30	570	11 (3 to 18)	10 (3 to 16)	4 (0 to 9)	12 (2 to 19)
	21	1603	15 (9 to 19)	13 (8 to 17)	8 (4 to 13)	17 (10 to 25)
	11	2023	15 (10 to 20)	13 (9 to 17)	8 (2 to 14)	22 (13 to 30)
	25	5326	14 (9 to 19)	12 (7 to 17)	6 (2 to 10)	15 (9 to 22)
	15	2262	17 (12 to 21)	15 (11 to 18)	8 (4 to 14)	20 (12 to 28)
	31	5912	15 (9 to 20)	13 (8 to 17)	6 (3 to 11)	17 (11 to 24)
	32	1516	13 (8 to 18)	12 (7 to 17)	4 (0 to 10)	14 (7 to 22)
	26	1441	15 (10 to 19)	13 (8 to 16)	6 (2 to 10)	17 (11 to 24)
	3	1618	15 (9 to 20)	13 (8 to 17)	6 (2 to 12)	18 (11 to 25)
	16	2550	16 (10 to 20)	14 (9 to 17)	6 (2 to 12)	17 (10 to 25)
	33	4103	15 (9 to 19)	13 (8 to 17)	6 (2 to 11)	16 (10 to 23)
	29	442	13 (9 to 18)	12 (8 to 17)	9 (4 to 12)	16 (11 to 24)
	13	1135	16 (10 to 21)	15 (9 to 18)	7 (3 to 13)	15 (9 to 23)
	12	1254	12 (7 to 18)	11 (6 to 16)	6 (2 to 11)	15 (9 to 22)
	28	1650	17 (11 to 21)	15 (10 to 18)	8 (2 to 14)	23 (14 to 31)
	6	3826	15 (9 to 20)	13 (9 to 17)	7 (3 to 13)	17 (10 to 25)
	27	3743	14 (9 to 19)	13 (8 to 17)	5 (2 to 10)	15 (10 to 23)
	18	626	13 (7 to 18)	13 (7 to 16)	7 (2 to 13)	13 (0 to 21)
	7	3120	13 (8 to 19)	13 (8 to 17)	6 (3 to 11)	16 (10 to 23)
	22	346	13 (8 to 18)	13 (8 to 16)	5 (2 to 12)	15 (9 to 23)
	17	2640	15 (9 to 20)	14 (8 to 18)	6 (2 to 11)	16 (8 to 24)
Total		79310	14 (9 to 19)	13 (8 to 17)	6 (2 to 12)	16 (10 to 24)

SS15

Totals for the three counts of patient contacts by site, and average contacts per patient.

Site	Site code	total patients	Session counts				Sessions per patient				Session ratios by treatment type		
			by therapist type	by treatment type	by purpose of session	by purpose where treatment included	by therapist type	by treatment type	by purpose of session	by purpose where treatment included	Low intensity only	High intensity only	Both low and high intensity
	4	1746	4190	10283	8258	6070	2.4	5.9	4.7	3.5	1.90	1.42	1.69
	23	3687	13260	15270	15273	11889	3.6	4.1	4.1	3.2	1.26	1.21	1.14
	20	1786	5778	5882	6131	4331	3.2	3.3	3.4	2.4	1.29	1.39	1.43
	19	1196	195	4610	5079	4039	0.2	3.9	4.2	3.4	1.18	1.11	1.20
	14	3801	15374	17681	17150	10659	4.0	4.7	4.5	2.8	2.11	1.45	1.74
	5	2891	800	9876	8929	5928	0.3	3.4	3.1	2.1	1.80	1.40	1.64
	8	2219	5179	8639	7924	5917	2.3	3.9	3.6	2.7	1.71	1.24	1.56
	9	1870	6746	8279	7106	4921	3.6	4.4	3.8	2.6	1.95	1.28	1.67
	24	6060	6008	14261	18426	12665	1.0	2.4	3.0	2.1	1.39	1.02	1.16
	36	4555	11046	15137	15146	10465	2.4	3.3	3.3	2.3	1.47	1.41	1.36
	10	1793	6347	7366	6380	3912	3.5	4.1	3.6	2.2	2.05	1.33	2.36
	30	570	1383	1284	321	189	2.4	2.3	0.6	0.3	10.63	8.61	3.72
	21	1603	5125	5952	5570	4536	3.2	3.7	3.5	2.8	1.41	1.17	1.55
	11	2023	7083	7508	7291	4578	3.5	3.7	3.6	2.3	2.03	1.21	1.57
	25	5326	11519	16613	9112	6086	2.2	3.1	1.7	1.1	4.41	1.44	3.06
	15	2262	8993	8860	6780	4542	4.0	3.9	3.0	2.0	2.00	1.93	-
	31	5912	5776	17100	17316	9999	1.0	2.9	2.9	1.7	1.87	1.49	1.79
	32	1516	3763	2459	3071	2498	2.5	1.6	2.0	1.6	1.29	-	-
	26	1441	3710	4872	3541	890	2.6	3.4	2.5	0.6	23.21	1.79	3.06
	3	1618	8354	6738	6917	4524	5.2	4.2	4.3	2.8	1.73	1.37	1.35
	16	2550	1960	8242	6861	4149	0.8	3.2	2.7	1.6	2.44	1.41	2.46
	33	4103	13830	13857	13856	10634	3.4	3.4	3.4	2.6	1.32	1.29	1.25
	29	442	0	0	0	0	-	-	-	-	-	-	-
	13	1135	2241	2967	2977	1698	2.0	2.6	2.6	1.5	1.33	1.38	1.20
	12	1254	4026	5364	5368	4044	3.2	4.3	4.3	3.2	1.72	1.19	1.20
	28	1650	0	6595	5338	3687	0.0	4.0	3.2	2.2	1.66	2.14	1.96
	6	3826	11672	16294	14329	9775	3.1	4.3	3.7	2.6	2.27	1.31	1.72
	27	3743	9260	15230	7320	5830	2.5	4.1	2.0	1.6	7.97	1.36	2.78
	18	626	1759	1815	1816	1720	2.8	2.9	2.9	2.7	1.11	1.01	1.07
	7	3120	10961	11393	11273	7600	3.5	3.7	3.6	2.4	1.61	1.35	1.53
	22	346	1506	1416	1416	1011	4.4	4.1	4.1	2.9	1.39	1.45	1.20
	17	2640	3607	9671	9225	5790	1.4	3.7	3.5	2.2	1.53	1.74	1.69
Total		79310	191451	281514	255500	174576	2.4	3.5	3.2	2.2	1.80	1.36	1.78

Note that rates in this table would be expected to be lower than counts later in the report showing activity for patients with terminated episodes as in many cases treatment was continuing.

SS16

Numbers of therapist contact sessions reported for study group patients; total by Agenda For Change grade and in broad categories of low skill (AFC 1 to 5) and high skill (AFC 6 and above)

Site	Site code	Total reported therapist sessions	All low skill	All high skill	Low skill				
					AFC grade 1	AFC grade 2	AFC grade 3	AFC grade 4	AFC grade 5
	4	4,190	0.1%	99.9%	-	-	0.1%	-	-
	23	13,260	38.4%	61.6%	-	-	-	5.9%	32.5%
	20	5,778	45.2%	54.8%	-	-	0.3%	42.4%	2.5%
	19	195	-	100.0%	-	-	-	-	-
	14	15,374	35.8%	64.2%	-	-	-	1.9%	33.9%
	5	800	55.6%	44.4%	-	-	-	55.6%	-
	8	5,179	47.2%	52.8%	-	-	-	34.6%	12.6%
	9	6,746	44.7%	55.3%	-	-	-	25.5%	19.2%
	24	6,008	55.6%	44.4%	7.7%	-	2.6%	9.3%	36.0%
	36	11,046	39.6%	60.4%	-	1.6%	-	3.0%	35.0%
	10	6,347	69.3%	30.7%	-	-	-	-	69.3%
	30	1,383	36.3%	63.7%	-	-	-	32.5%	3.8%
	21	5,125	60.8%	39.2%	-	-	0.5%	0.5%	59.7%
	11	7,083	52.9%	47.1%	-	-	-	12.4%	40.5%
	25	11,519	86.4%	13.6%	-	-	4.1%	32.2%	50.1%
	15	8,993	44.9%	55.1%	-	-	-	19.7%	25.2%
	31	5,776	23.8%	76.2%	-	-	-	9.6%	14.2%
	32	3,763	42.5%	57.5%	-	-	-	21.6%	21.0%
	26	3,710	67.8%	32.2%	-	-	2.2%	65.5%	-
	3	8,354	20.9%	79.1%	-	-	-	5.8%	15.2%
	16	1,960	74.9%	25.1%	-	-	-	55.7%	19.2%
	33	13,830	58.4%	41.6%	-	-	-	21.3%	37.1%
	29	-	-	-	-	-	-	-	-
	13	2,241	30.8%	69.2%	14.8%	-	2.4%	7.7%	6.0%
	12	4,026	28.5%	71.5%	-	-	-	7.8%	20.7%
	28	-	-	-	-	-	-	-	-
	6	11,672	56.7%	43.3%	-	-	-	56.7%	-
	27	9,260	84.3%	15.7%	-	-	0.5%	23.2%	60.6%
	18	1,759	41.6%	58.4%	-	-	-	7.3%	34.2%
	7	10,961	45.3%	54.7%	-	-	-	7.0%	38.2%
	22	1,506	38.3%	61.7%	-	-	-	38.3%	-
	17	3,607	7.3%	92.7%	-	-	-	7.3%	-
Total		191,451	48.1%	51.9%	0.4%	0.1%	0.5%	18.0%	29.2%

SS16 (cont)

Numbers of therapist contact sessions reported for study group patients; total by Agenda For Change grade and in broad categories of low skill (AFC 1 to 5) and high skill (AFC 6 and above)

Site	Site code	High skill					
		AFC grade 6	AFC grade 7	AFC grade 8a	AFC grade 8b	AFC grade 8c	AFC grade 8d
	4	62.7%	22.5%	14.7%	-	-	-
	23	37.0%	23.4%	0.9%	0.3%	-	-
	20	54.4%	-	0.4%	-	-	-
	19	53.3%	46.7%	-	-	-	-
	14	55.2%	6.7%	0.8%	-	1.6%	-
	5	17.4%	27.0%	-	-	-	-
	8	20.3%	28.1%	1.4%	2.7%	-	0.3%
	9	24.4%	11.8%	8.6%	8.9%	1.6%	-
	24	37.6%	5.3%	-	-	-	1.5%
	36	37.3%	22.2%	-	1.0%	-	-
	10	19.3%	11.3%	-	-	-	-
	30	58.7%	0.9%	4.1%	-	-	-
	21	32.0%	6.7%	0.5%	-	-	-
	11	23.6%	12.8%	6.4%	4.2%	-	-
	25	11.9%	0.9%	0.7%	-	-	-
	15	44.7%	10.3%	0.1%	-	-	-
	31	72.2%	3.0%	1.0%	-	-	-
	32	56.0%	1.4%	0.1%	-	-	-
	26	28.2%	4.0%	-	-	-	-
	3	60.9%	10.7%	4.3%	2.1%	0.5%	0.5%
	16	24.0%	1.0%	-	-	-	-
	33	29.0%	8.1%	3.6%	0.9%	-	-
	29	-	-	-	-	-	-
	13	53.5%	15.6%	-	-	-	-
	12	6.7%	40.6%	15.9%	7.3%	-	0.9%
	28	-	-	-	-	-	-
	6	36.9%	5.8%	0.1%	0.5%	-	-
	27	10.7%	2.2%	2.7%	-	-	-
	18	39.5%	18.8%	0.1%	-	-	-
	7	21.0%	33.2%	0.5%	-	-	-
	22	61.7%	-	-	-	-	-
	17	79.0%	4.7%	6.6%	1.2%	1.1%	-
Total		36.4%	11.9%	2.2%	1.0%	0.2%	0.1%

SS17

Totals for treatment sessions by type of therapy reported by sites for study group patients.

Site code	Low intensity						High intensity (% of high intensity)				Other inter-ventions
	Computer-ised CBT	Pure self help	Guided self help	Behavioural activation	Structured exercise	Psycho-educ'l group	CBT	IPT	Counselling	Couple therapy	
4	558	2174	447	683	536	63	4,387 (98.8%)	2 (.%)	43 (1.%)	7 (.2%)	1383
23	27	50	3052	94	1	1654	4,961 (67.6%)	5 (.1%)	2,366 (32.3%)	3 (.%)	3057
20	78	440	389	192	29	937	3,448 (98.4%)	1 (.%)	54 (1.5%)	-	314
19	198	828	227	1	0	428	2,581 (99.5%)	-	11 (.4%)	1 (.%)	335
14	132	1999	2637	643	262	165	6,362 (60.1%)	131 (1.2%)	4,099 (38.7%)	2 (.%)	1249
5	68	1796	2383	210	219	135	3,611 (93.2%)	66 (1.7%)	193 (5.%)	4 (.1%)	1191
8	159	637	2219	265	112	65	4,049 (97.7%)	1 (.%)	92 (2.2%)	1 (.%)	1039
9	57	706	2520	811	81	61	3,603 (98.5%)	3 (.1%)	42 (1.1%)	11 (.3%)	384
24	1662	407	2726	653	53	69	4,188 (51.9%)	85 (1.1%)	3,793 (47.%)	8 (.1%)	617
36	141	50	3306	67	11	745	4,699 (47.6%)	148 (1.5%)	5,004 (50.7%)	17 (.2%)	949
10	69	1834	2371	129	9	20	2,023 (90.%)	1 (.%)	218 (9.7%)	5 (.2%)	687
30	107	82	314	104	8	4	390 (66.6%)	1 (.2%)	195 (33.3%)	-	79
21	14	966	1049	167	99	540	2,307 (92.4%)	10 (.4%)	177 (7.1%)	3 (.1%)	620
11	455	560	2535	194	9	436	2,311 (77.8%)	1 (.%)	659 (22.2%)	1 (.%)	347
25	317	1648	386	160	140	5392	1,304 (19.8%)	5 (.1%)	5,244 (79.7%)	29 (.4%)	1988
15	25	0	2919	3	0	0	2,777 (47.3%)	180 (3.1%)	2,919 (49.7%)	-	37
31	10	2821	2792	1070	600	361	4,318 (61.8%)	196 (2.8%)	2,461 (35.2%)	10 (.1%)	2461
32	1583	876	0	0	0	0	-	-	-	-	-
26	117	870	130	8	7	1518	915 (73.7%)	1 (.1%)	325 (26.2%)	1 (.1%)	980
3	7	9	601	25	7	14	2,560 (66.2%)	423 (10.9%)	857 (22.2%)	26 (.7%)	2209
16	207	1793	1263	1211	77	0	2,625 (85.7%)	6 (.2%)	430 (14.%)	1 (.%)	629
33	229	305	4420	686	290	183	3,642 (51.7%)	57 (.8%)	3,328 (47.3%)	16 (.2%)	701
29	-	-	-	-	-	-	-	-	-	-	-
13	22	0	279	0	0	176	723 (52.4%)	-	640 (46.4%)	17 (1.2%)	1110
12	173	152	516	46	0	192	3,486 (99.8%)	-	7 (.2%)	(.%)	792
28	185	284	3271	118	35	24	657 (46.3%)	3 (.2%)	756 (53.3%)	3 (.2%)	1259
6	528	2590	1562	883	707	15	5,288 (64.7%)	1 (.%)	2,853 (34.9%)	34 (.4%)	1833
27	476	1393	367	180	85	5406	1,952 (29.3%)	12 (.2%)	4,657 (69.8%)	47 (.7%)	655
18	109	3	153	22	0	166	750 (99.7%)	-	2 (.3%)	(.%)	610
7	631	1798	2421	314	307	149	5,223 (96.3%)	1 (.%)	198 (3.7%)	2 (.%)	349
22	0	0	483	0	0	2	931 (100.%)	-	-	-	-
17	11	946	495	756	500	5	3,144 (61.2%)	-	1,992 (38.8%)	3 (.1%)	1819
Total	8355	28017	48233	9695	4184	18925	89,215 (66.4%)	1,340 (1.%)	43,615 (32.4%)	252 (.2%)	29683

Pattern of treatments for study group patients with finished episodes of care who received at least some treatment.

Site	Site code	Total treated	Low no high			High no low			Both low and high		
			Number (% of total)	1 contact	2+ contacts	Number (% of total)	1 contact	2+ contacts	Number (% of total)	1 contact	2+ contacts
	4	1223	599 (49.0%)	21%	79%	226 (18.5%)	23%	77%	377 (30.8%)	4%	96%
	23	2574	1,079 (41.9%)	19%	81%	531 (20.6%)	4%	96%	165 (6.4%)	0%	100%
	20	1237	559 (45.2%)	5%	95%	441 (35.7%)	12%	88%	166 (13.4%)	2%	98%
	19	379	138 (36.4%)	18%	82%	151 (39.8%)	33%	67%	60 (15.8%)	3%	97%
	14	2330	714 (30.6%)	21%	79%	942 (40.4%)	14%	86%	589 (25.3%)	3%	97%
	5	1783	921 (51.7%)	35%	65%	376 (21.1%)	38%	63%	277 (15.5%)	14%	86%
	8	1189	726 (61.1%)	31%	69%	292 (24.6%)	17%	83%	85 (7.1%)	4%	96%
	9	748	373 (49.9%)	27%	73%	106 (14.2%)	27%	73%	226 (30.2%)	4%	96%
	24	223	97 (43.5%)	44%	56%	67 (30.0%)	30%	70%	38 (17.0%)	0%	100%
	36	1833	440 (24.0%)	30%	70%	992 (54.1%)	48%	52%	234 (12.8%)	0%	100%
	10	1193	699 (58.6%)	49%	51%	164 (13.7%)	51%	49%	176 (14.8%)	65%	35%
	30	109	61 (56.0%)	36%	64%	25 (22.9%)	28%	72%	7 (6.4%)	0%	100%
	21	1029	583 (56.7%)	10%	90%	243 (23.6%)	10%	90%	135 (13.1%)	4%	96%
	11	1153	736 (63.8%)	30%	70%	175 (15.2%)	14%	86%	74 (6.4%)	8%	92%
	25	3726	1,190 (31.9%)	71%	29%	910 (24.4%)	52%	48%	1,225 (32.9%)	41%	59%
	15	1125	526 (46.8%)	25%	75%	568 (50.5%)	10%	90%	(0.0%)	-	-
	31	2996	1,247 (41.6%)	44%	56%	480 (16.0%)	20%	80%	695 (23.2%)	4%	96%
	26	503	334 (66.4%)	10%	90%	28 (5.6%)	18%	82%	57 (11.3%)	2%	98%
	3	562	72 (12.8%)	8%	92%	260 (46.3%)	3%	97%	9 (1.6%)	0%	100%
	16	1504	784 (52.1%)	33%	67%	324 (21.5%)	23%	77%	310 (20.6%)	13%	87%
	33	2121	1,087 (51.2%)	33%	67%	765 (36.1%)	26%	74%	143 (6.7%)	0%	100%
	29	127	(0.0%)	-	-	(0.0%)	-	-	(0.0%)	-	-
	13	356	43 (12.1%)	28%	72%	121 (34.0%)	23%	77%	6 (1.7%)	0%	100%
	12	569	185 (32.5%)	31%	69%	242 (42.5%)	26%	74%	35 (6.2%)	0%	100%
	28	951	637 (67.0%)	23%	77%	67 (7.0%)	39%	61%	123 (12.9%)	12%	88%
	6	2376	1,087 (45.7%)	32%	68%	699 (29.4%)	20%	80%	396 (16.7%)	13%	87%
	27	2678	510 (19.0%)	46%	54%	726 (27.1%)	60%	40%	1,406 (52.5%)	40%	60%
	18	226	3 (1.3%)	0%	100%	37 (16.4%)	5%	95%	3 (1.3%)	0%	100%
	7	1795	918 (51.1%)	41%	59%	509 (28.4%)	31%	69%	280 (15.6%)	6%	94%
	22	155	45 (29.0%)	7%	93%	91 (58.7%)	7%	93%	19 (12.3%)	0%	100%
	17	1046	465 (44.5%)	22%	78%	376 (35.9%)	5%	95%	58 (5.5%)	2%	98%
Totals		39819	16,858 (42.3%)	32%	68%	10,934 (27.5%)	27%	73%	7,374 (18.5%)	19%	81%

SS18 (cont)

Pattern of treatments for study group patients with finished episodes of care who received at least some treatment.

Site	Site code	Other treatment only			Treated - type not recorded		
		Number (% of total)	1 contact	2+ contacts	Number (% of total)	1 contact	2+ contacts
	4	21 (1.7%)	71%	29%	(0.0%)	-	-
	23	799 (31.0%)	79%	21%	(0.0%)	-	-
	20	52 (4.2%)	23%	77%	19 (1.5%)	11%	89%
	19	18 (4.7%)	78%	22%	12 (3.2%)	75%	25%
	14	34 (1.5%)	47%	53%	51 (2.2%)	67%	33%
	5	201 (11.3%)	91%	9%	8 (0.4%)	25%	75%
	8	66 (5.6%)	74%	26%	20 (1.7%)	60%	40%
	9	26 (3.5%)	77%	23%	17 (2.3%)	35%	65%
	24	20 (9.0%)	85%	15%	1 (0.4%)	100%	0%
	36	167 (9.1%)	93%	7%	(0.0%)	-	-
	10	150 (12.6%)	95%	5%	4 (0.3%)	75%	25%
	30	10 (9.2%)	90%	10%	6 (5.5%)	50%	50%
	21	67 (6.5%)	3%	97%	1 (0.1%)	0%	100%
	11	122 (10.6%)	87%	13%	46 (4.0%)	91%	9%
	25	327 (8.8%)	89%	11%	74 (2.0%)	84%	16%
	15	26 (2.3%)	85%	15%	5 (0.4%)	20%	80%
	31	379 (12.7%)	65%	35%	195 (6.5%)	69%	31%
	26	80 (15.9%)	51%	49%	4 (0.8%)	50%	50%
	3	200 (35.6%)	28%	73%	21 (3.7%)	62%	38%
	16	25 (1.7%)	76%	24%	61 (4.1%)	15%	85%
	33	126 (5.9%)	69%	31%	(0.0%)	-	-
	29	(0.0%)	-	-	127 (100.0%)	100%	0%
	13	186 (52.2%)	86%	14%	(0.0%)	-	-
	12	106 (18.6%)	71%	29%	1 (0.2%)	100%	0%
	28	115 (12.1%)	71%	29%	9 (0.9%)	56%	44%
	6	177 (7.4%)	47%	53%	17 (0.7%)	41%	59%
	27	18 (0.7%)	72%	28%	18 (0.7%)	83%	17%
	18	37 (16.4%)	46%	54%	146 (64.6%)	100%	0%
	7	71 (4.0%)	86%	14%	17 (0.9%)	47%	53%
	22	(0.0%)	-	-	(0.0%)	-	-
	17	99 (9.5%)	45%	55%	48 (4.6%)	42%	58%
Totals		3,725 (9.4%)	72%	28%	928 (2.3%)	72%	28%

SS19

Patterns of low intensity treatments received by study group patients with finished episodes

Site	Site code	Total with Low Intensity treatments	Numbers having multiple types				
			1 type	2 types	3 types	4 types	5 types
	4	976	49.2%	32.5%	15.0%	3.3%	0.1%
	23	1244	90.4%	9.6%	-	-	-
	20	725	82.2%	16.4%	1.4%	-	-
	19	198	71.2%	26.8%	2.0%	-	-
	14	1303	60.2%	31.2%	7.1%	1.4%	0.2%
	5	1198	76.8%	18.6%	4.2%	0.3%	0.1%
	8	811	63.0%	28.7%	7.5%	0.7%	-
	9	599	61.9%	29.2%	7.8%	1.0%	-
	24	135	79.3%	17.0%	3.7%	-	-
	36	674	90.5%	9.3%	0.1%	-	-
	10	875	73.3%	24.0%	2.4%	0.3%	-
	30	68	70.6%	23.5%	5.9%	-	-
	21	718	65.2%	28.8%	5.3%	0.7%	-
	11	810	73.8%	22.0%	3.8%	0.4%	-
	25	2415	73.4%	20.8%	4.3%	1.2%	0.2%
	15	526	100.0%	-	-	-	-
	31	1942	70.1%	22.5%	6.9%	0.5%	-
	26	391	63.2%	29.2%	6.9%	0.8%	-
	3	81	93.8%	6.2%	-	-	-
	16	1094	49.4%	35.1%	14.1%	1.5%	-
	33	1230	78.9%	17.1%	3.7%	0.3%	-
	13	49	95.9%	4.1%	-	-	-
	12	220	88.6%	10.0%	1.4%	-	-
	28	760	80.8%	16.7%	2.4%	0.1%	-
	6	1483	60.1%	26.1%	11.1%	2.4%	0.3%
	27	1916	72.0%	22.9%	4.4%	0.5%	0.2%
	18	6	83.3%	16.7%	-	-	-
	7	1198	69.1%	24.1%	5.7%	1.1%	-
	22	64	100.0%	-	-	-	-
	17	523	57.6%	33.8%	7.6%	1.0%	-
Totals		24232	71.1%	22.4%	5.6%	0.8%	0.1%

The table shows total numbers of patients having low intensity interventions (irrespective of whether they received high intensity as well), numbers having multiple types, having each type (patients may be multiply counted in this section) and receiving the most common combinations of approach.

SS19 (cont)

Patterns of low intensity treatments received by study group patients with finished episodes

Site	Site code	Number having each type					Psychoed. group
		Computerised CBT	Pure self help	Guided self help	Behavioural activation	Structured exercise	
	4	23.1%	86.8%	17.3%	26.3%	17.3%	1.8%
	23	0.9%	2.5%	66.8%	3.2%	0.1%	36.2%
	20	3.3%	36.6%	20.7%	8.3%	1.4%	49.0%
	19	12.1%	70.2%	23.2%	0.5% -		24.7%
	14	4.1%	58.9%	59.7%	17.7%	6.3%	3.2%
	5	1.9%	53.3%	56.1%	7.3%	7.2%	2.6%
	8	5.9%	35.9%	83.2%	12.5%	5.2%	3.3%
	9	0.8%	37.1%	81.3%	21.2%	3.5%	4.0%
	24	40.0%	16.3%	39.3%	25.9%	2.2%	0.7%
	36	6.7%	4.3%	81.2%	3.1% -		14.4%
	10	1.7%	89.5%	33.8%	3.7%	0.5%	0.7%
	30	10.3%	39.7%	66.2%	14.7%	4.4% -	
	21	0.7%	55.8%	44.7%	8.1%	5.8%	26.3%
	11	18.5%	38.3%	59.9%	7.5%	0.5%	6.0%
	25	9.8%	41.0%	8.4%	2.7%	2.9%	69.3%
	15	1.3% -		98.5%	0.2% -	-	
	31	0.5%	63.7%	43.7%	16.8%	8.5%	4.6%
	26	11.3%	69.1%	13.8% -		1.0%	50.1%
	3	2.5%	2.5%	91.4%	6.2%	3.7% -	
	16	3.6%	79.2%	45.6%	35.9%	3.4% -	
	33	3.7%	10.7%	84.0%	15.6%	7.3%	4.0%
	13	16.3% -		44.9% -	-		42.9%
	12	12.3%	29.5%	38.6%	5.5% -		26.8%
	28	9.6%	18.3%	86.2%	5.1%	1.1%	1.6%
	6	14.5%	70.9%	38.2%	17.9%	14.7%	0.3%
	27	14.3%	32.7%	7.7%	4.0%	1.1%	74.1%
	18	66.7% -		16.7% -	-		33.3%
	7	11.6%	71.8%	41.2%	6.7%	5.3%	2.1%
	22	-	-	96.9% -	-		3.1%
	17	0.8%	72.5%	30.4%	30.0%	18.4% -	
Totals		7.5%	47.0%	45.3%	11.3%	5.1%	20.2%

The table shows total numbers of patients having low intensity interventions (irrespective of whether they received high intensity as well), numbers having multiple types, having each type (patients may be multiply counted in this section) and receiving the most common combinations of approach.

SS19 (cont)

Patterns of low intensity treatments received by study group patients with finished episodes

Site	Site code	The five most common combinations				
		PSH and GSH	PSH and PsyEd Group	cCBT and PSH	GSH and BA	PSH and BA
	4	11.2%	6.4%	22.1%	0.4%	20.3%
	23	0.2%	1.8%	-	0.2%	-
	20	7.3%	1.8%	1.8%	3.3%	1.7%
	19	13.1%	-	0.5%	9.6%	5.6%
	14	24.3%	9.8%	9.7%	1.2%	2.5%
	5	12.8%	2.3%	5.1%	0.6%	0.9%
	8	24.2%	11.5%	4.6%	-	1.8%
	9	22.0%	17.0%	7.7%	0.8%	0.2%
	24	1.5%	5.9%	4.4%	-	0.7%
	36	1.0%	1.3%	0.1%	0.1%	-
	10	24.9%	2.6%	3.2%	0.1%	0.8%
	30	14.7%	11.8%	4.4%	-	1.5%
	21	21.9%	4.7%	3.2%	6.4%	0.4%
	11	14.0%	6.2%	2.8%	1.6%	2.7%
	25	3.1%	1.0%	1.0%	16.6%	4.7%
	15	-	-	-	-	-
	31	16.4%	8.3%	7.2%	1.6%	0.2%
	26	6.4%	-	-	22.8%	6.1%
	3	1.2%	3.7%	-	-	-
	16	29.3%	19.8%	26.0%	-	2.1%
	33	5.4%	12.2%	2.0%	0.2%	-
	13	-	-	-	-	-
	12	8.2%	1.8%	0.5%	0.5%	0.5%
	28	7.5%	4.6%	0.3%	-	1.1%
	6	18.5%	8.1%	8.5%	0.2%	7.8%
	27	2.0%	0.6%	1.8%	17.5%	4.0%
	18	-	-	-	-	-
	7	19.4%	3.8%	4.3%	1.0%	6.1%
	22	-	-	-	-	-
	17	18.0%	8.2%	16.1%	-	0.2%
Totals		12.4%	5.8%	5.6%	4.2%	3.1%

The table shows total numbers of patients having low intensity interventions (irrespective of whether they received high intensity as well), numbers having multiple types, having each type (patients may be multiply counted in this section) and receiving the most common combinations of approach.

In this final section of the table, combinations accounting for more than 15% of a site's low intensity patients are marked in bold. Individuals in this section may be having other treatments as well.

SS20

Patterns of high intensity treatments received by study group patients with finished episodes

Site	Site code	Total having high intensity treatments	Having multiple types			Having each type			
			1 type	2 types	3 types	CBT	Counselling	Interpersonal therapy	Couple therapy
	4	603	585 (97.0%)	18 (3.0%)	-	578 (95.9%)	35 (5.8%)	1 (0.2%)	7 (1.2%)
	23	696	662 (95.1%)	34 (4.9%)	-	396 (56.9%)	331 (47.6%)	1 (0.1%)	2 (0.3%)
	20	607	600 (98.8%)	7 (1.2%)	-	569 (93.7%)	44 (7.2%)	1 (0.2%)	-
	19	211	211 (100.0%)	-	-	201 (95.3%)	10 (4.7%)	-	-
	14	1,531	1,381 (90.2%)	147 (9.6%)	3 (0.2%)	987 (64.5%)	674 (44.0%)	21 (1.4%)	2 (0.1%)
	5	653	629 (96.3%)	24 (3.7%)	-	500 (76.6%)	135 (20.7%)	38 (5.8%)	4 (0.6%)
	8	377	370 (98.1%)	6 (1.6%)	1 (0.3%)	352 (93.4%)	32 (8.5%)	1 (0.3%)	-
	9	332	325 (97.9%)	7 (2.1%)	-	323 (97.3%)	15 (4.5%)	1 (0.3%)	-
	24	105	84 (80.0%)	21 (20.0%)	-	80 (76.2%)	46 (43.8%)	-	-
	36	1,226	1,098 (89.6%)	123 (10.0%)	5 (0.4%)	531 (43.3%)	794 (64.8%)	29 (2.4%)	5 (0.4%)
	10	340	334 (98.2%)	6 (1.8%)	-	137 (40.3%)	204 (60.0%)	1 (0.3%)	4 (1.2%)
	30	32	32 (100.0%)	-	-	21 (65.6%)	11 (34.4%)	-	-
	21	378	361 (95.5%)	17 (4.5%)	-	301 (79.6%)	87 (23.0%)	5 (1.3%)	2 (0.5%)
	11	249	239 (96.0%)	10 (4.0%)	-	179 (71.9%)	79 (31.7%)	-	1 (0.4%)
	25	2,135	1,801 (84.4%)	333 (15.6%)	1 (0.0%)	445 (20.8%)	2,008 (94.1%)	4 (0.2%)	13 (0.6%)
	15	568	568 (100.0%)	-	-	271 (47.7%)	285 (50.2%)	12 (2.1%)	-
	31	1,175	950 (80.9%)	214 (18.2%)	11 (0.9%)	726 (61.8%)	624 (53.1%)	54 (4.6%)	7 (0.6%)
	26	85	49 (57.6%)	36 (42.4%)	-	66 (77.6%)	54 (63.5%)	1 (1.2%)	-
	3	269	251 (93.3%)	18 (6.7%)	-	166 (61.7%)	70 (26.0%)	38 (14.1%)	13 (4.8%)
	16	634	620 (97.8%)	14 (2.2%)	-	528 (83.3%)	118 (18.6%)	2 (0.3%)	-
	33	908	872 (96.0%)	35 (3.9%)	1 (0.1%)	512 (56.4%)	405 (44.6%)	21 (2.3%)	7 (0.8%)
	13	127	122 (96.1%)	5 (3.9%)	-	41 (32.3%)	87 (68.5%)	-	4 (3.1%)
	12	277	276 (99.6%)	1 (0.4%)	-	273 (98.6%)	5 (1.8%)	-	-
	28	190	185 (97.4%)	5 (2.6%)	-	47 (24.7%)	144 (75.8%)	3 (1.6%)	1 (0.5%)
	6	1,095	1,045 (95.4%)	50 (4.6%)	-	685 (62.6%)	452 (41.3%)	-	8 (0.7%)
	27	2,132	1,742 (81.7%)	385 (18.1%)	5 (0.2%)	465 (21.8%)	2,032 (95.3%)	8 (0.4%)	22 (1.0%)
	18	40	40 (100.0%)	-	-	40 (100.0%)	-	-	-
	7	789	762 (96.6%)	27 (3.4%)	-	714 (90.5%)	100 (12.7%)	-	2 (0.3%)
	22	110	110 (100.0%)	-	-	110 (100.0%)	-	-	-
	17	434	225 (51.8%)	209 (48.2%)	-	343 (79.0%)	299 (68.9%)	-	1 (0.2%)
Totals		18,308	16,529 (90.3%)	1,752 (9.6%)	27 (0.1%)	10,587 (57.8%)	9,180 (50.1%)	242 (1.3%)	105 (0.6%)

SS21		Reasons for ending care episodes, all study group patients with completed episodes							
Site	Site code	Total patients	Completed treatment	Died	Declined treatment	Dropped out of treatment	Not suitable for treatment	Unknown	Unfinished episode or missing or illegal code
	4	1,230	49.8%	-	5.8%	27.3%	14.2%	-	2.8%
	23	2,574	41.1%	-	13.3%	29.6%	16.0%	-	-
	20	1,285	72.0%	-	5.0%	12.1%	8.1%	-	2.9%
	19	486	43.0%	-	14.8%	12.6%	21.0%	-	8.6%
	14	2,372	47.2%	0.2%	13.0%	25.1%	6.1%	-	8.5%
	5	1,891	46.2%	0.1%	14.2%	15.4%	24.2%	-	-
	8	1,290	44.0%	0.2%	9.0%	19.8%	17.9%	-	9.1%
	9	840	31.4%	0.1%	19.6%	25.0%	15.7%	-	8.1%
	24	231	84.4%	-	3.5%	10.0%	2.2%	-	-
	36	1,834	39.3%	-	3.3%	38.6%	18.9%	-	-
	10	1,244	71.8%	-	4.9%	11.5%	10.2%	-	1.6%
	30	172	42.4%	-	9.3%	33.7%	7.0%	7.6%	-
	21	1,042	59.5%	0.1%	4.9%	22.3%	7.5%	-	5.8%
	11	1,265	38.0%	0.1%	12.8%	22.4%	21.2%	-	5.5%
	25	3,782	2.9%	-	0.6%	0.1%	1.0%	95.2%	0.3%
	15	1,163	22.1%	-	8.0%	50.0%	0.7%	19.3%	-
	31	3,587	38.2%	-	10.4%	24.4%	21.3%	-	5.7%
	26	546	26.0%	0.4%	21.8%	33.0%	8.8%	-	10.1%
	3	563	39.8%	-	8.7%	19.5%	-	32.0%	-
	16	1,594	25.2%	0.1%	12.0%	47.6%	9.7%	-	5.5%
	33	2,121	50.6%	0.1%	9.9%	23.3%	7.4%	8.7%	-
	29	147	51.0%	-	8.8%	21.8%	10.2%	7.5%	0.7%
	13	358	74.0%	-	8.1%	17.9%	-	-	-
	12	569	69.8%	-	7.9%	21.8%	0.5%	-	-
	28	969	49.2%	-	12.9%	18.4%	14.3%	-	5.2%
	6	2,421	37.1%	0.1%	12.1%	20.9%	18.0%	-	11.9%
	27	2,700	0.8%	-	0.2%	0.1%	0.0%	98.6%	0.2%
	18	226	33.2%	-	5.8%	11.1%	7.5%	10.2%	32.3%
	7	1,971	42.6%	0.1%	9.8%	23.8%	21.2%	-	2.5%
	22	155	14.8%	-	10.3%	23.9%	-	51.0%	-
	17	1,096	55.5%	0.1%	4.7%	30.2%	3.9%	-	5.6%
Total		41,724	38.0%	0.1%	8.6%	21.3%	11.6%	16.7%	3.7%

SS22

Numbers of recorded contacts for treatment by broad treatment category: study group patients with finished episodes and recorded as having received treatment by site.

Site	Site code	Total patients	Missing data	Low no high treatment				Median (IQR)
				1	2 to 4	5 to 9	10 or more	
	4	599	22.7%	19.9%	57.7%	22.5%	0.0%	3 (2 to 4)
	23	1079	6.3%	30.8%	52.3%	16.5%	0.4%	3 (1 to 4)
	20	559	10.0%	23.9%	71.6%	4.4%	0.2%	2 (2 to 3)
	19	138	21.7%	22.2%	17.6%	58.3%	1.9%	5 (2 to 6)
	14	714	38.2%	35.1%	49.9%	13.4%	1.6%	2 (1 to 4)
	5	921	36.6%	27.9%	51.2%	20.7%	0.2%	2 (1 to 4)
	8	726	18.3%	39.3%	56.7%	4.0%	0.0%	2 (1 to 3)
	9	373	42.6%	31.8%	48.1%	18.7%	1.4%	2 (1 to 4)
	24	97	37.1%	57.4%	41.0%	1.6%	0.0%	1 (1 to 2)
	36	440	24.8%	32.6%	48.3%	18.4%	0.6%	2 (1 to 4)
	10	699	62.8%	20.0%	33.8%	28.8%	17.3%	4 (2 to 8)
	30	61	95.1%	66.7%	33.3%	0.0%	0.0%	1 (1 to 1.5)
	21	583	10.8%	28.7%	58.7%	11.7%	1.0%	2 (1 to 3)
	11	736	45.4%	26.4%	39.6%	33.8%	0.2%	3 (1 to 5)
	25	1190	56.7%	83.3%	14.6%	2.1%	0.0%	1 (1 to 1)
	15	526	41.6%	28.7%	43.3%	27.0%	1.0%	2 (1 to 5)
	31	1247	50.4%	30.7%	51.5%	17.6%	0.2%	2 (1 to 4)
	26	334	86.5%	53.3%	44.4%	2.2%	0.0%	1 (1 to 2)
	3	72	18.1%	32.2%	57.6%	10.2%	0.0%	2 (1 to 3)
	16	784	46.9%	48.1%	44.2%	7.2%	0.5%	2 (1 to 3)
	33	1087	23.5%	33.8%	48.1%	17.3%	0.8%	2 (1 to 4)
	13	43	20.9%	38.2%	44.1%	14.7%	2.9%	2 (1 to 4)
	12	185	33.0%	52.4%	34.7%	12.1%	0.8%	1 (1 to 3)
	28	637	24.6%	27.5%	50.8%	20.8%	0.8%	2 (1 to 4)
	6	1087	41.7%	41.0%	48.3%	10.6%	0.2%	2 (1 to 3)
	27	510	71.4%	83.6%	16.4%	0.0%	0.0%	1 (1 to 1)
	18	3	0.0%	33.3%	0.0%	66.7%	0.0%	5 (3 to 5)
	7	918	45.0%	28.3%	34.5%	33.7%	3.6%	3 (1 to 6)
	22	45	13.3%	15.4%	41.0%	41.0%	2.6%	4 (3 to 6.5)
	17	465	28.6%	16.0%	56.9%	25.6%	1.5%	3 (2 to 5)
Total		16858	37.2%	34.4%	47.7%	16.8%	1.1%	2 (1 to 4)

Table shows for each broad treatment group, the number of patients, the proportion with missing appointment count by purpose (treatment) data, the range of session counts and the median and IQR for the number of sessions where reported.

Two sites (site 32 and Site 29) are missing as they did not report session numbers by session purpose.

SS22 (cont)

Numbers of recorded contacts for treatment by broad treatment category: study group patients with finished episodes and recorded as having received treatment by site.

Site	Site code	Total patients	Missing data	High, no low treatment				Median (IQR)
				1	2 to 4	5 to 9	10 or more	
	4	226	27.0%	21.8%	32.7%	32.7%	12.7%	4 (2 to 7)
	23	531	4.7%	12.6%	30.8%	39.7%	16.8%	5 (2.25 to 8)
	20	441	27.9%	27.4%	29.6%	25.8%	17.3%	4 (1 to 8)
	19	151	20.5%	33.3%	25.0%	25.8%	15.8%	3.5 (1 to 8)
	14	942	22.8%	23.5%	42.2%	26.3%	8.0%	3 (2 to 6)
	5	376	43.1%	20.1%	39.7%	25.2%	15.0%	4 (2 to 6.75)
	8	292	32.9%	7.7%	26.0%	37.2%	29.1%	6.5 (3 to 10.25)
	9	106	36.8%	26.9%	23.9%	32.8%	16.4%	4 (1 to 7.5)
	24	67	25.4%	36.0%	46.0%	18.0%	0.0%	2 (1 to 4)
	36	992	48.5%	22.1%	34.2%	33.9%	9.8%	4 (2 to 6)
	10	164	59.8%	4.5%	28.8%	34.8%	31.8%	6 (3.25 to 10)
	30	25	96.0%	100.0%	0.0%	0.0%	0.0%	1 (1 to 1)
	21	243	11.1%	25.0%	31.5%	24.5%	19.0%	3 (1.75 to 8)
	11	175	25.7%	6.2%	17.7%	34.6%	41.5%	8.5 (5 to 11)
	25	910	23.2%	62.2%	33.6%	3.9%	0.3%	1 (1 to 2)
	15	568	39.1%	34.4%	36.7%	23.4%	5.5%	2 (1 to 5)
	31	480	30.4%	29.3%	42.5%	19.2%	9.0%	3 (1 to 5)
	26	28	50.0%	21.4%	35.7%	42.9%	0.0%	3 (2 to 6)
	3	260	18.1%	13.6%	47.9%	24.9%	13.6%	4 (2 to 6)
	16	324	42.3%	36.4%	46.5%	10.7%	6.4%	2 (1 to 4)
	33	765	25.1%	25.3%	34.0%	30.4%	10.3%	3 (1 to 7)
	13	121	21.5%	33.7%	27.4%	35.8%	3.2%	3 (1 to 6)
	12	242	28.1%	11.5%	23.6%	18.4%	46.6%	9 (3 to 12)
	28	67	58.2%	46.4%	35.7%	10.7%	7.1%	2 (1 to 3)
	6	699	26.8%	16.6%	37.9%	31.1%	14.5%	4 (2 to 7)
	27	726	17.2%	68.9%	26.8%	3.0%	1.3%	1 (1 to 2)
	18	37	0.0%	5.4%	35.1%	29.7%	29.7%	6 (3 to 11)
	7	509	35.2%	29.1%	41.2%	22.7%	7.0%	3 (1 to 5)
	22	91	20.9%	19.4%	38.9%	22.2%	19.4%	4 (2 to 6.25)
	17	376	14.1%	18.0%	35.6%	32.2%	14.2%	4 (2 to 7)
Total		10934	28.4%	29.4%	34.7%	24.1%	11.7%	3 (1 to 6)

Table shows for each broad treatment group, the number of patients, the proportion with missing appointment count by purpose (treatment) data, the range of session counts and the median and IQR for the number of sessions where reported.

Two sites (site 32 and Site 29) are missing as they did not report session numbers by session purpose.

SS22 (cont)

Numbers of recorded contacts for treatment by broad treatment category: study group patients with finished episodes and recorded as having received treatment by site.

Site	Site code	Total patients	Missing data	Both low and high treatment				Median (IQR)
				1	2 to 4	5 to 9	10 or more	
	4	377	8.8%	9.6%	44.8%	32.8%	12.8%	4 (3 to 6)
	23	165	0.6%	1.8%	25.6%	45.7%	26.8%	7 (4 to 10)
	20	166	7.8%	25.5%	46.4%	20.9%	7.2%	3 (1 to 5)
	19	60	5.0%	5.3%	28.1%	52.6%	14.0%	6 (4 to 7)
	14	589	10.4%	17.2%	50.6%	25.4%	6.8%	3 (2 to 5)
	5	277	20.2%	14.0%	41.6%	41.2%	3.2%	4 (2 to 6)
	8	85	9.4%	14.3%	44.2%	24.7%	16.9%	4 (2 to 8)
	9	226	11.1%	13.9%	35.8%	32.8%	17.4%	5 (2 to 8)
	24	38	0.0%	15.8%	60.5%	23.7%	0.0%	3 (2 to 4)
	36	234	4.7%	17.9%	42.6%	29.1%	10.3%	4 (2 to 6)
	10	176	76.7%	22.0%	34.1%	34.1%	9.8%	4 (2 to 7)
	30	7	100.0%	-	-	-	-	0 (0 to 0)
	21	135	7.4%	27.2%	45.6%	22.4%	4.8%	3 (1 to 5)
	11	74	20.3%	18.6%	20.3%	27.1%	33.9%	5 (3 to 11)
	25	1225	31.8%	51.1%	42.0%	6.5%	0.5%	1 (1 to 3)
	15	0	-	-	-	-	-	0 (0 to 0)
	31	695	9.2%	16.0%	48.3%	31.5%	4.1%	3 (2 to 5.5)
	26	57	35.1%	27.0%	40.5%	24.3%	8.1%	3 (1 to 5)
	3	9	0.0%	0.0%	33.3%	44.4%	22.2%	5 (4 to 7)
	16	310	31.3%	29.1%	51.2%	17.4%	2.3%	2 (1 to 4)
	33	143	7.7%	11.4%	37.9%	37.9%	12.9%	5 (2 to 7.25)
	13	6	0.0%	0.0%	16.7%	50.0%	33.3%	7.5 (6.25 to 11)
	12	35	2.9%	5.9%	20.6%	50.0%	23.5%	6.5 (4.25 to 9)
	28	123	22.8%	24.2%	47.4%	21.1%	7.4%	3 (2 to 5)
	6	396	22.2%	17.5%	41.2%	30.5%	10.7%	4 (2 to 6)
	27	1406	15.0%	64.0%	30.3%	4.5%	1.2%	1 (1 to 2)
	18	3	0.0%	0.0%	0.0%	33.3%	66.7%	10 (7.5 to 13)
	7	280	9.3%	22.4%	43.7%	27.6%	6.3%	3 (2 to 5)
	22	19	0.0%	5.3%	31.6%	52.6%	10.5%	6 (2 to 8)
	17	58	15.5%	10.2%	38.8%	44.9%	6.1%	5 (3 to 6)
Total		7374	17.9%	30.8%	40.6%	22.1%	6.5%	3 (1 to 5)

Table shows for each broad treatment group, the number of patients, the proportion with missing appointment count by purpose (treatment) data, the range of session counts and the median and IQR for the number of sessions where reported.

Two sites (site 32 and Site 29) are missing as they did not report session numbers by session purpose.

SS23 Treatment in relation to primary diagnosis. Numbers of study group patients with finished episodes in each of the four largest diagnostic categories and proportion receiving each type of high intensity treatment by site.

Site	Site code	Depressive episode					Generalised anxiety disorder				
		n	CBT	Counselling	IPT	Couple therapy	n	CBT	Counselling	IPT	Couple therapy
	4	186	39.8%	~	-	~	418	45.5%	3.1%	-	~
	23	294	23.5%	14.6%	-	-	210	11.0%	4.3%	-	-
	20	359	34.8%	4.5%	~	-	288	35.4%	~	-	-
	19	65	44.6%	6.2%	-	-	39	41.0%	-	-	-
	14	474	32.5%	32.1%	~	-	274	45.3%	19.3%	-	-
	5	371	22.9%	9.2%	6.2%	~	278	35.6%	4.0%	-	-
	8	347	21.0%	3.5%	-	-	145	9.7%	2.8%	-	-
	9	145	41.4%	2.8%	-	-	79	41.8%	-	-	-
	24	0	-	-	-	-	0	-	-	-	-
	36	77	51.9%	22.1%	~	~	33	33.3%	39.4%	~	-
	10	362	6.4%	20.7%	-	-	84	8.3%	13.1%	-	-
	30	17	-	~	-	-	13	~	~	-	-
	21	175	17.1%	16.0%	~	-	215	23.7%	7.9%	~	~
	11	180	9.4%	5.6%	-	-	88	13.6%	~	-	-
	25	903	16.9%	62.7%	~	0.6%	517	17.6%	71.4%	-	0.8%
	15	314	26.1%	23.9%	-	-	0	-	-	-	-
	31	458	22.5%	30.6%	2.6%	-	264	27.7%	14.4%	1.9%	-
	26	231	9.5%	11.7%	~	-	78	9.0%	~	-	-
	3	4	~	-	~	-	0	-	-	-	-
	16	436	32.3%	6.9%	-	-	100	53.0%	12.0%	~	-
	33	20	20.0%	60.0%	-	-	13	~	30.8%	-	~
	29	12	-	-	-	-	24	-	-	-	-
	13	0	-	-	-	-	0	-	-	-	-
	12	32	43.8%	~	-	-	15	66.7%	-	-	-
	28	61	~	23.0%	-	-	23	~	~	~	-
	6	593	23.8%	21.2%	-	~	415	28.7%	10.4%	-	~
	27	556	19.8%	86.2%	-	0.7%	474	14.6%	86.7%	~	~
	18	0	-	-	-	-	0	-	-	-	-
	7	339	45.7%	5.9%	-	~	268	30.2%	4.5%	-	-
	22	0	-	-	-	-	0	-	-	-	-
	17	161	29.2%	29.8%	-	-	170	12.4%	13.5%	-	-
Totals		7172	24.5%	27.0%	0.6%	0.2%	4525	26.7%	23.3%	0.2%	0.3%

- = No patient; ~ = 1 to 5 patients.

Note, individual patients may have more than one type of treatment.

SS23 (cont)

Treatment in relation to primary diagnosis. Numbers of study group patients with finished episodes in each of the four largest diagnostic categories and proportion receiving each type of high intensity treatment by site.

Site	Site code	Mixed anxiety depressive disorder					Recurrent depressive disorder				
		n	CBT	Counselling	IPT	Couple therapy	n	CBT	Counselling	IPT	Couple therapy
	4	363	46.0%	3.0%	~	~	129	57.4%	4.7%	-	~
	23	411	18.5%	11.9%	-	-	117	32.5%	11.1%	-	-
	20	230	47.8%	4.8%	-	-	118	46.6%	6.8%	-	-
	19	29	51.7%	-	-	-	6	~	-	-	-
	14	316	47.2%	25.0%	~	~	103	41.7%	30.1%	~	-
	5	290	32.8%	4.5%	2.1%	~	131	36.6%	6.9%	~	-
	8	226	38.5%	1.8%	-	-	71	39.4%	~	-	-
	9	59	50.8%	~	-	-	50	42.0%	~	-	-
	24	0	-	-	-	-	0	-	-	-	-
	36	113	48.7%	23.9%	5.3%	-	28	67.9%	~	-	~
	10	223	7.6%	20.6%	-	~	103	17.5%	11.7%	~	~
	30	6	~	-	-	-	1	~	~	~	~
	21	374	16.8%	7.2%	~	~	56	58.9%	8.9%	~	-
	11	345	15.4%	4.6%	-	~	72	11.1%	11.1%	-	-
	25	1104	10.1%	68.4%	~	~	91	14.3%	57.1%	-	-
	15	0	-	-	-	-	0	-	-	-	-
	31	303	25.4%	24.1%	2.0%	-	114	28.9%	23.7%	4.4%	-
	26	104	12.5%	10.6%	-	-	19	~	~	-	-
	3	0	-	-	-	-	5	80.0%	-	-	-
	16	238	49.2%	11.3%	-	-	68	35.3%	5.9%	-	-
	33	64	21.9%	51.6%	-	~	20	65.0%	~	-	-
	29	28	-	-	-	-	9	-	-	-	-
	13	0	-	-	-	-	0	-	-	-	-
	12	33	24.2%	-	-	-	15	60.0%	~	-	-
	28	110	5.5%	25.5%	-	-	19	21.1%	31.6%	~	-
	6	695	29.5%	10.4%	-	~	146	41.1%	13.0%	-	-
	27	861	21.8%	87.7%	0.5%	0.7%	76	26.3%	85.5%	~	-
	18	0	-	-	-	-	1	~	~	~	~
	7	413	39.0%	5.8%	-	-	73	45.2%	~	-	-
	22	0	-	-	-	-	0	-	-	-	-
	17	249	20.9%	21.3%	-	~	35	31.4%	25.7%	-	-
Totals		7187	26.0%	29.4%	0.4%	0.3%	1676	36.8%	17.1%	0.7%	0.2%

- = No patient; ~ = 1 to 5 patients.

Note, individual patients may have more than one type of treatment.

Recovery and incidence rates, net rate changes, seven recovery markers - 'complete data only method'; study group patients with finished episodes including more than one contact and treatment treatment by site. 95% confidence intervals in parentheses.

Site	Site code	Depression - PHQ9 score 10+		
		Recovery rate for cases	Incidence in non-cases	Net change in rate
	4	63.0% (59.2% to 66.7%) n=633	6.2% (4.0% to 9.4%) n=323	-39.6% (-43.7% to -35.5%) n=956
	23	45.0% (42.3% to 47.7%) n=1,315	13.6% (10.6% to 17.3%) n=397	-31.4% (-34.5% to -28.3%) n=1,712
	20	30.3% (27.2% to 33.7%) n=748	10.3% (7.4% to 14.2%) n=311	-18.4% (-22.5% to -14.3%) n=1,059
	19	55.6% (47.9% to 63.0%) n=162	11.5% (6.7% to 19.1%) n=104	-29.3% (-37.4% to -21.2%) n=266
	14	58.0% (55.0% to 60.9%) n=1,071	7.6% (5.5% to 10.4%) n=458	-38.3% (-41.6% to -35.1%) n=1,529
	5	53.1% (49.3% to 56.8%) n=671	7.9% (5.4% to 11.3%) n=330	-33.0% (-37.1% to -28.8%) n=1,001
	8	44.5% (40.3% to 48.8%) n=510	11.8% (8.2% to 16.6%) n=229	-27.1% (-31.9% to -22.2%) n=739
	9	44.5% (39.2% to 49.9%) n=326	12.6% (8.2% to 18.8%) n=151	-26.4% (-32.5% to -20.3%) n=477
	24	57.4% (47.7% to 66.6%) n=101	8.8% (3.0% to 23.0%) n=34	-40.7% (-51.6% to -29.9%) n=135
	36	54.2% (50.6% to 57.8%) n=745	13.1% (9.8% to 17.3%) n=313	-34.3% (-38.3% to -30.3%) n=1,058
	10	39.8% (34.6% to 45.1%) n=327	10.7% (6.3% to 17.4%) n=122	-26.1% (-32.2% to -19.9%) n=449
	30	53.8% (38.6% to 68.4%) n=39	13.3% (5.3% to 29.7%) n=30	-24.6% (-40.7% to -8.6%) n=69
	21	32.7% (29.1% to 36.6%) n=599	12.7% (8.9% to 17.7%) n=221	-20.5% (-25.1% to -15.9%) n=820
	11	43.6% (39.4% to 47.9%) n=521	14.6% (10.1% to 20.7%) n=171	-29.2% (-34.1% to -24.3%) n=692
	25	43.8% (40.7% to 46.9%) n=955	12.2% (9.1% to 16.3%) n=319	-29.7% (-33.4% to -26.1%) n=1,274
	15	32.0% (27.2% to 37.1%) n=341	19.3% (12.2% to 29.0%) n=83	-21.9% (-28.0% to -15.9%) n=424
	31	46.3% (43.5% to 49.0%) n=1,273	11.9% (9.2% to 15.1%) n=463	-30.8% (-33.9% to -27.6%) n=1,736
	26	38.9% (32.5% to 45.6%) n=211	12.5% (6.5% to 22.8%) n=64	-26.9% (-34.6% to -19.2%) n=275
	3	53.5% (47.2% to 59.7%) n=243	14.8% (8.7% to 24.1%) n=81	-36.4% (-43.5% to -29.3%) n=324
	16	41.0% (37.3% to 44.9%) n=653	9.7% (6.1% to 14.9%) n=176	-30.3% (-34.7% to -25.9%) n=829
	33	47.6% (44.6% to 50.6%) n=1,055	11.1% (8.4% to 14.4%) n=425	-30.7% (-34.1% to -27.3%) n=1,480
	13	39.3% (30.9% to 48.4%) n=117	12.9% (5.1% to 28.9%) n=31	-28.4% (-38.8% to -18.0%) n=148
	12	52.1% (45.4% to 58.6%) n=217	7.4% (4.2% to 12.7%) n=149	-27.9% (-34.8% to -20.9%) n=366
	28	48.0% (43.8% to 52.3%) n=525	6.9% (3.5% to 13.0%) n=116	-38.1% (-42.9% to -33.2%) n=641
	6	52.2% (49.3% to 55.0%) n=1,152	6.3% (4.3% to 9.1%) n=400	-37.1% (-40.4% to -33.9%) n=1,552
	27	43.4% (40.0% to 46.8%) n=821	14.8% (11.2% to 19.4%) n=290	-28.2% (-32.1% to -24.3%) n=1,111
	18	30.6% (19.5% to 44.5%) n=49	18.2% (5.1% to 47.7%) n=11	-21.7% (-37.5% to -5.9%) n=60
	7	49.4% (45.9% to 52.9%) n=781	8.1% (5.7% to 11.4%) n=358	-31.3% (-35.2% to -27.5%) n=1,139
	22	57.0% (46.0% to 67.3%) n=79	12.8% (5.6% to 26.7%) n=39	-33.9% (-45.9% to -21.9%) n=118
	17	49.1% (44.9% to 53.4%) n=527	12.2% (8.3% to 17.5%) n=197	-32.5% (-37.3% to -27.6%) n=724
Total		46.9% (46.1% to 47.7%) n=16,767	10.7% (10.0% to 11.5%) n=6,396	-31.0% (-31.9% to -30.1%) n=23,163

ST24 (cont)

Recovery and incidence rates, net rate changes, seven recovery markers - 'complete data only method'; study group patients with finished episodes including more than one contact and treatment treatment by site. 95% confidence intervals in parentheses.

Site	Site code	Anxiety - GAD7 8+		
		Recovery rate for cases	Incidence in non-cases	Net change in rate
	4	60.3% (56.7% to 63.8%) n=731	9.4% (6.2% to 13.9%) n=224	-44.0% (-48.0% to -40.0%) n=955
	23	44.0% (41.4% to 46.6%) n=1,366	18.8% (15.0% to 23.2%) n=346	-31.3% (-34.3% to -28.3%) n=1,712
	20	29.9% (26.9% to 33.2%) n=802	16.5% (12.5% to 21.6%) n=254	-18.8% (-22.7% to -14.8%) n=1,056
	19	51.3% (44.2% to 58.4%) n=187	18.2% (11.2% to 28.2%) n=77	-31.1% (-39.1% to -23.0%) n=264
	14	55.4% (52.5% to 58.2%) n=1,149	9.4% (6.8% to 12.7%) n=385	-39.1% (-42.3% to -35.9%) n=1,534
	5	51.5% (47.9% to 55.0%) n=746	10.6% (7.4% to 15.0%) n=255	-35.7% (-39.7% to -31.6%) n=1,001
	8	42.9% (38.9% to 47.1%) n=557	18.8% (13.8% to 25.1%) n=181	-27.8% (-32.5% to -23.0%) n=738
	9	41.6% (36.6% to 46.8%) n=358	13.4% (8.4% to 20.7%) n=119	-27.9% (-33.8% to -22.0%) n=477
	24	55.6% (46.2% to 64.6%) n=108	14.3% (5.7% to 31.5%) n=28	-41.2% (-51.8% to -30.6%) n=136
	36	51.3% (47.9% to 54.6%) n=835	16.6% (12.3% to 22.0%) n=223	-37.0% (-40.8% to -33.1%) n=1,058
	10	41.1% (36.0% to 46.3%) n=348	18.0% (11.7% to 26.7%) n=100	-27.9% (-33.9% to -21.9%) n=448
	30	46.5% (32.5% to 61.1%) n=43	11.5% (4.0% to 29.0%) n=26	-24.6% (-40.8% to -8.5%) n=69
	21	33.7% (30.1% to 37.5%) n=623	16.0% (11.5% to 21.8%) n=194	-21.9% (-26.4% to -17.4%) n=817
	11	43.9% (39.8% to 48.1%) n=549	18.4% (12.9% to 25.6%) n=141	-31.2% (-36.0% to -26.4%) n=690
	25	40.8% (37.7% to 43.9%) n=959	18.6% (14.6% to 23.4%) n=296	-26.8% (-30.4% to -23.1%) n=1,255
	15	32.1% (27.5% to 37.1%) n=358	19.0% (10.9% to 30.9%) n=58	-25.0% (-30.7% to -19.3%) n=416
	31	45.4% (42.8% to 48.0%) n=1,368	14.2% (11.0% to 18.2%) n=365	-32.8% (-35.9% to -29.8%) n=1,733
	26	40.5% (33.4% to 47.9%) n=173	23.6% (14.4% to 36.3%) n=55	-25.0% (-33.5% to -16.5%) n=228
	3	51.2% (45.1% to 57.2%) n=260	13.8% (7.5% to 24.3%) n=65	-38.2% (-45.1% to -31.2%) n=325
	16	40.6% (36.9% to 44.5%) n=645	12.9% (8.6% to 18.9%) n=163	-29.8% (-34.2% to -25.4%) n=808
	33	43.7% (40.8% to 46.6%) n=1,136	13.9% (10.6% to 18.0%) n=338	-30.5% (-33.8% to -27.1%) n=1,474
	13	39.8% (31.5% to 48.8%) n=118	13.3% (5.3% to 29.7%) n=30	-29.1% (-39.4% to -18.7%) n=148
	12	54.6% (48.1% to 61.0%) n=227	9.4% (5.5% to 15.3%) n=139	-30.3% (-37.2% to -23.4%) n=366
	28	46.0% (41.9% to 50.2%) n=550	12.2% (7.0% to 20.6%) n=90	-37.8% (-42.5% to -33.1%) n=640
	6	49.8% (47.0% to 52.6%) n=1,218	12.4% (9.3% to 16.4%) n=331	-36.5% (-39.7% to -33.3%) n=1,549
	27	42.7% (39.4% to 46.1%) n=845	18.3% (14.0% to 23.5%) n=252	-28.7% (-32.6% to -24.8%) n=1,097
	18	38.5% (26.5% to 52.0%) n=52	25.0% (7.1% to 59.1%) n=8	-30.0% (-45.2% to -14.8%) n=60
	7	52.4% (49.1% to 55.7%) n=868	12.1% (8.8% to 16.5%) n=272	-37.0% (-40.8% to -33.3%) n=1,140
	22	60.6% (50.5% to 69.9%) n=94	16.7% (6.7% to 35.9%) n=24	-44.9% (-56.2% to -33.7%) n=118
	17	48.1% (44.0% to 52.2%) n=570	14.8% (10.1% to 21.3%) n=155	-34.6% (-39.3% to -29.9%) n=725
Total		45.8% (45.1% to 46.5%) n=17,843	14.6% (13.7% to 15.6%) n=5,194	-32.2% (-33.0% to -31.3%) n=23,037

ST24 (cont)

Recovery and incidence rates, net rate changes, seven recovery markers - 'complete data only method'; study group patients with finished episodes including more than one contact and treatment treatment by site. 95% confidence intervals in parentheses.

Site	Site code	Phobias - Any question 4+		
		Recovery rate for cases	Incidence in non-cases	Net change in rate
	4	59.6% (55.2% to 63.8%) n=500	9.5% (7.1% to 12.5%) n=453	-26.8% (-31.0% to -22.5%) n=953
	23	45.5% (42.4% to 48.7%) n=960	16.0% (13.5% to 18.7%) n=752	-18.5% (-21.8% to -15.2%) n=1,712
	20	32.4% (28.6% to 36.4%) n=553	14.6% (11.7% to 18.1%) n=466	-10.9% (-15.2% to -6.6%) n=1,019
	19	53.7% (44.9% to 62.2%) n=123	14.4% (9.5% to 21.2%) n=139	-17.6% (-25.7% to -9.4%) n=262
	14	58.3% (54.8% to 61.6%) n=798	9.8% (7.8% to 12.2%) n=713	-26.1% (-29.5% to -22.8%) n=1,511
	5	49.7% (45.5% to 53.9%) n=535	9.2% (6.8% to 12.2%) n=437	-23.3% (-27.5% to -19.0%) n=972
	8	50.3% (44.9% to 55.7%) n=330	13.8% (10.7% to 17.6%) n=385	-15.8% (-20.8% to -10.8%) n=715
	9	45.9% (39.6% to 52.3%) n=231	13.5% (9.7% to 18.6%) n=229	-16.3% (-22.6% to -10.0%) n=460
	24	54.8% (42.5% to 66.6%) n=62	9.0% (4.2% to 18.2%) n=67	-21.7% (-33.2% to -10.2%) n=129
	36	54.1% (50.0% to 58.2%) n=558	12.9% (10.2% to 16.1%) n=498	-22.5% (-26.6% to -18.4%) n=1,056
	10	47.0% (40.9% to 53.2%) n=251	12.8% (8.7% to 18.3%) n=188	-21.4% (-27.9% to -15.0%) n=439
	30	42.1% (23.1% to 63.7%) n=19	8.8% (3.0% to 23.0%) n=34	-9.4% (-27.0% to +8.1%) n=53
	21	29.2% (25.3% to 33.5%) n=465	13.9% (10.4% to 18.4%) n=294	-12.5% (-17.5% to -7.6%) n=759
	11	42.9% (38.3% to 47.6%) n=431	15.3% (11.3% to 20.3%) n=249	-21.6% (-26.8% to -16.4%) n=680
	25	38.5% (34.4% to 42.7%) n=530	14.5% (11.7% to 17.9%) n=482	-13.2% (-17.5% to -8.9%) n=1,012
	15	37.1% (31.4% to 43.2%) n=256	9.5% (5.8% to 15.4%) n=147	-20.1% (-26.8% to -13.4%) n=403
	31	45.9% (42.6% to 49.2%) n=889	11.2% (9.2% to 13.6%) n=793	-19.0% (-22.3% to -15.7%) n=1,682
	26	45.3% (35.3% to 55.8%) n=86	26.0% (17.3% to 37.1%) n=73	-12.6% (-23.5% to -1.7%) n=159
	3	41.5% (33.0% to 50.5%) n=118	13.0% (7.9% to 20.6%) n=108	-15.5% (-24.5% to -6.4%) n=226
	16	44.8% (38.8% to 51.0%) n=250	12.6% (8.8% to 17.5%) n=223	-17.8% (-24.0% to -11.5%) n=473
	33	46.4% (42.8% to 50.0%) n=718	9.7% (7.7% to 12.0%) n=746	-17.8% (-21.3% to -14.3%) n=1,464
	13	38.4% (28.8% to 48.9%) n=86	16.1% (9.0% to 27.2%) n=62	-15.5% (-26.8% to -4.3%) n=148
	12	43.1% (36.0% to 50.5%) n=174	11.5% (7.7% to 16.8%) n=191	-14.5% (-21.6% to -7.5%) n=365
	28	38.0% (33.1% to 43.1%) n=358	11.7% (8.2% to 16.5%) n=231	-18.5% (-24.1% to -12.9%) n=589
	6	55.2% (49.4% to 60.8%) n=290	19.8% (15.1% to 25.6%) n=222	-22.7% (-28.6% to -16.7%) n=512
	27	43.5% (39.2% to 47.9%) n=497	17.9% (14.8% to 21.4%) n=515	-12.3% (-16.5% to -8.0%) n=1,012
	18	35.6% (23.2% to 50.2%) n=45	6.7% (1.2% to 29.8%) n=15	-25.0% (-41.7% to -8.3%) n=60
	7	51.0% (46.9% to 55.1%) n=569	10.1% (7.8% to 12.8%) n=557	-20.8% (-24.7% to -16.8%) n=1,126
	22	47.9% (34.5% to 61.7%) n=48	11.8% (6.1% to 21.5%) n=68	-12.9% (-25.1% to -0.8%) n=116
	17	44.4% (39.3% to 49.6%) n=356	13.3% (10.1% to 17.3%) n=339	-16.3% (-21.4% to -11.1%) n=695
Total		46.1% (45.2% to 47.1%) n=11,086	12.7% (12.1% to 13.4%) n=9,676	-18.7% (-19.6% to -17.8%) n=20,762

ST24 (cont)

Recovery and incidence rates, net rate changes, seven recovery markers - 'complete data only method'; study group patients with finished episodes including more than one contact and treatment treatment by site. 95% confidence intervals in parentheses.

Site	Site code	MTR1 marker - PHQ9 and GAD7		
		Recovery rate for cases	Incidence in non-cases	Net change in rate
	4	57.5% (54.0% to 60.9%) n=788	9.5% (5.9% to 14.9%) n=168	-45.7% (-49.6% to -41.8%) n=956
	23	39.5% (37.0% to 42.0%) n=1,482	14.8% (10.8% to 19.9%) n=230	-32.2% (-35.0% to -29.3%) n=1,712
	20	27.1% (24.3% to 30.1%) n=885	14.5% (10.0% to 20.6%) n=172	-20.3% (-24.0% to -16.7%) n=1,057
	19	48.8% (42.0% to 55.6%) n=203	24.2% (15.2% to 36.2%) n=62	-31.7% (-39.6% to -23.8%) n=265
	14	52.9% (50.1% to 55.6%) n=1,246	9.9% (6.9% to 13.9%) n=284	-41.2% (-44.4% to -38.1%) n=1,530
	5	49.3% (45.8% to 52.7%) n=810	11.0% (7.3% to 16.2%) n=191	-37.8% (-41.7% to -33.8%) n=1,001
	8	38.9% (35.1% to 42.8%) n=610	15.5% (10.3% to 22.7%) n=129	-29.4% (-33.9% to -24.8%) n=739
	9	39.3% (34.6% to 44.3%) n=389	13.5% (7.9% to 22.1%) n=89	-29.5% (-35.2% to -23.8%) n=478
	24	48.3% (39.6% to 57.2%) n=120	6.7% (1.2% to 29.8%) n=15	-42.2% (-52.2% to -32.3%) n=135
	36	49.1% (45.8% to 52.4%) n=890	16.1% (11.3% to 22.4%) n=168	-38.8% (-42.5% to -35.0%) n=1,058
	10	37.4% (32.7% to 42.4%) n=382	14.9% (8.3% to 25.3%) n=67	-29.6% (-35.3% to -24.0%) n=449
	30	41.3% (28.3% to 55.7%) n=46	13.0% (4.5% to 32.1%) n=23	-23.2% (-39.3% to -7.0%) n=69
	21	28.5% (25.3% to 32.0%) n=684	14.0% (9.1% to 20.8%) n=136	-21.5% (-25.6% to -17.3%) n=820
	11	40.2% (36.3% to 44.2%) n=597	23.2% (15.8% to 32.6%) n=95	-31.5% (-36.0% to -27.0%) n=692
	25	36.5% (33.6% to 39.4%) n=1,075	16.5% (11.9% to 22.5%) n=188	-28.6% (-31.9% to -25.2%) n=1,263
	15	28.7% (24.4% to 33.4%) n=380	22.7% (12.8% to 37.0%) n=44	-23.3% (-28.7% to -18.0%) n=424
	31	43.2% (40.7% to 45.7%) n=1,485	15.6% (11.6% to 20.6%) n=250	-34.7% (-37.6% to -31.8%) n=1,735
	26	30.7% (25.0% to 37.0%) n=225	17.6% (8.3% to 33.5%) n=34	-24.3% (-31.5% to -17.1%) n=259
	3	45.2% (39.4% to 51.0%) n=279	13.3% (6.3% to 26.2%) n=45	-37.0% (-43.7% to -30.4%) n=324
	16	36.4% (33.0% to 40.0%) n=714	12.3% (7.3% to 19.9%) n=106	-30.1% (-34.2% to -26.0%) n=820
	33	41.3% (38.6% to 44.1%) n=1,240	13.8% (10.0% to 18.8%) n=239	-32.4% (-35.6% to -29.2%) n=1,479
	13	37.5% (29.6% to 46.1%) n=128	10.0% (2.8% to 30.1%) n=20	-31.1% (-40.8% to -21.4%) n=148
	12	51.7% (45.7% to 57.6%) n=267	6.1% (2.8% to 12.6%) n=99	-36.1% (-42.8% to -29.3%) n=366
	28	42.0% (38.0% to 46.0%) n=581	10.0% (4.7% to 20.1%) n=60	-37.1% (-41.6% to -32.7%) n=641
	6	46.8% (44.1% to 49.5%) n=1,322	11.0% (7.5% to 15.7%) n=228	-38.3% (-41.4% to -35.3%) n=1,550
	27	37.5% (34.5% to 40.6%) n=936	19.0% (13.8% to 25.7%) n=168	-28.9% (-32.5% to -25.3%) n=1,104
	18	29.1% (18.8% to 42.1%) n=55	20.0% (3.6% to 62.4%) n=5	-25.0% (-38.8% to -11.2%) n=60
	7	48.0% (44.8% to 51.2%) n=937	12.3% (8.5% to 17.5%) n=203	-37.3% (-40.9% to -33.6%) n=1,140
	22	56.6% (46.7% to 65.9%) n=99	10.5% (2.9% to 31.4%) n=19	-45.8% (-56.8% to -34.8%) n=118
	17	45.1% (41.2% to 49.1%) n=612	11.5% (6.8% to 18.7%) n=113	-36.3% (-40.8% to -31.8%) n=725
Total		42.2% (41.6% to 42.9%) n=19,467	13.8% (12.7% to 14.9%) n=3,650	-33.4% (-34.2% to -32.6%) n=23,117

ST24 (cont)

Recovery and incidence rates, net rate changes, seven recovery markers - 'complete data only method'; study group patients with finished episodes including more than one contact and treatment treatment by site. 95% confidence intervals in parentheses.

Site	Site code	MTR2 markers - PHQ9, GAD7 and Phobia questions		
		Recovery rate for cases	Incidence in non-cases	Net change in rate
	4	51.0% (47.6% to 54.4%) n=843	12.5% (7.6% to 19.9%) n=112	-43.6% (-47.3% to -39.8%) n=955
	23	33.6% (31.3% to 36.0%) n=1,548	19.5% (14.2% to 26.2%) n=164	-28.5% (-31.2% to -25.8%) n=1,712
	20	22.7% (20.1% to 25.5%) n=916	20.5% (14.4% to 28.3%) n=127	-17.4% (-20.9% to -14.0%) n=1,043
	19	44.8% (38.4% to 51.4%) n=221	34.1% (21.9% to 48.9%) n=44	-31.7% (-39.2% to -24.2%) n=265
	14	47.7% (45.1% to 50.4%) n=1,330	12.0% (8.2% to 17.4%) n=191	-40.2% (-43.2% to -37.2%) n=1,521
	5	41.7% (38.5% to 45.1%) n=860	12.0% (7.4% to 18.9%) n=125	-34.9% (-38.7% to -31.2%) n=985
	8	35.3% (31.7% to 39.1%) n=638	23.7% (16.4% to 33.1%) n=97	-27.5% (-31.8% to -23.2%) n=735
	9	34.5% (30.0% to 39.3%) n=403	13.0% (7.0% to 23.0%) n=69	-27.5% (-33.0% to -22.1%) n=472
	24	42.7% (34.4% to 51.5%) n=124	9.1% (1.6% to 37.7%) n=11	-38.5% (-48.1% to -28.9%) n=135
	36	43.2% (40.1% to 46.4%) n=944	22.1% (15.5% to 30.6%) n=113	-36.2% (-39.8% to -32.7%) n=1,057
	10	33.3% (28.8% to 38.0%) n=400	19.1% (10.4% to 32.5%) n=47	-27.7% (-33.1% to -22.4%) n=447
	30	34.0% (22.2% to 48.3%) n=47	15.4% (4.3% to 42.2%) n=13	-23.3% (-39.7% to -7.0%) n=60
	21	20.6% (17.8% to 23.6%) n=725	20.0% (12.5% to 30.4%) n=75	-16.8% (-20.4% to -13.1%) n=800
	11	33.0% (29.5% to 36.8%) n=639	25.5% (15.5% to 38.9%) n=51	-28.7% (-32.8% to -24.6%) n=690
	25	26.8% (24.3% to 29.6%) n=1,058	25.8% (18.9% to 34.2%) n=124	-21.3% (-24.5% to -18.1%) n=1,182
	15	22.5% (18.8% to 26.7%) n=431	27.3% (13.2% to 48.2%) n=22	-20.1% (-24.5% to -15.6%) n=453
	31	37.7% (35.3% to 40.1%) n=1,552	18.9% (13.7% to 25.5%) n=169	-32.1% (-34.9% to -29.4%) n=1,721
	26	19.9% (15.1% to 25.7%) n=216	17.6% (6.2% to 41.0%) n=17	-17.2% (-23.6% to -10.7%) n=233
	3	31.8% (26.4% to 37.7%) n=255	21.7% (9.7% to 41.9%) n=23	-27.3% (-33.8% to -20.8%) n=278
	16	24.0% (20.9% to 27.5%) n=637	18.8% (10.2% to 31.9%) n=48	-21.0% (-24.9% to -17.2%) n=685
	33	37.4% (34.8% to 40.1%) n=1,293	22.7% (17.2% to 29.3%) n=181	-30.1% (-33.1% to -27.0%) n=1,474
	13	33.6% (26.1% to 41.9%) n=134	14.3% (4.0% to 39.9%) n=14	-29.1% (-38.2% to -19.9%) n=148
	12	42.2% (36.7% to 47.9%) n=294	12.5% (6.7% to 22.1%) n=72	-31.4% (-38.0% to -24.9%) n=366
	28	32.8% (29.1% to 36.8%) n=573	19.5% (10.2% to 34.0%) n=41	-29.3% (-33.6% to -25.0%) n=614
	6	22.6% (20.1% to 25.3%) n=996	21.1% (12.5% to 33.3%) n=57	-20.2% (-23.2% to -17.3%) n=1,053
	27	29.3% (26.5% to 32.3%) n=962	24.1% (17.1% to 32.8%) n=112	-23.7% (-27.1% to -20.4%) n=1,074
	18	25.4% (16.1% to 37.8%) n=59	100.0% (20.7% to 100.0%) n=1	-23.3% (-34.8% to -11.9%) n=60
	7	41.9% (38.8% to 45.0%) n=981	14.3% (9.6% to 20.7%) n=154	-34.3% (-37.8% to -30.7%) n=1,135
	22	43.3% (34.2% to 52.9%) n=104	14.3% (4.0% to 39.9%) n=14	-36.4% (-47.2% to -25.7%) n=118
	17	39.8% (36.1% to 43.7%) n=640	11.3% (5.8% to 20.7%) n=71	-34.7% (-39.0% to -30.5%) n=711
Total		34.8% (34.2% to 35.5%) n=19,823	18.7% (17.2% to 20.3%) n=2,359	-29.1% (-29.9% to -28.4%) n=22,182

ST24 (cont)

Recovery and incidence rates, net rate changes, seven recovery markers - 'complete data only method'; study group patients with finished episodes including more than one contact and treatment treatment by site. 95% confidence intervals in parentheses.

Site	Site code	Benefit / Sick pay status		
		Recovery rate for cases	Incidence in non-cases	Net change in rate
	4	28.0% (21.9% to 35.1%) n=175	4.7% (3.4% to 6.4%) n=772	-1.4% (-4.8% to +2.1%) n=947
	23	23.7% (20.3% to 27.5%) n=532	8.5% (7.0% to 10.3%) n=1,121	-1.9% (-5.0% to +1.3%) n=1,653
	20	14.6% (11.2% to 18.9%) n=322	6.5% (4.9% to 8.5%) n=710	-0.1% (-4.1% to +3.9%) n=1,032
	19	30.0% (19.1% to 43.8%) n=50	3.9% (2.0% to 7.4%) n=207	-2.7% (-9.4% to +3.9%) n=257
	14	26.4% (22.4% to 31.0%) n=397	6.9% (5.6% to 8.5%) n=1,191	-1.4% (-4.4% to +1.5%) n=1,588
	5	23.0% (18.3% to 28.3%) n=270	5.0% (3.6% to 6.9%) n=717	-2.6% (-6.5% to +1.2%) n=987
	8	16.1% (11.9% to 21.5%) n=223	7.0% (5.1% to 9.5%) n=530	+0.1% (-4.5% to +4.7%) n=753
	9	20.6% (14.6% to 28.3%) n=131	6.7% (4.4% to 10.2%) n=297	-1.6% (-7.8% to +4.5%) n=428
	24	22.6% (11.4% to 39.8%) n=31	9.5% (4.7% to 18.3%) n=74	0.0% (-12.3% to +12.3%) n=105
	36	27.0% (22.0% to 32.7%) n=259	9.1% (7.1% to 11.4%) n=685	-0.8% (-4.9% to +3.2%) n=944
	10	27.4% (20.6% to 35.5%) n=135	5.5% (3.5% to 8.7%) n=307	-4.5% (-10.5% to +1.4%) n=442
	30	16.7% (4.7% to 44.8%) n=12	5.3% (1.5% to 17.3%) n=38	0.0% (-16.7% to +16.7%) n=50
	21	19.9% (15.8% to 24.7%) n=302	6.9% (5.0% to 9.6%) n=475	-3.5% (-8.3% to +1.3%) n=777
	11	20.9% (16.3% to 26.4%) n=244	5.6% (3.8% to 8.1%) n=432	-4.0% (-9.0% to +1.1%) n=676
	25	25.1% (20.5% to 30.4%) n=291	6.7% (5.2% to 8.5%) n=872	-1.3% (-4.8% to +2.2%) n=1,163
	15	14.5% (10.7% to 19.4%) n=248	2.4% (1.0% to 5.5%) n=210	-6.8% (-13.2% to -0.3%) n=458
	31	29.5% (25.6% to 33.8%) n=464	6.9% (5.6% to 8.4%) n=1,276	-2.8% (-5.7% to +0.1%) n=1,740
	26	19.0% (10.0% to 33.3%) n=42	10.8% (5.9% to 18.7%) n=93	+1.5% (-9.6% to +12.6%) n=135
	3	6.1% (3.0% to 12.1%) n=114	4.6% (2.6% to 8.0%) n=240	+1.1% (-5.8% to +8.0%) n=354
	16	20.9% (16.3% to 26.3%) n=254	7.7% (5.5% to 10.7%) n=404	-3.3% (-8.6% to +1.9%) n=658
	33	28.2% (24.2% to 32.5%) n=458	6.6% (5.2% to 8.4%) n=979	-4.5% (-7.8% to -1.1%) n=1,437
	13	17.2% (9.6% to 28.9%) n=58	12.8% (7.1% to 22.0%) n=78	0.0% (-11.8% to +11.8%) n=136
	12	15.1% (9.5% to 23.1%) n=106	6.0% (3.6% to 9.8%) n=235	-0.6% (-7.5% to +6.3%) n=341
	28	22.3% (17.7% to 27.8%) n=260	9.0% (6.5% to 12.4%) n=355	-4.2% (-9.7% to +1.2%) n=615
	6	33.5% (26.9% to 40.9%) n=170	6.1% (4.3% to 8.6%) n=475	-4.3% (-9.0% to +0.3%) n=645
	27	20.9% (16.2% to 26.6%) n=234	10.6% (8.4% to 13.2%) n=642	+2.2% (-2.0% to +6.4%) n=876
	18	15.4% (4.3% to 42.2%) n=13	14.6% (6.9% to 28.4%) n=41	+7.4% (-9.4% to +24.2%) n=54
	7	23.2% (18.2% to 29.0%) n=233	6.8% (5.3% to 8.6%) n=887	+0.5% (-2.8% to +3.9%) n=1,120
	22	14.8% (5.9% to 32.5%) n=27	2.2% (0.6% to 7.7%) n=91	-1.7% (-12.3% to +8.9%) n=118
	17	29.4% (23.6% to 36.0%) n=204	6.5% (4.6% to 9.1%) n=474	-4.3% (-9.0% to +0.5%) n=678
Total		23.1% (22.1% to 24.2%) n=6,259	6.9% (6.5% to 7.3%) n=14,908	-2.0% (-2.9% to -1.1%) n=21,167

ST24 (cont)

Recovery and incidence rates, net rate changes, seven recovery markers - 'complete data only method'; study group patients with finished episodes including more than one contact and treatment treatment by site. 95% confidence intervals in parentheses.

Site	Site code	Employment status		
		Recovery rate for cases	Incidence in non-cases	Net change in rate
	4	12.8% (8.4% to 19.2%) n=148	3.4% (2.2% to 5.3%) n=556	0.0% (-4.3% to +4.3%) n=704
	23	9.7% (7.2% to 13.1%) n=390	4.9% (3.7% to 6.5%) n=894	+0.5% (-3.1% to +4.0%) n=1,284
	20	3.2% (1.7% to 6.0%) n=282	4.3% (2.9% to 6.3%) n=580	+1.9% (-2.6% to +6.3%) n=862
	19	12.9% (5.1% to 28.9%) n=31	7.3% (4.2% to 12.4%) n=164	+4.1% (-3.5% to +11.7%) n=195
	14	13.1% (9.6% to 17.5%) n=283	4.8% (3.6% to 6.4%) n=934	+0.7% (-2.7% to +4.0%) n=1,217
	5	10.1% (6.5% to 15.4%) n=178	3.7% (2.5% to 5.5%) n=625	+0.6% (-3.5% to +4.7%) n=803
	8	12.0% (8.3% to 17.0%) n=217	5.1% (3.3% to 7.8%) n=374	-1.2% (-6.7% to +4.3%) n=591
	9	16.4% (11.2% to 23.4%) n=140	4.4% (2.5% to 7.7%) n=250	-3.1% (-9.7% to +3.6%) n=390
	24	15.0% (5.2% to 36.0%) n=20	2.9% (0.8% to 9.8%) n=70	-1.1% (-13.1% to +10.9%) n=90
	36	13.4% (9.1% to 19.3%) n=172	5.4% (3.8% to 7.6%) n=559	+1.0% (-3.4% to +5.3%) n=731
	10	15.0% (9.3% to 23.3%) n=100	5.0% (3.0% to 8.4%) n=259	-0.6% (-7.1% to +6.0%) n=359
	30	0.0% (0.0% to 22.8%) n=13	0.0% (0.0% to 11.0%) n=31	0.0% (-19.1% to +19.1%) n=44
	21	10.1% (6.9% to 14.6%) n=237	5.7% (3.8% to 8.6%) n=366	-0.5% (-6.0% to +5.0%) n=603
	11	8.4% (5.1% to 13.7%) n=166	7.1% (4.9% to 10.3%) n=350	+2.1% (-3.6% to +7.9%) n=516
	25	12.9% (8.8% to 18.5%) n=186	4.1% (2.9% to 5.8%) n=749	+0.7% (-2.9% to +4.4%) n=935
	15	4.3% (2.3% to 7.9%) n=211	2.6% (1.1% to 5.9%) n=194	-1.0% (-7.9% to +5.9%) n=405
	31	10.3% (7.4% to 14.1%) n=320	3.9% (2.9% to 5.2%) n=1,033	+0.5% (-2.7% to +3.7%) n=1,353
	26	0.0% (0.0% to 16.1%) n=20	12.7% (6.8% to 22.4%) n=71	+9.9% (-2.9% to +22.7%) n=91
	3	6.9% (3.0% to 15.2%) n=72	4.0% (2.0% to 8.0%) n=175	+0.8% (-7.2% to +8.9%) n=247
	16	7.6% (4.7% to 12.2%) n=197	4.5% (2.8% to 7.1%) n=379	+0.3% (-5.1% to +5.8%) n=576
	33	6.3% (4.1% to 9.6%) n=301	3.9% (2.7% to 5.5%) n=776	+1.0% (-2.8% to +4.8%) n=1,077
	13	4.3% (1.2% to 14.5%) n=46	9.0% (4.4% to 17.4%) n=78	+4.0% (-8.1% to +16.2%) n=124
	12	10.9% (6.0% to 18.9%) n=92	5.2% (2.9% to 9.3%) n=192	0.0% (-7.7% to +7.7%) n=284
	28	6.5% (3.8% to 11.1%) n=184	5.8% (3.7% to 8.8%) n=329	+1.4% (-4.5% to +7.3%) n=513
	6	16.2% (10.4% to 24.4%) n=105	6.1% (4.1% to 8.9%) n=395	+1.4% (-3.7% to +6.5%) n=500
	27	13.6% (9.1% to 19.9%) n=154	4.7% (3.4% to 6.5%) n=738	+1.6% (-2.0% to +5.1%) n=892
	18	12.5% (3.5% to 36.0%) n=16	6.1% (1.7% to 19.6%) n=33	0.0% (-18.6% to +18.6%) n=49
	7	8.3% (5.1% to 13.3%) n=180	5.4% (4.0% to 7.4%) n=701	+2.6% (-1.2% to +6.5%) n=881
	22	7.7% (1.4% to 33.3%) n=13	4.7% (1.6% to 12.9%) n=64	+2.6% (-9.6% to +14.8%) n=77
	17	6.1% (3.0% to 12.1%) n=114	5.8% (3.9% to 8.6%) n=395	+3.1% (-2.1% to +8.4%) n=509
Total		9.7% (8.9% to 10.6%) n=4,588	4.8% (4.4% to 5.2%) n=12,314	+0.9% (-0.1% to +1.8%) n=16,902

SS25 Recovery and incidence rates, net rate changes, seven recovery markers - 'second unknown, no change method'; study group patients with finished episodes including more than one contact and treatment treatment by site. 95% confidence intervals in parentheses.

Site	Site code	Recovery rate for cases	Depression - PHQ9 score 10+ Incidence in non-cases	Net change in rate
	4	59.4% (55.6% to 63.0%) n=672	5.8% (3.8% to 8.8%) n=345	-37.3% (-41.3% to -33.2%) n=1,017
	23	45.0% (42.3% to 47.6%) n=1,317	13.6% (10.6% to 17.3%) n=397	-31.4% (-34.5% to -28.3%) n=1,714
	20	28.0% (25.0% to 31.1%) n=812	9.4% (6.7% to 12.9%) n=342	-16.9% (-20.8% to -13.0%) n=1,154
	19	52.3% (44.9% to 59.7%) n=172	10.9% (6.4% to 18.1%) n=110	-27.7% (-35.6% to -19.7%) n=282
	14	45.1% (42.5% to 47.8%) n=1,376	5.8% (4.2% to 7.9%) n=606	-29.6% (-32.5% to -26.6%) n=1,982
	5	47.5% (44.0% to 51.1%) n=749	7.3% (5.0% to 10.5%) n=355	-29.9% (-33.9% to -25.9%) n=1,104
	8	37.8% (34.0% to 41.8%) n=600	10.2% (7.1% to 14.5%) n=264	-23.1% (-27.7% to -18.6%) n=864
	9	35.9% (31.4% to 40.7%) n=404	10.3% (6.7% to 15.6%) n=184	-21.4% (-26.9% to -15.9%) n=588
	24	53.7% (44.3% to 62.8%) n=108	8.8% (3.0% to 23.0%) n=34	-38.7% (-49.3% to -28.1%) n=142
	36	53.7% (50.1% to 57.2%) n=753	13.0% (9.7% to 17.1%) n=316	-34.0% (-37.9% to -30.0%) n=1,069
	10	34.4% (29.8% to 39.3%) n=378	9.8% (5.8% to 16.1%) n=132	-22.9% (-28.7% to -17.2%) n=510
	30	53.8% (38.6% to 68.4%) n=39	13.3% (5.3% to 29.7%) n=30	-24.6% (-40.7% to -8.6%) n=69
	21	28.1% (24.9% to 31.6%) n=697	11.5% (8.1% to 16.1%) n=243	-17.9% (-22.1% to -13.6%) n=940
	11	39.6% (35.7% to 43.7%) n=573	13.7% (9.5% to 19.5%) n=182	-26.8% (-31.4% to -22.1%) n=755
	25	36.4% (33.7% to 39.2%) n=1,148	9.5% (7.0% to 12.7%) n=411	-24.3% (-27.6% to -21.0%) n=1,559
	15	16.3% (13.7% to 19.3%) n=669	10.9% (6.8% to 16.9%) n=147	-11.4% (-15.5% to -7.3%) n=816
	31	40.9% (38.4% to 43.5%) n=1,440	10.4% (8.0% to 13.2%) n=531	-27.1% (-30.0% to -24.1%) n=1,971
	26	25.9% (21.4% to 31.0%) n=317	7.1% (3.7% to 13.5%) n=112	-17.2% (-23.5% to -11.0%) n=429
	3	37.8% (32.8% to 43.0%) n=344	9.6% (5.6% to 16.0%) n=125	-25.2% (-31.2% to -19.1%) n=469
	16	31.4% (28.4% to 34.6%) n=854	6.8% (4.3% to 10.7%) n=249	-22.8% (-26.6% to -18.9%) n=1,103
	33	47.6% (44.6% to 50.6%) n=1,055	11.1% (8.4% to 14.4%) n=425	-30.7% (-34.1% to -27.3%) n=1,480
	13	36.8% (28.9% to 45.5%) n=125	12.9% (5.1% to 28.9%) n=31	-26.9% (-36.9% to -16.9%) n=156
	12	51.4% (44.8% to 57.9%) n=220	7.2% (4.1% to 12.5%) n=152	-27.4% (-34.3% to -20.5%) n=372
	28	46.4% (42.3% to 50.6%) n=543	6.1% (3.1% to 11.5%) n=132	-36.1% (-40.9% to -31.4%) n=675
	6	46.8% (44.1% to 49.5%) n=1,285	5.4% (3.7% to 7.9%) n=462	-33.0% (-36.1% to -29.9%) n=1,747
	27	34.7% (31.8% to 37.6%) n=1,027	11.2% (8.4% to 14.7%) n=384	-22.2% (-25.7% to -18.7%) n=1,411
	18	30.0% (19.1% to 43.8%) n=50	18.2% (5.1% to 47.7%) n=11	-21.3% (-36.9% to -5.7%) n=61
	7	47.1% (43.7% to 50.5%) n=820	7.8% (5.5% to 11.0%) n=370	-30.0% (-33.8% to -26.2%) n=1,190
	22	45.9% (36.4% to 55.8%) n=98	10.4% (4.5% to 22.2%) n=48	-27.4% (-38.4% to -16.4%) n=146
	17	41.7% (37.9% to 45.6%) n=621	10.0% (6.8% to 14.4%) n=241	-27.3% (-31.7% to -22.8%) n=862
Total		40.8% (40.1% to 41.5%) n=19,266	9.3% (8.6% to 10.0%) n=7,371	-27.0% (-27.8% to -26.2%) n=26,637

SS25 (cont)

Recovery and incidence rates, net rate changes, seven recovery markers - 'second unknown, no change method'; study group patients with finished episodes including more than one contact and treatment treatment by site. 95% confidence intervals in parentheses.

Site	Site code	Anxiety - GAD7 8+		
		Recovery rate for cases	Incidence in non-cases	Net change in rate
	4	56.8% (53.2% to 60.2%) n=777	8.8% (5.8% to 13.0%) n=240	-41.3% (-45.2% to -37.4%) n=1,017
	23	43.9% (41.3% to 46.6%) n=1,368	18.8% (15.0% to 23.2%) n=346	-31.3% (-34.3% to -28.2%) n=1,714
	20	27.3% (24.4% to 30.3%) n=880	15.3% (11.5% to 20.1%) n=274	-17.2% (-20.9% to -13.4%) n=1,154
	19	48.0% (41.2% to 54.9%) n=200	17.1% (10.5% to 26.6%) n=82	-29.1% (-36.9% to -21.3%) n=282
	14	43.5% (41.0% to 46.1%) n=1,461	6.9% (5.0% to 9.4%) n=523	-30.2% (-33.2% to -27.3%) n=1,984
	5	47.1% (43.7% to 50.5%) n=816	9.5% (6.6% to 13.5%) n=284	-32.5% (-36.4% to -28.6%) n=1,100
	8	36.5% (32.9% to 40.2%) n=655	16.3% (11.9% to 22.0%) n=208	-23.8% (-28.1% to -19.4%) n=863
	9	33.9% (29.6% to 38.4%) n=440	10.8% (6.8% to 16.8%) n=148	-22.6% (-28.0% to -17.3%) n=588
	24	53.6% (44.4% to 62.5%) n=112	12.9% (5.1% to 28.9%) n=31	-39.2% (-49.6% to -28.7%) n=143
	36	50.7% (47.3% to 54.1%) n=844	16.4% (12.2% to 21.8%) n=225	-36.6% (-40.4% to -32.7%) n=1,069
	10	35.2% (30.7% to 40.0%) n=406	17.1% (11.1% to 25.5%) n=105	-24.5% (-30.0% to -18.9%) n=511
	30	46.5% (32.5% to 61.1%) n=43	11.5% (4.0% to 29.0%) n=26	-24.6% (-40.8% to -8.5%) n=69
	21	29.1% (25.9% to 32.5%) n=722	14.3% (10.3% to 19.6%) n=217	-19.1% (-23.2% to -14.9%) n=939
	11	40.2% (36.4% to 44.2%) n=599	16.7% (11.6% to 23.3%) n=156	-28.5% (-33.1% to -23.9%) n=755
	25	33.6% (30.9% to 36.4%) n=1,164	14.1% (11.0% to 17.9%) n=390	-21.6% (-24.9% to -18.3%) n=1,554
	15	16.2% (13.7% to 19.1%) n=708	10.7% (6.1% to 18.1%) n=103	-12.8% (-16.6% to -9.0%) n=811
	31	39.9% (37.5% to 42.3%) n=1,558	12.5% (9.7% to 16.1%) n=415	-28.8% (-31.7% to -26.0%) n=1,973
	26	22.8% (18.5% to 27.8%) n=307	12.1% (7.2% to 19.7%) n=107	-13.8% (-20.1% to -7.4%) n=414
	3	35.6% (30.9% to 40.5%) n=374	8.6% (4.6% to 15.5%) n=105	-25.9% (-31.7% to -20.1%) n=479
	16	30.1% (27.2% to 33.3%) n=869	9.1% (6.0% to 13.6%) n=230	-21.9% (-25.7% to -18.1%) n=1,099
	33	43.7% (40.8% to 46.6%) n=1,136	13.9% (10.6% to 18.0%) n=338	-30.5% (-33.8% to -27.1%) n=1,474
	13	37.9% (29.8% to 46.7%) n=124	12.5% (5.0% to 28.1%) n=32	-27.6% (-37.6% to -17.5%) n=156
	12	53.7% (47.2% to 60.0%) n=231	9.2% (5.5% to 15.1%) n=141	-29.8% (-36.7% to -23.0%) n=372
	28	43.9% (39.9% to 48.0%) n=576	11.0% (6.3% to 18.6%) n=100	-35.8% (-40.4% to -31.2%) n=676
	6	44.5% (41.9% to 47.2%) n=1,364	10.7% (8.0% to 14.2%) n=383	-32.4% (-35.4% to -29.4%) n=1,747
	27	34.1% (31.3% to 37.0%) n=1,060	13.5% (10.3% to 17.6%) n=340	-22.5% (-25.9% to -19.1%) n=1,400
	18	37.7% (25.9% to 51.2%) n=53	25.0% (7.1% to 59.1%) n=8	-29.5% (-44.5% to -14.5%) n=61
	7	50.2% (46.9% to 53.4%) n=907	11.7% (8.4% to 15.9%) n=283	-35.5% (-39.2% to -31.8%) n=1,190
	22	49.1% (40.2% to 58.1%) n=116	13.3% (5.3% to 29.7%) n=30	-36.3% (-46.7% to -25.9%) n=146
	17	40.7% (37.1% to 44.5%) n=673	12.0% (8.1% to 17.3%) n=192	-29.0% (-33.3% to -24.7%) n=865
Total		39.8% (39.1% to 40.5%) n=20,543	12.5% (11.7% to 13.4%) n=6,062	-27.9% (-28.7% to -27.1%) n=26,605

SS25 (cont)

Recovery and incidence rates, net rate changes, seven recovery markers - 'second unknown, no change method'; study group patients with finished episodes including more than one contact and treatment treatment by site. 95% confidence intervals in parentheses.

Site	Site code	Phobias - Any question 4+		
		Recovery rate for cases	Incidence in non-cases	Net change in rate
	4	55.9% (51.7% to 60.1%) n=533	8.9% (6.7% to 11.8%) n=483	-25.1% (-29.2% to -21.0%) n=1,016
	23	45.5% (42.4% to 48.7%) n=960	15.9% (13.5% to 18.7%) n=754	-18.5% (-21.8% to -15.2%) n=1,714
	20	29.2% (25.7% to 32.9%) n=613	13.0% (10.3% to 16.1%) n=525	-9.8% (-13.8% to -5.7%) n=1,138
	19	50.0% (41.6% to 58.4%) n=132	13.6% (9.0% to 20.1%) n=147	-16.5% (-24.5% to -8.5%) n=279
	14	45.5% (42.5% to 48.6%) n=1,021	7.4% (5.9% to 9.2%) n=950	-20.0% (-23.1% to -17.0%) n=1,971
	5	44.3% (40.4% to 48.3%) n=600	8.2% (6.1% to 10.9%) n=489	-20.8% (-24.8% to -16.7%) n=1,089
	8	41.5% (36.8% to 46.4%) n=400	11.9% (9.2% to 15.2%) n=446	-13.4% (-18.0% to -8.7%) n=846
	9	36.9% (31.6% to 42.7%) n=287	10.8% (7.7% to 14.9%) n=287	-13.1% (-18.8% to -7.4%) n=574
	24	48.6% (37.2% to 60.0%) n=70	8.6% (4.0% to 17.5%) n=70	-20.0% (-31.2% to -8.8%) n=140
	36	53.5% (49.4% to 57.6%) n=564	12.7% (10.1% to 15.9%) n=504	-22.3% (-26.4% to -18.2%) n=1,068
	10	39.6% (34.2% to 45.2%) n=298	11.4% (7.8% to 16.4%) n=211	-18.5% (-24.5% to -12.4%) n=509
	30	40.0% (21.9% to 61.3%) n=20	8.1% (2.8% to 21.3%) n=37	-8.8% (-25.6% to +8.1%) n=57
	21	24.1% (20.8% to 27.8%) n=564	11.5% (8.6% to 15.2%) n=357	-10.3% (-14.8% to -5.8%) n=921
	11	38.5% (34.3% to 43.0%) n=480	14.0% (10.4% to 18.7%) n=271	-19.6% (-24.5% to -14.6%) n=751
	25	29.6% (26.3% to 33.1%) n=689	10.6% (8.5% to 13.2%) n=660	-9.9% (-13.7% to -6.2%) n=1,349
	15	17.1% (14.2% to 20.4%) n=556	5.1% (3.0% to 8.3%) n=277	-9.7% (-14.4% to -5.1%) n=833
	31	39.9% (36.9% to 42.9%) n=1,023	9.7% (8.0% to 11.8%) n=915	-16.5% (-19.5% to -13.4%) n=1,938
	26	19.1% (14.3% to 25.1%) n=204	9.6% (6.2% to 14.5%) n=198	-5.0% (-11.9% to +1.9%) n=402
	3	22.7% (17.6% to 28.7%) n=216	6.9% (4.2% to 11.3%) n=202	-8.4% (-15.1% to -1.6%) n=418
	16	24.3% (20.6% to 28.4%) n=461	7.0% (4.9% to 9.9%) n=400	-9.8% (-14.5% to -5.1%) n=861
	33	46.3% (42.6% to 49.9%) n=720	9.6% (7.7% to 12.0%) n=748	-17.8% (-21.3% to -14.3%) n=1,468
	13	35.9% (26.8% to 46.1%) n=92	15.6% (8.7% to 26.4%) n=64	-14.7% (-25.7% to -3.8%) n=156
	12	42.4% (35.3% to 49.7%) n=177	11.3% (7.6% to 16.6%) n=194	-14.3% (-21.3% to -7.3%) n=371
	28	34.5% (30.0% to 39.3%) n=394	10.0% (7.0% to 14.2%) n=269	-16.4% (-21.7% to -11.1%) n=663
	6	19.9% (17.3% to 22.8%) n=805	6.9% (5.2% to 9.2%) n=635	-8.1% (-11.7% to -4.4%) n=1,440
	27	33.3% (29.8% to 37.0%) n=649	13.3% (11.0% to 16.1%) n=690	-9.3% (-13.0% to -5.5%) n=1,339
	18	34.8% (22.7% to 49.2%) n=46	6.7% (1.2% to 29.8%) n=15	-24.6% (-41.1% to -8.0%) n=61
	7	49.0% (45.0% to 53.0%) n=592	9.4% (7.3% to 12.0%) n=595	-19.7% (-23.6% to -15.9%) n=1,187
	22	36.5% (25.7% to 48.9%) n=63	10.0% (5.2% to 18.5%) n=80	-10.5% (-21.7% to +0.7%) n=143
	17	37.4% (32.9% to 42.1%) n=423	10.7% (8.1% to 14.1%) n=419	-13.4% (-18.1% to -8.7%) n=842
Total		37.5% (36.6% to 38.3%) n=13,652	10.4% (9.8% to 10.9%) n=11,892	-15.2% (-16.0% to -14.3%) n=25,544

SS25 (cont)

Recovery and incidence rates, net rate changes, seven recovery markers - 'second unknown, no change method'; study group patients with finished episodes including more than one contact and treatment treatment by site. 95% confidence intervals in parentheses.

Site	Site code	MTR1 marker - PHQ9 and GAD7		
		Recovery rate for cases	Incidence in non-cases	Net change in rate
	4	54.1% (50.7% to 57.5%) n=837	8.9% (5.5% to 14.0%) n=180	-43.0% (-46.8% to -39.2%) n=1,017
	23	39.4% (37.0% to 41.9%) n=1,484	14.8% (10.8% to 19.9%) n=230	-32.1% (-35.0% to -29.3%) n=1,714
	20	24.8% (22.2% to 27.6%) n=967	13.4% (9.2% to 19.0%) n=187	-18.6% (-22.1% to -15.2%) n=1,154
	19	46.0% (39.5% to 52.7%) n=215	22.4% (14.1% to 33.7%) n=67	-29.8% (-37.4% to -22.1%) n=282
	14	41.4% (39.0% to 43.8%) n=1,592	7.1% (5.0% to 10.1%) n=392	-31.8% (-34.6% to -29.0%) n=1,984
	5	44.5% (41.3% to 47.8%) n=896	10.1% (6.7% to 14.9%) n=208	-34.2% (-38.0% to -30.5%) n=1,104
	8	33.1% (29.8% to 36.6%) n=716	13.5% (8.9% to 20.0%) n=148	-25.1% (-29.3% to -21.0%) n=864
	9	32.1% (28.1% to 36.5%) n=476	10.7% (6.2% to 17.8%) n=112	-24.0% (-29.1% to -18.9%) n=588
	24	45.7% (37.3% to 54.3%) n=127	6.7% (1.2% to 29.8%) n=15	-40.1% (-49.8% to -30.5%) n=142
	36	48.6% (45.3% to 51.8%) n=900	16.0% (11.2% to 22.2%) n=169	-38.4% (-42.1% to -34.7%) n=1,069
	10	32.5% (28.3% to 37.0%) n=440	14.1% (7.8% to 24.0%) n=71	-26.0% (-31.2% to -20.8%) n=511
	30	41.3% (28.3% to 55.7%) n=46	13.0% (4.5% to 32.1%) n=23	-23.2% (-39.3% to -7.0%) n=69
	21	24.7% (21.9% to 27.9%) n=788	12.4% (8.1% to 18.6%) n=153	-18.7% (-22.6% to -14.9%) n=941
	11	36.8% (33.1% to 40.5%) n=653	21.6% (14.7% to 30.5%) n=102	-28.9% (-33.2% to -24.6%) n=755
	25	30.1% (27.6% to 32.6%) n=1,304	12.3% (8.8% to 16.9%) n=253	-23.2% (-26.2% to -20.1%) n=1,557
	15	14.7% (12.3% to 17.4%) n=742	13.7% (7.6% to 23.4%) n=73	-12.1% (-15.6% to -8.7%) n=815
	31	38.2% (35.9% to 40.5%) n=1,678	13.3% (9.9% to 17.6%) n=294	-30.5% (-33.2% to -27.8%) n=1,972
	26	19.5% (15.7% to 23.9%) n=354	8.2% (3.8% to 16.8%) n=73	-14.8% (-20.4% to -9.1%) n=427
	3	31.0% (26.7% to 35.6%) n=407	8.0% (3.7% to 16.4%) n=75	-24.9% (-30.3% to -19.4%) n=482
	16	27.4% (24.7% to 30.3%) n=949	8.4% (5.0% to 13.8%) n=155	-22.4% (-25.9% to -18.9%) n=1,104
	33	41.3% (38.6% to 44.1%) n=1,240	13.8% (10.0% to 18.8%) n=239	-32.4% (-35.6% to -29.2%) n=1,479
	13	35.3% (27.8% to 43.6%) n=136	10.0% (2.8% to 30.1%) n=20	-29.5% (-38.8% to -20.1%) n=156
	12	50.9% (45.0% to 56.8%) n=271	5.9% (2.8% to 12.4%) n=101	-35.5% (-42.2% to -28.8%) n=372
	28	40.2% (36.4% to 44.1%) n=607	8.7% (4.0% to 17.7%) n=69	-35.2% (-39.6% to -30.8%) n=676
	6	41.9% (39.4% to 44.5%) n=1,476	9.2% (6.3% to 13.3%) n=271	-34.0% (-36.9% to -31.1%) n=1,747
	27	29.7% (27.2% to 32.4%) n=1,180	14.1% (10.2% to 19.2%) n=227	-22.7% (-25.9% to -19.5%) n=1,407
	18	28.6% (18.4% to 41.5%) n=56	20.0% (3.6% to 62.4%) n=5	-24.6% (-38.2% to -10.9%) n=61
	7	46.0% (42.9% to 49.1%) n=979	11.8% (8.2% to 16.9%) n=211	-35.7% (-39.3% to -32.1%) n=1,190
	22	45.9% (37.3% to 54.7%) n=122	8.3% (2.3% to 25.8%) n=24	-37.0% (-47.1% to -26.9%) n=146
	17	38.4% (35.0% to 42.1%) n=718	9.0% (5.3% to 14.7%) n=145	-30.5% (-34.6% to -26.3%) n=863
Total		36.8% (36.2% to 37.4%) n=22,356	11.7% (10.8% to 12.7%) n=4,292	-29.0% (-29.7% to -28.2%) n=26,648

SS25 (cont)

Recovery and incidence rates, net rate changes, seven recovery markers - 'second unknown, no change method'; study group patients with finished episodes including more than one contact and treatment treatment by site. 95% confidence intervals in parentheses.

Site	Site code	MTR2 markers - PHQ9, GAD7 and Phobia questions		
		Recovery rate for cases	Incidence in non-cases	Net change in rate
	4	48.0% (44.8% to 51.3%) n=895	11.6% (7.0% to 18.5%) n=121	-40.9% (-44.6% to -37.3%) n=1,016
	23	33.5% (31.2% to 35.9%) n=1,550	19.5% (14.2% to 26.2%) n=164	-28.5% (-31.2% to -25.8%) n=1,714
	20	20.6% (18.2% to 23.2%) n=1,010	18.1% (12.6% to 25.1%) n=144	-15.8% (-19.0% to -12.5%) n=1,154
	19	42.3% (36.2% to 48.7%) n=234	31.9% (20.4% to 46.2%) n=47	-29.9% (-37.2% to -22.6%) n=281
	14	37.3% (35.0% to 39.6%) n=1,702	8.3% (5.6% to 12.2%) n=277	-30.9% (-33.6% to -28.3%) n=1,979
	5	37.3% (34.3% to 40.4%) n=962	10.6% (6.5% to 16.7%) n=142	-31.2% (-34.7% to -27.6%) n=1,104
	8	30.0% (26.9% to 33.4%) n=749	20.0% (13.7% to 28.2%) n=115	-23.4% (-27.3% to -19.4%) n=864
	9	27.8% (24.1% to 31.9%) n=500	10.5% (5.6% to 18.7%) n=86	-22.2% (-27.0% to -17.3%) n=586
	24	40.5% (32.4% to 49.0%) n=131	9.1% (1.6% to 37.7%) n=11	-36.6% (-45.9% to -27.3%) n=142
	36	42.7% (39.6% to 45.9%) n=955	21.9% (15.3% to 30.4%) n=114	-35.8% (-39.3% to -32.3%) n=1,069
	10	28.9% (24.9% to 33.1%) n=461	18.4% (10.0% to 31.4%) n=49	-24.3% (-29.2% to -19.5%) n=510
	30	31.4% (20.3% to 45.0%) n=51	15.4% (4.3% to 42.2%) n=13	-21.9% (-37.5% to -6.3%) n=64
	21	17.5% (15.1% to 20.2%) n=853	17.4% (10.9% to 26.8%) n=86	-14.3% (-17.5% to -11.0%) n=939
	11	30.1% (26.9% to 33.6%) n=700	23.6% (14.4% to 36.3%) n=55	-26.2% (-30.1% to -22.4%) n=755
	25	20.9% (18.8% to 23.2%) n=1,358	18.3% (13.3% to 24.7%) n=175	-16.4% (-19.2% to -13.7%) n=1,533
	15	11.7% (9.7% to 14.1%) n=828	14.0% (6.6% to 27.3%) n=43	-10.4% (-13.2% to -7.7%) n=871
	31	33.1% (31.0% to 35.4%) n=1,765	15.7% (11.3% to 21.3%) n=204	-28.1% (-30.6% to -25.5%) n=1,969
	26	11.5% (8.7% to 15.2%) n=373	5.9% (2.0% to 15.9%) n=51	-9.4% (-14.4% to -4.4%) n=424
	3	19.1% (15.7% to 23.2%) n=423	10.2% (4.4% to 21.8%) n=49	-16.1% (-20.9% to -11.3%) n=472
	16	15.6% (13.4% to 18.0%) n=982	10.3% (5.5% to 18.5%) n=87	-13.5% (-16.4% to -10.5%) n=1,069
	33	37.4% (34.8% to 40.0%) n=1,295	22.7% (17.2% to 29.3%) n=181	-30.0% (-33.0% to -27.0%) n=1,476
	13	31.7% (24.6% to 39.7%) n=142	14.3% (4.0% to 39.9%) n=14	-27.6% (-36.4% to -18.8%) n=156
	12	41.6% (36.2% to 47.3%) n=298	12.2% (6.5% to 21.5%) n=74	-30.9% (-37.4% to -24.4%) n=372
	28	30.2% (26.7% to 33.9%) n=623	16.0% (8.3% to 28.5%) n=50	-26.7% (-30.8% to -22.7%) n=673
	6	14.6% (13.0% to 16.5%) n=1,536	8.2% (4.7% to 13.7%) n=147	-12.7% (-15.0% to -10.3%) n=1,683
	27	22.7% (20.4% to 25.1%) n=1,243	17.2% (12.1% to 23.9%) n=157	-18.2% (-21.1% to -15.3%) n=1,400
	18	25.0% (15.8% to 37.2%) n=60	100.0% (20.7% to 100.0%) n=1	-23.0% (-34.2% to -11.7%) n=61
	7	39.9% (37.0% to 42.9%) n=1,030	13.8% (9.3% to 19.9%) n=160	-32.7% (-36.1% to -29.3%) n=1,190
	22	34.9% (27.2% to 43.4%) n=129	11.8% (3.3% to 34.3%) n=17	-29.5% (-39.0% to -19.9%) n=146
	17	33.7% (30.4% to 37.1%) n=757	7.8% (4.0% to 14.7%) n=102	-28.8% (-32.7% to -24.8%) n=859
Total		29.3% (28.7% to 29.8%) n=23,595	15.0% (13.8% to 16.4%) n=2,936	-24.4% (-25.0% to -23.7%) n=26,531

SS25 (cont)

Recovery and incidence rates, net rate changes, seven recovery markers - 'second unknown, no change method'; study group patients with finished episodes including more than one contact and treatment treatment by site. 95% confidence intervals in parentheses.

Site	Site code	Benefit / Sick pay status		
		Recovery rate for cases	Incidence in non-cases	Net change in rate
	4	25.3% (19.7% to 31.8%) n=194	4.4% (3.2% to 6.0%) n=816	-1.3% (-4.7% to +2.1%) n=1,010
	23	23.4% (20.0% to 27.2%) n=538	8.3% (6.9% to 10.1%) n=1,140	-1.8% (-5.0% to +1.3%) n=1,678
	20	12.9% (9.9% to 16.7%) n=364	6.0% (4.5% to 7.9%) n=769	-0.1% (-3.9% to +3.8%) n=1,133
	19	28.3% (18.0% to 41.6%) n=53	3.5% (1.8% to 6.8%) n=226	-2.5% (-8.8% to +3.8%) n=279
	14	20.6% (17.3% to 24.3%) n=510	5.7% (4.6% to 7.0%) n=1,433	-1.2% (-3.9% to +1.6%) n=1,943
	5	20.1% (16.0% to 24.9%) n=309	4.6% (3.3% to 6.3%) n=781	-2.4% (-6.1% to +1.3%) n=1,090
	8	13.7% (10.1% to 18.4%) n=263	6.3% (4.6% to 8.6%) n=583	+0.1% (-4.3% to +4.5%) n=846
	9	15.5% (10.9% to 21.6%) n=174	5.6% (3.7% to 8.6%) n=354	-1.3% (-7.0% to +4.3%) n=528
	24	19.4% (9.8% to 35.0%) n=36	8.0% (3.9% to 15.5%) n=88	0.0% (-11.3% to +11.3%) n=124
	36	25.5% (20.7% to 30.9%) n=275	8.6% (6.7% to 10.8%) n=723	-0.8% (-4.7% to +3.1%) n=998
	10	23.9% (17.8% to 31.2%) n=155	4.9% (3.1% to 7.7%) n=349	-4.0% (-9.6% to +1.6%) n=504
	30	14.3% (4.0% to 39.9%) n=14	4.3% (1.2% to 14.5%) n=46	0.0% (-15.1% to +15.1%) n=60
	21	16.5% (13.1% to 20.7%) n=363	6.1% (4.4% to 8.4%) n=542	-3.0% (-7.5% to +1.5%) n=905
	11	18.7% (14.5% to 23.7%) n=273	5.1% (3.5% to 7.5%) n=470	-3.6% (-8.5% to +1.2%) n=743
	25	19.7% (16.0% to 24.1%) n=370	5.1% (4.0% to 6.6%) n=1,128	-1.0% (-4.1% to +2.1%) n=1,498
	15	7.7% (5.6% to 10.4%) n=470	1.3% (0.6% to 3.0%) n=385	-3.6% (-8.4% to +1.1%) n=855
	31	25.6% (22.0% to 29.4%) n=536	6.2% (5.1% to 7.6%) n=1,409	-2.5% (-5.3% to +0.2%) n=1,945
	26	6.7% (3.4% to 12.7%) n=119	3.5% (1.9% to 6.3%) n=288	+0.5% (-5.8% to +6.8%) n=407
	3	4.7% (2.3% to 9.4%) n=148	3.7% (2.1% to 6.4%) n=300	+0.9% (-5.3% to +7.1%) n=448
	16	12.7% (9.8% to 16.2%) n=418	5.3% (3.7% to 7.4%) n=589	-2.2% (-6.5% to +2.1%) n=1,007
	33	28.1% (24.2% to 32.4%) n=459	6.5% (5.1% to 8.2%) n=1,001	-4.4% (-7.7% to -1.1%) n=1,460
	13	15.6% (8.7% to 26.4%) n=64	11.6% (6.4% to 20.1%) n=86	0.0% (-11.2% to +11.2%) n=150
	12	14.5% (9.2% to 22.3%) n=110	5.8% (3.5% to 9.6%) n=240	-0.6% (-7.4% to +6.3%) n=350
	28	20.4% (16.1% to 25.5%) n=284	8.3% (6.0% to 11.5%) n=384	-3.9% (-9.2% to +1.4%) n=668
	6	12.9% (10.1% to 16.3%) n=443	2.4% (1.7% to 3.4%) n=1,216	-1.7% (-4.7% to +1.3%) n=1,659
	27	14.5% (11.1% to 18.6%) n=338	7.6% (6.0% to 9.5%) n=895	+1.5% (-2.0% to +5.1%) n=1,233
	18	15.4% (4.3% to 42.2%) n=13	14.0% (6.6% to 27.3%) n=43	+7.1% (-9.2% to +23.5%) n=56
	7	21.3% (16.7% to 26.7%) n=254	6.5% (5.0% to 8.2%) n=930	+0.5% (-2.8% to +3.8%) n=1,184
	22	11.8% (4.7% to 26.6%) n=34	1.8% (0.5% to 6.3%) n=112	-1.4% (-11.0% to +8.2%) n=146
	17	23.0% (18.3% to 28.5%) n=261	5.5% (3.9% to 7.7%) n=565	-3.5% (-7.9% to +0.9%) n=826
Total		18.5% (17.6% to 19.3%) n=7,842	5.7% (5.4% to 6.1%) n=17,891	-1.6% (-2.4% to -0.9%) n=25,733

SS25 (cont)

Recovery and incidence rates, net rate changes, seven recovery markers - 'second unknown, no change method'; study group patients with finished episodes including more than one contact and treatment treatment by site. 95% confidence intervals in parentheses.

Site	Site code	Employment status		
		Recovery rate for cases	Incidence in non-cases	Net change in rate
	4	11.6% (7.5% to 17.4%) n=164	3.2% (2.1% to 4.9%) n=596	0.0% (-4.1% to +4.1%) n=760
	23	9.7% (7.2% to 13.1%) n=390	4.9% (3.7% to 6.5%) n=895	+0.5% (-3.1% to +4.0%) n=1,285
	20	2.8% (1.5% to 5.3%) n=320	4.0% (2.7% to 5.8%) n=632	+1.7% (-2.6% to +5.9%) n=952
	19	11.1% (4.4% to 25.3%) n=36	6.9% (4.0% to 11.7%) n=173	+3.8% (-3.7% to +11.4%) n=209
	14	9.7% (7.1% to 13.1%) n=382	4.0% (3.0% to 5.4%) n=1,114	+0.5% (-2.6% to +3.7%) n=1,496
	5	8.7% (5.6% to 13.4%) n=206	3.4% (2.3% to 5.0%) n=681	+0.6% (-3.4% to +4.5%) n=887
	8	10.6% (7.3% to 15.0%) n=246	4.7% (3.0% to 7.2%) n=408	-1.1% (-6.3% to +4.2%) n=654
	9	12.7% (8.6% to 18.3%) n=181	3.7% (2.1% to 6.6%) n=295	-2.5% (-8.6% to +3.6%) n=476
	24	14.3% (5.0% to 34.6%) n=21	2.7% (0.8% to 9.5%) n=73	-1.1% (-12.9% to +10.7%) n=94
	36	13.2% (9.0% to 19.1%) n=174	5.3% (3.8% to 7.5%) n=564	+0.9% (-3.4% to +5.3%) n=738
	10	12.9% (8.0% to 20.2%) n=116	4.5% (2.6% to 7.5%) n=291	-0.5% (-6.7% to +5.7%) n=407
	30	0.0% (0.0% to 21.5%) n=14	0.0% (0.0% to 10.4%) n=33	0.0% (-18.5% to +18.5%) n=47
	21	8.3% (5.7% to 12.1%) n=288	5.1% (3.4% to 7.7%) n=411	-0.4% (-5.6% to +4.7%) n=699
	11	7.3% (4.4% to 11.8%) n=193	6.7% (4.6% to 9.7%) n=374	+1.9% (-3.6% to +7.5%) n=567
	25	10.9% (7.4% to 15.6%) n=221	3.3% (2.3% to 4.6%) n=943	+0.6% (-2.6% to +3.8%) n=1,164
	15	2.1% (1.1% to 4.0%) n=423	1.4% (0.6% to 3.3%) n=348	-0.5% (-5.5% to +4.5%) n=771
	31	8.7% (6.3% to 11.9%) n=380	3.6% (2.6% to 4.8%) n=1,124	+0.5% (-2.6% to +3.6%) n=1,504
	26	0.0% (0.0% to 4.4%) n=83	4.0% (2.1% to 7.4%) n=225	+2.9% (-4.2% to +10.0%) n=308
	3	4.8% (2.1% to 10.8%) n=104	3.1% (1.5% to 6.3%) n=225	+0.6% (-6.5% to +7.7%) n=329
	16	4.7% (2.8% to 7.5%) n=322	3.2% (2.0% to 5.0%) n=537	+0.2% (-4.3% to +4.8%) n=859
	33	6.3% (4.1% to 9.6%) n=302	3.9% (2.7% to 5.5%) n=777	+1.0% (-2.8% to +4.8%) n=1,079
	13	4.2% (1.2% to 14.0%) n=48	8.8% (4.3% to 17.0%) n=80	+3.9% (-8.1% to +15.9%) n=128
	12	10.9% (6.0% to 18.9%) n=92	5.2% (2.8% to 9.3%) n=193	0.0% (-7.7% to +7.7%) n=285
	28	6.0% (3.5% to 10.2%) n=200	5.4% (3.5% to 8.3%) n=352	+1.3% (-4.4% to +7.0%) n=552
	6	5.2% (3.3% to 8.2%) n=327	2.5% (1.7% to 3.7%) n=948	+0.5% (-2.9% to +4.0%) n=1,275
	27	10.2% (6.8% to 15.2%) n=205	3.9% (2.8% to 5.3%) n=909	+1.3% (-2.0% to +4.5%) n=1,114
	18	12.5% (3.5% to 36.0%) n=16	6.1% (1.7% to 19.6%) n=33	0.0% (-18.6% to +18.6%) n=49
	7	7.6% (4.7% to 12.2%) n=197	5.2% (3.8% to 7.1%) n=727	+2.5% (-1.3% to +6.3%) n=924
	22	5.3% (0.9% to 24.6%) n=19	3.9% (1.4% to 11.0%) n=76	+2.1% (-9.5% to +13.7%) n=95
	17	4.4% (2.2% to 8.9%) n=158	4.9% (3.3% to 7.3%) n=465	+2.6% (-2.3% to +7.5%) n=623
Total		7.6% (7.0% to 8.3%) n=5,828	4.1% (3.8% to 4.4%) n=14,502	+0.7% (-0.2% to +1.6%) n=20,330

SS26

Employment / benefit status progress, study group patients with finished episodes, more than one contact and records at both points.

Site	Data		total working / no benefits		proportion in work with no benefits		
	Usable records / Total records	% of records usable	pre-treatment	post-treatment	pre-treatment	post-treatment	difference in proportions
	940/1,017	92.4%	524	545	55.7% (52.6% to 58.9%)	58.0% (54.8% to 61.1%)	+2.2% (-2.2% to +6.7%)
	1,638/1,714	95.6%	779	824	47.6% (45.1% to 50.0%)	50.3% (47.9% to 52.7%)	+2.7% (-0.7% to +6.2%)
	1,018/1,154	88.2%	529	525	52.0% (48.9% to 55.0%)	51.6% (48.5% to 54.6%)	-0.4% (-4.7% to +3.9%)
	251/282	89.0%	141	147	56.2% (50.0% to 62.2%)	58.6% (52.4% to 64.5%)	+2.4% (-6.3% to +11.0%)
	1,579/1,986	79.5%	803	834	50.9% (48.4% to 53.3%)	52.8% (50.4% to 55.3%)	+2.0% (-1.5% to +5.4%)
	983/1,105	89.0%	546	581	55.5% (52.4% to 58.6%)	59.1% (56.0% to 62.1%)	+3.6% (-0.8% to +7.9%)
	747/866	86.3%	338	359	45.2% (41.7% to 48.8%)	48.1% (44.5% to 51.6%)	+2.8% (-2.2% to +7.9%)
	424/589	72.0%	226	233	53.3% (48.5% to 58.0%)	55.0% (50.2% to 59.6%)	+1.7% (-5.1% to +8.4%)
	99/143	69.2%	48	52	48.5% (38.9% to 58.2%)	52.5% (42.8% to 62.1%)	+4.0% (-9.9% to +18.0%)
	935/1,069	87.5%	443	452	47.4% (44.2% to 50.6%)	48.3% (45.2% to 51.5%)	+1.0% (-3.6% to +5.5%)
	438/511	85.7%	220	238	50.2% (45.6% to 54.9%)	54.3% (49.7% to 58.9%)	+4.1% (-2.5% to +10.7%)
	49/69	71.0%	24	24	49.0% (35.6% to 62.5%)	49.0% (35.6% to 62.5%)	0.0% (-19.8% to +19.8%)
	760/943	80.6%	300	327	39.5% (36.1% to 43.0%)	43.0% (39.5% to 46.6%)	+3.6% (-1.4% to +8.5%)
	674/755	89.3%	318	325	47.2% (43.4% to 51.0%)	48.2% (44.5% to 52.0%)	+1.0% (-4.3% to +6.4%)
	1,131/1,559	72.5%	606	627	53.6% (50.7% to 56.5%)	55.4% (52.5% to 58.3%)	+1.9% (-2.2% to +6.0%)
	458/919	49.8%	163	189	35.6% (31.3% to 40.1%)	41.3% (36.8% to 45.8%)	+5.7% (-0.6% to +12.0%)
	1,722/1,974	87.2%	888	933	51.6% (49.2% to 53.9%)	54.2% (51.8% to 56.5%)	+2.6% (-0.7% to +5.9%)
	131/429	30.5%	61	55	46.6% (38.2% to 55.1%)	42.0% (33.9% to 50.5%)	-4.6% (-16.6% to +7.4%)
	291/482	60.4%	145	150	49.8% (44.1% to 55.5%)	51.5% (45.8% to 57.2%)	+1.7% (-6.4% to +9.8%)
	649/1,105	58.7%	299	325	46.1% (42.3% to 49.9%)	50.1% (46.2% to 53.9%)	+4.0% (-1.4% to +9.4%)
	1,431/1,480	96.7%	626	677	43.7% (41.2% to 46.3%)	47.3% (44.7% to 49.9%)	+3.6% (-0.1% to +7.2%)
	131/156	84.0%	60	60	45.8% (37.5% to 54.3%)	45.8% (37.5% to 54.3%)	0.0% (-12.1% to +12.1%)
	333/372	89.5%	160	167	48.0% (42.7% to 53.4%)	50.2% (44.8% to 55.5%)	+2.1% (-5.5% to +9.7%)
	610/676	90.2%	268	281	43.9% (40.0% to 47.9%)	46.1% (42.1% to 50.0%)	+2.1% (-3.5% to +7.7%)
	637/1,747	36.5%	333	349	52.3% (48.4% to 56.1%)	54.8% (50.9% to 58.6%)	+2.5% (-3.0% to +8.0%)
	848/1,416	59.9%	489	473	57.7% (54.3% to 60.9%)	55.8% (52.4% to 59.1%)	-1.9% (-6.6% to +2.8%)
	53/61	86.9%	28	28	52.8% (39.7% to 65.6%)	52.8% (39.7% to 65.6%)	0.0% (-19.0% to +19.0%)
	1,116/1,190	93.8%	645	639	57.8% (54.9% to 60.7%)	57.3% (54.3% to 60.1%)	-0.5% (-4.6% to +3.6%)
	104/146	71.2%	60	62	57.7% (48.1% to 66.7%)	59.6% (50.0% to 68.5%)	+1.9% (-11.5% to +15.3%)
	664/865	76.8%	330	335	49.7% (45.9% to 53.5%)	50.5% (46.7% to 54.2%)	+0.8% (-4.6% to +6.1%)
Sites combined	20,844/26,780	77.8%	10400	10816	49.9% (49.2% to 50.6%)	51.9% (51.2% to 52.6%)	+2.0% (+1.0% to +3.0%)

SS26 (cont)

Employment / benefit status progress, study group patients with finished episodes, more than one contact and records at both points.

Site	on benefits to:			working / no benefits to:			other categories to:		
	on benefits (no change)	working full or part time	other categories	on benefits	working full or part time (no change)	other categories	on benefits	working full or part time	other categories (no change)
	122	31	18	13	485	26	23	29	193
	392	72	53	34	713	32	61	39	242
	264	20	25	18	497	14	27	8	145
	30	10	5	3	130	8	5	7	53
	287	74	30	40	739	24	40	21	324
	205	44	17	17	519	10	19	18	134
	182	22	14	12	313	13	25	24	142
	102	15	12	9	208	9	10	10	49
	19	5	2	1	44	3	5	3	17
	182	37	33	24	395	24	37	20	183
	95	29	7	7	205	8	10	4	73
	9	1	1	0	23	1	2	0	12
	229	35	24	13	273	14	18	19	135
	191	23	28	11	290	17	13	12	89
	193	47	25	35	552	19	18	28	214
	212	31	5	4	158	1	1	0	46
	314	83	51	40	818	30	48	32	306
	31	4	4	8	49	4	2	2	27
	74	5	0	3	136	6	0	9	58
	195	39	14	14	279	6	16	7	79
	326	85	43	33	576	17	30	16	305
	43	7	3	6	52	2	4	1	13
	82	7	9	6	149	5	8	11	56
	197	30	28	19	245	4	13	6	68
	109	34	19	19	301	13	10	14	118
	167	37	7	46	426	17	17	10	121
	10	0	2	1	26	1	5	2	6
	176	38	16	29	584	32	30	17	194
	15	1	0	0	58	2	1	3	24
	133	34	23	18	293	19	13	8	123
Sites combined	4586	900	518	483	9536	381	511	380	3549

SS27

Changes in symptom and W&SAS scores for patients having CBT in four main diagnostic groups.

Site	Site code	Depressive episode					Mixed anxiety depressive disorder				
		Patients	PHQ9 change	GAD7 Change	Phobia total change	W&SAS change	Patients	PHQ9 change	GAD7 Change	Phobia total change	W&SAS change
	4	65	-6.80(+6.61)	-5.57(+4.85)	-1.27(+5.25)	-6.95(+8.91)	143	-6.57(+6.50)	-6.36(+6.40)	-3.03(+4.73)	-6.64(+9.73)
	23	69	-5.39(+8.70)	-3.35(+7.57)	-1.77(+6.45)	-6.42(+11.97)	74	-5.31(+8.26)	-4.36(+6.76)	-2.15(+7.60)	-6.03(+11.67)
	20	117	-3.95(+6.74)	-2.76(+5.65)	-1.41(+4.28)	-4.81(+9.05)	95	-2.69(+6.74)	-2.36(+5.45)	-0.56(+5.97)	-2.42(+7.79)
	19	25	-7.80(+6.84)	-5.28(+5.81)	-1.44(+3.52)	-5.52(+6.29)	13	-3.92(+8.32)	-5.00(+9.36)	-0.75(+8.18)	-0.83(+9.20)
	14	144	-7.62(+7.03)	-5.97(+6.30)	-2.38(+5.37)	-8.45(+10.98)	137	-5.87(+7.05)	-5.22(+5.32)	-2.94(+5.96)	-6.98(+9.22)
	5	74	-6.40(+6.44)	-4.28(+5.54)	-1.31(+4.76)	-6.63(+9.92)	78	-5.66(+7.66)	-5.51(+6.71)	-3.11(+6.05)	-5.71(+9.25)
	8	69	-5.61(+6.12)	-4.27(+5.32)	-1.89(+4.83)	-5.22(+8.82)	76	-2.95(+6.15)	-2.33(+5.21)	-2.02(+6.48)	-1.52(+7.12)
	9	53	-4.04(+7.11)	-3.54(+4.89)	-0.04(+5.86)	-5.15(+11.68)	27	-6.24(+8.05)	-4.28(+6.59)	-2.91(+7.01)	-7.08(+12.11)
	36	38	-4.45(+8.86)	-4.26(+8.00)	-2.32(+5.14)	-5.97(+9.70)	46	-4.24(+7.58)	-4.30(+6.95)	-2.78(+4.73)	-4.89(+11.88)
	10	19	-3.29(+5.83)	-2.82(+5.08)	-2.47(+6.58)	-8.12(+6.97)	13	-1.92(+4.66)	-2.00(+5.70)	-0.77(+4.07)	-1.58(+7.84)
	30						~				
	21	29	-4.35(+5.97)	-2.92(+5.25)	-1.17(+3.96)	-3.09(+9.43)	56	-2.48(+5.32)	-2.95(+5.34)	-2.50(+5.07)	-4.41(+8.54)
	11	17	-5.80(+7.16)	-4.87(+6.31)	+0.40(+5.34)	-8.93(+12.45)	51	-4.31(+7.31)	-4.43(+6.00)	-1.63(+6.56)	-3.65(+10.16)
	25	144	-5.01(+6.91)	-3.58(+5.83)	-1.50(+5.04)	-5.23(+9.32)	103	-4.39(+6.97)	-3.03(+5.70)	-0.34(+5.21)	-2.96(+9.71)
	15	79	-4.97(+6.51)	-3.27(+5.32)	-3.31(+3.79)	-3.72(+10.75)					
	31	99	-5.60(+7.71)	-4.63(+6.27)	-1.53(+4.75)	-5.69(+10.09)	74	-6.73(+6.61)	-5.97(+7.07)	-3.52(+5.98)	-7.59(+10.69)
	26	20	-6.41(+8.90)	-6.24(+6.46)	-1.00(+4.50)	-6.38(+13.08)	13	-7.08(+7.03)	-8.18(+4.75)	-3.27(+5.02)	-7.45(+7.37)
	3	~									
	16	112	-4.74(+7.40)	-4.41(+5.41)	-2.00(+5.81)	-8.27(+9.85)	102	-4.65(+6.33)	-4.29(+5.27)	-2.04(+5.14)	-7.93(+9.48)
	33	~					10	-5.10(+5.24)	-3.60(+4.67)	-0.40(+2.59)	-2.70(+4.97)
	12	10	-10.30(+7.76)	-6.00(+5.35)	-4.50(+4.43)	-10.90(+9.79)	7				
	28	~					~				
	6	116	-7.89(+7.65)	-6.21(+6.32)	-2.75(+6.10)	-8.51(+12.59)	169	-6.81(+7.37)	-5.49(+6.51)	-3.47(+6.24)	-7.42(+9.64)
	27	99	-6.08(+8.22)	-4.78(+5.36)	-0.12(+5.40)	-4.81(+10.23)	175	-5.27(+5.91)	-4.41(+5.23)	-0.92(+5.20)	-4.30(+8.30)
	18										
	7	131	-5.94(+6.67)	-4.38(+5.28)	-1.45(+4.70)	-6.13(+8.08)	131	-5.69(+7.10)	-5.48(+5.99)	-1.94(+4.71)	-6.18(+9.53)
	17	45	-8.05(+6.88)	-5.14(+5.82)	-2.46(+4.29)	-8.00(+9.41)	50	-5.22(+6.15)	-3.35(+6.23)	-0.98(+7.10)	-2.36(+10.20)
Sites combined		1581	-5.92(+7.26)	-4.53(+5.93)	-1.65(+5.11)	-6.32(+10.02)	1651	-5.30(+7.01)	-4.70(+6.17)	-2.19(+5.84)	-5.34(+9.74)

Table shows counts of patients, means (and standard deviations) for symptom changes. Calculations suppressed where n<10.

~ indicates less than 5 patients or suppressed to prevent other row implicit, blank row indicates no patient.

SS27 (cont)

Changes in symptom and W&SAS scores for patients having CBT in four main diagnostic groups.

Site	Generalised anxiety disorder						Recurrent depressive disorder				
	Site code	Patients	PHQ9 change	GAD7 Change	Phobia total change	W&SAS change	Patients	PHQ9 change	GAD7 Change	Phobia total change	W&SAS change
4		173	-6.33(+6.87)	-6.84(+5.65)	-3.71(+5.59)	-6.61(+7.16)	69	-5.91(+5.43)	-4.78(+5.07)	-2.55(+5.05)	-6.43(+7.84)
23		23	-3.22(+6.13)	-3.65(+6.60)	-2.83(+4.91)	-8.00(+7.40)	38	-6.00(+6.60)	-3.45(+5.72)	-2.18(+6.08)	-6.37(+10.15)
20		92	-3.13(+4.92)	-3.97(+4.79)	-1.57(+4.99)	-3.28(+7.33)	45	-4.00(+5.97)	-3.58(+5.33)	-0.76(+6.00)	-4.20(+8.73)
19		13	-2.08(+5.74)	-4.00(+6.22)	-0.92(+7.93)	-1.58(+8.73)	~				
14		115	-4.71(+6.17)	-5.65(+5.96)	-2.60(+4.57)	-6.46(+8.25)	39	-7.11(+7.17)	-5.41(+6.15)	-1.89(+8.20)	-7.83(+11.17)
5		87	-5.07(+6.07)	-5.29(+6.15)	-3.61(+5.77)	-6.69(+8.03)	40	-6.14(+6.37)	-4.50(+4.99)	-2.44(+3.59)	-7.67(+9.99)
8		14	-3.79(+4.58)	-5.71(+5.11)	-3.93(+5.62)	-9.50(+7.88)	24	-3.77(+7.38)	-2.50(+5.71)	-1.32(+3.41)	-3.36(+5.24)
9		30	-2.75(+4.93)	-2.46(+4.91)	-3.71(+5.28)	-3.78(+6.61)	20	-6.88(+8.31)	-3.67(+5.86)	-0.35(+5.10)	-5.71(+14.29)
36		11	-6.45(+7.71)	-5.64(+6.95)	-4.45(+6.99)	-8.64(+8.73)	15	-5.40(+8.73)	-2.67(+8.36)	+1.07(+4.28)	-5.20(+7.77)
10		6					13	-3.91(+6.46)	-4.55(+5.15)	-4.27(+3.69)	-6.91(+9.01)
30		~					~				
21		48	-3.40(+5.54)	-4.28(+5.27)	-2.26(+5.16)	-4.30(+9.50)	30	-7.33(+7.59)	-4.47(+6.46)	-1.14(+5.23)	-7.14(+8.42)
11		10	-1.60(+2.88)	-2.30(+6.00)	-2.20(+6.34)	-5.70(+10.91)	8				
25		76	-1.96(+5.39)	-3.49(+4.87)	-1.35(+4.50)	-3.17(+7.77)	12	-6.00(+5.29)	-1.75(+5.50)	-1.50(+1.29)	-2.25(+4.35)
15											
31		69	-5.26(+6.21)	-5.58(+5.63)	-3.22(+5.39)	-4.65(+8.95)	29	-3.46(+6.64)	-2.21(+4.63)	-0.64(+4.43)	-1.75(+8.55)
26		6					~				
3							~				
16		47	-4.97(+7.17)	-5.54(+6.32)	-3.00(+3.77)	-7.69(+9.62)	19	-6.92(+7.50)	-5.62(+6.65)	-2.80(+6.70)	-7.70(+15.37)
33		~					10	-7.50(+8.14)	-2.90(+7.82)	-3.60(+4.38)	-6.90(+10.13)
12		7					9				
28		~					~				
6		104	-6.34(+6.58)	-6.45(+5.83)	-5.22(+7.72)	-8.18(+9.69)	49	-5.85(+7.96)	-3.96(+6.93)	-2.93(+7.85)	-11.32(+8.77)
27		64	-4.43(+7.42)	-6.00(+7.41)	-1.85(+4.00)	-4.25(+8.57)	19	-3.25(+8.07)	-2.42(+5.71)	+0.09(+7.29)	-3.67(+9.90)
18							~				
7		72	-4.66(+5.05)	-6.10(+5.95)	-2.29(+4.60)	-4.34(+7.01)	30	-4.67(+6.26)	-4.27(+5.13)	-2.14(+3.71)	-5.10(+8.60)
17		21	-6.22(+4.71)	-6.83(+5.62)	-2.94(+3.29)	-4.56(+9.57)	11	-3.00(+6.73)	-1.40(+4.86)	+0.00(+7.54)	-0.30(+11.10)
Sites combined		1092	-4.76(+6.19)	-5.46(+5.83)	-2.92(+5.32)	-5.54(+8.16)	540	-5.42(+6.88)	-3.83(+5.78)	-1.85(+5.55)	-5.76(+9.45)

SS28
PHQ change measures

Symptom score changes, effect sizes and 'remission' and 'recovery' rates for comparison with Pilot work

Site	Site code	Pre treatment		Post treatment		Effect size	Case rate		Remission rate' (Post / Pre)
		mean (s.d.)	Median (IQR)	mean (s.d.)	Median (IQR)		Pre-treatment	Post-treatment	
	4	12.42 (6.24)	12 (8 - 17)	6.51 (6.22)	4 (2 - 10)	0.95	66.2% (63.2% to 69.1%)	26.6% (23.9% to 29.5%)	0.40 (0.36 to 0.45)
	23	14.77 (6.65)	15 (10 - 20)	9.77 (7.18)	13 (9 - 17)	0.70	76.8% (74.8% to 78.7%)	45.4% (43.0% to 47.8%)	0.59 (0.56 to 0.63)
	20	13.51 (6.50)	13 (8 - 19)	10.76 (7.05)	12 (8 - 16)	0.39	70.6% (67.8% to 73.3%)	52.2% (49.2% to 55.2%)	0.74 (0.69 to 0.79)
	19	12.29 (6.68)	12 (7 - 17.75)	7.65 (6.66)	12 (7 - 17)	0.70	60.9% (54.9% to 66.6%)	31.6% (26.3% to 37.4%)	0.52 (0.42 to 0.63)
	14	13.53 (6.72)	14 (8 - 19)	7.60 (7.00)	12 (7 - 17)	0.85	70.0% (67.7% to 72.3%)	31.7% (29.4% to 34.1%)	0.45 (0.42 to 0.49)
	5	12.77 (6.49)	13 (8 - 18)	7.96 (6.66)	12 (7 - 17)	0.72	67.0% (64.1% to 69.9%)	34.1% (31.2% to 37.1%)	0.51 (0.46 to 0.56)
	8	13.42 (6.63)	14 (8 - 19)	9.12 (6.70)	12 (8 - 16)	0.64	69.0% (65.6% to 72.2%)	41.9% (38.4% to 45.5%)	0.61 (0.55 to 0.67)
	9	13.35 (6.81)	13 (8 - 18)	9.06 (7.22)	12 (8 - 16)	0.59	68.3% (64.0% to 72.4%)	41.9% (37.6% to 46.4%)	0.61 (0.54 to 0.69)
	24	13.77 (6.40)	13 (9.5 - 18.5)	8.33 (6.86)	12 (8 - 16)	0.79	74.8% (66.9% to 81.4%)	34.1% (26.6% to 42.4%)	0.46 (0.35 to 0.59)
	36	13.63 (6.92)	14 (9 - 19)	8.17 (7.25)	13 (8.25 - 17)	0.75	70.4% (67.6% to 73.1%)	36.1% (33.3% to 39.0%)	0.51 (0.47 to 0.56)
	10	13.53 (6.11)	14 (9 - 18)	9.72 (7.06)	12 (8 - 16)	0.54	72.8% (68.5% to 76.7%)	46.8% (42.2% to 51.4%)	0.64 (0.57 to 0.72)
	30	10.45 (7.73)	11 (3 - 16)	7.19 (7.12)	9 (5 - 16)	0.46	56.5% (44.8% to 67.6%)	31.9% (22.1% to 43.6%)	0.56 (0.38 to 0.84)
	21	13.79 (6.67)	14 (9 - 19)	10.42 (7.12)	13 (8 - 17)	0.47	73.0% (69.9% to 76.0%)	52.6% (49.1% to 56.0%)	0.72 (0.67 to 0.78)
	11	14.18 (6.19)	15 (10 - 19)	9.59 (7.16)	13 (9 - 17)	0.64	75.3% (71.9% to 78.4%)	46.1% (42.4% to 49.8%)	0.61 (0.56 to 0.67)
	25	14.27 (6.53)	14 (9.25 - 19)	9.72 (6.84)	13 (8 - 17)	0.67	75.0% (72.5% to 77.3%)	45.2% (42.5% to 48.0%)	0.60 (0.56 to 0.65)
	15	15.30 (6.10)	16 (11 - 20)	11.59 (7.63)	15 (10 - 18)	0.49	80.4% (76.4% to 83.9%)	58.5% (53.7% to 63.1%)	0.73 (0.66 to 0.80)
	31	14.15 (6.46)	14 (9 - 19)	9.42 (7.19)	13 (8 - 17)	0.66	73.3% (71.2% to 75.4%)	42.6% (40.3% to 44.9%)	0.58 (0.55 to 0.62)
	26	14.48 (6.06)	15 (10 - 19)	10.34 (7.03)	13 (8 - 17)	0.59	76.7% (71.4% to 81.3%)	49.8% (44.0% to 55.7%)	0.65 (0.57 to 0.74)
	3	14.25 (6.81)	15 (9.75 - 19.25)	9.11 (7.12)	14 (8 - 17)	0.72	75.0% (70.0% to 79.4%)	38.6% (33.4% to 44.0%)	0.51 (0.44 to 0.60)
	16	14.97 (6.37)	15 (10 - 20)	10.04 (7.27)	14 (9 - 18)	0.68	78.8% (75.9% to 81.4%)	48.5% (45.1% to 51.9%)	0.62 (0.57 to 0.67)
	33	13.75 (6.48)	14 (9 - 19)	8.99 (6.95)	13 (8 - 17)	0.68	71.3% (68.9% to 73.5%)	40.5% (38.1% to 43.1%)	0.57 (0.53 to 0.61)
	13	15.18 (6.83)	16 (10 - 21)	10.42 (8.01)	14 (9 - 18)	0.59	79.1% (71.8% to 84.8%)	50.7% (42.7% to 58.6%)	0.64 (0.54 to 0.77)
	12	12.12 (7.14)	12 (6 - 18)	7.98 (7.18)	10 (6 - 15)	0.58	59.3% (54.2% to 64.2%)	31.4% (26.9% to 36.3%)	0.53 (0.45 to 0.63)
	28	15.45 (6.24)	16 (11 - 20)	9.52 (7.54)	14 (10 - 18)	0.79	81.9% (78.7% to 84.7%)	43.8% (40.0% to 47.7%)	0.54 (0.49 to 0.59)
	6	14.35 (6.73)	15 (9 - 20)	8.25 (7.21)	13 (8 - 17)	0.85	74.2% (72.0% to 76.3%)	37.1% (34.7% to 39.5%)	0.50 (0.47 to 0.54)
	27	14.19 (6.55)	14 (9 - 19)	9.57 (6.64)	13 (8 - 17)	0.70	73.9% (71.2% to 76.4%)	45.7% (42.8% to 48.7%)	0.62 (0.58 to 0.67)
	18	15.13 (5.76)	16 (11 - 19)	12.35 (7.39)	15 (11 - 18)	0.38	81.7% (70.1% to 89.4%)	60.0% (47.4% to 71.4%)	0.73 (0.58 to 0.93)
	7	13.49 (6.72)	14 (8 - 19)	8.20 (6.97)	13 (8 - 17)	0.76	68.6% (65.8% to 71.2%)	37.2% (34.5% to 40.1%)	0.54 (0.50 to 0.59)
	22	12.77 (6.47)	13 (8 - 18)	7.25 (6.25)	12.5 (8 - 15)	0.88	66.9% (58.0% to 74.8%)	33.1% (25.2% to 42.0%)	0.49 (0.37 to 0.66)
	17	14.42 (6.80)	15 (9 - 20)	8.73 (7.18)	14 (8 - 18)	0.79	72.8% (69.4% to 75.9%)	40.3% (36.8% to 43.9%)	0.55 (0.50 to 0.61)
Sites Combined	0	13.91 (6.61)	14 (9 - 19)	9.03 (7.11)	13 (8 - 17)	0.69	72.4% (71.8% to 73.0%)	41.4% (40.8% to 42.0%)	0.57 (0.56 to 0.58)

Analyses include all patient with completed episodes including two or more contacts and both initial and final scores on the relevant rating scale

SS28 (cont)
GAD 7 change measures

Symptom score changes, effect sizes and 'remission' and 'recovery' rates for comparison with Pilot work

Site	Site code	Pre treatment		Post treatment		Effect size	Case rate		Remission rate' (Post / Pre)
		mean (s.d.)	Median (IQR)	mean (s.d.)	Median (IQR)		Pre-treatment	Post-treatment	
	4	11.89 (5.25)	12 (8 - 16)	6.06 (5.37)	4 (2 - 9)	1.09	76.5% (73.8% to 79.1%)	32.6% (29.7% to 35.6%)	0.43 (0.39 to 0.47)
	23	12.81 (5.55)	13 (9 - 17)	8.53 (6.07)	7 (3 - 13)	0.71	79.8% (77.8% to 81.6%)	48.5% (46.1% to 50.8%)	0.61 (0.58 to 0.64)
	20	12.10 (5.43)	12 (8 - 16)	9.65 (6.03)	9 (5 - 15)	0.41	75.9% (73.3% to 78.4%)	57.2% (54.2% to 60.1%)	0.75 (0.71 to 0.80)
	19	11.58 (5.77)	12 (7 - 17)	7.21 (5.80)	6.5 (2 - 11)	0.76	70.8% (65.1% to 76.0%)	39.8% (34.1% to 45.8%)	0.56 (0.47 to 0.66)
	14	11.96 (5.61)	12 (7 - 17)	6.77 (6.06)	5 (2 - 11)	0.86	74.9% (72.7% to 77.0%)	35.8% (33.4% to 38.2%)	0.48 (0.44 to 0.51)
	5	11.85 (5.55)	12 (7 - 17)	7.14 (5.86)	6 (2 - 11)	0.81	74.5% (71.7% to 77.1%)	38.9% (35.9% to 41.9%)	0.52 (0.48 to 0.57)
	8	11.96 (5.35)	12 (8 - 16)	8.15 (5.67)	7 (4 - 12)	0.67	75.5% (72.2% to 78.4%)	47.7% (44.1% to 51.3%)	0.63 (0.58 to 0.69)
	9	11.68 (5.47)	12 (8 - 16)	8.28 (6.12)	7 (3 - 13)	0.56	75.1% (71.0% to 78.7%)	47.2% (42.7% to 51.7%)	0.63 (0.56 to 0.70)
	24	11.98 (5.33)	12 (8 - 16)	7.04 (5.46)	6 (3 - 10)	0.90	79.4% (71.9% to 85.4%)	38.2% (30.5% to 46.6%)	0.48 (0.38 to 0.61)
	36	12.58 (5.57)	13 (8.25 - 17)	7.56 (6.07)	6 (3 - 12)	0.83	78.9% (76.4% to 81.3%)	42.0% (39.0% to 45.0%)	0.53 (0.49 to 0.57)
	10	12.07 (5.30)	12 (8 - 16)	8.48 (5.92)	7 (3 - 13)	0.61	77.7% (73.6% to 81.3%)	49.8% (45.2% to 54.4%)	0.64 (0.58 to 0.71)
	30	10.01 (6.59)	9 (5 - 16)	6.35 (5.84)	5 (1 - 11)	0.63	62.3% (50.5% to 72.8%)	37.7% (27.2% to 49.5%)	0.60 (0.42 to 0.86)
	21	12.14 (5.58)	13 (8 - 17)	8.96 (6.04)	8 (4 - 14)	0.53	76.3% (73.2% to 79.0%)	54.3% (50.9% to 57.7%)	0.71 (0.66 to 0.77)
	11	12.52 (5.14)	13 (9 - 17)	8.61 (6.06)	7 (3.25 - 13)	0.65	79.6% (76.4% to 82.4%)	48.4% (44.7% to 52.1%)	0.61 (0.56 to 0.66)
	25	12.36 (5.62)	13 (8 - 17)	8.64 (5.84)	7 (4 - 13)	0.64	76.4% (74.0% to 78.7%)	49.6% (46.9% to 52.4%)	0.65 (0.61 to 0.69)
	15	13.82 (5.28)	15 (10 - 18)	10.10 (6.50)	10 (4 - 16)	0.57	86.1% (82.4% to 89.1%)	61.1% (56.3% to 65.6%)	0.71 (0.65 to 0.77)
	31	12.54 (5.47)	13 (8 - 17)	8.26 (6.17)	7 (3 - 13)	0.70	78.9% (77.0% to 80.8%)	46.1% (43.8% to 48.5%)	0.58 (0.55 to 0.62)
	26	12.47 (5.46)	13 (8 - 17)	8.61 (6.17)	8 (3 - 13)	0.62	75.9% (69.9% to 81.0%)	50.9% (44.4% to 57.3%)	0.67 (0.58 to 0.78)
	3	12.68 (5.56)	14 (8 - 17)	7.95 (6.10)	7 (3 - 13)	0.78	80.0% (75.3% to 84.0%)	41.8% (36.6% to 47.3%)	0.52 (0.46 to 0.60)
	16	13.08 (5.54)	14 (9 - 18)	8.62 (6.29)	7.5 (3 - 14)	0.71	79.8% (76.9% to 82.4%)	50.0% (46.6% to 53.4%)	0.63 (0.58 to 0.68)
	33	12.25 (5.44)	13 (8 - 17)	8.11 (5.96)	7 (3 - 13)	0.70	77.1% (74.9% to 79.1%)	46.6% (44.1% to 49.2%)	0.60 (0.57 to 0.64)
	13	13.22 (5.82)	14 (9 - 18)	9.20 (7.34)	8 (2 - 16.25)	0.55	79.7% (72.5% to 85.4%)	50.7% (42.7% to 58.6%)	0.64 (0.53 to 0.76)
	12	10.53 (6.03)	10 (6 - 15)	6.87 (5.96)	5 (2 - 10)	0.61	62.0% (56.9% to 66.8%)	31.7% (27.1% to 36.6%)	0.51 (0.43 to 0.61)
	28	13.65 (5.19)	14 (10 - 18)	8.40 (6.32)	7 (3 - 14)	0.83	85.9% (83.0% to 88.4%)	48.1% (44.3% to 52.0%)	0.56 (0.51 to 0.61)
	6	12.66 (5.39)	13 (8 - 17)	7.47 (6.19)	6 (2 - 12)	0.84	78.6% (76.5% to 80.6%)	42.1% (39.7% to 44.6%)	0.54 (0.50 to 0.57)
	27	12.23 (5.44)	13 (8 - 17)	8.45 (5.85)	7 (4 - 13)	0.65	77.0% (74.4% to 79.4%)	48.3% (45.4% to 51.3%)	0.63 (0.59 to 0.67)
	18	13.98 (4.80)	15 (11 - 18)	10.40 (6.30)	11.5 (5 - 15)	0.57	86.7% (75.8% to 93.1%)	56.7% (44.1% to 68.4%)	0.65 (0.51 to 0.83)
	7	12.10 (5.48)	13 (8 - 17)	7.20 (5.74)	6 (2 - 11)	0.86	76.1% (73.6% to 78.5%)	39.1% (36.3% to 42.0%)	0.51 (0.47 to 0.56)
	22	12.04 (5.14)	12.5 (8 - 15)	6.33 (5.70)	5 (2 - 10)	1.00	79.7% (71.5% to 85.9%)	34.7% (26.8% to 43.7%)	0.44 (0.34 to 0.57)
	17	13.01 (5.59)	14 (8 - 18)	7.87 (6.33)	6 (3 - 13)	0.81	78.6% (75.5% to 81.5%)	44.0% (40.4% to 47.6%)	0.56 (0.51 to 0.61)
Sites Combined	0	12.37 (5.50)	13 (8 - 17)	8.01 (6.08)	7 (3 - 13)	0.72	77.5% (76.9% to 78.0%)	45.3% (44.6% to 45.9%)	0.58 (0.58 to 0.59)

Analyses include all patient with completed episodes including two or more contacts and both initial and final scores on the relevant rating scale

SS29

Service level outcome and service characteristics used for correlation analysis i. values (See text for details).

Site	Site code	MTR1 recovery rate	PHQ9 recovery rate	GAD7 recovery rate	Phobia questions recovery rate	Study group size	Proportion still in system	Proportion of episodes finished 'completed'	Proportion of therapist sessions high skill	Proportion of pts with high intensity therapy having CBT	Proportion of patients having low intensity only	Step fraction
	4	0.5412	0.5938	0.5676	0.5591	1746	0.2955	0.49837398	0.9990	0.9682	0.4898	0.6252
	23	0.3942	0.4495	0.4393	0.4552	3687	0.3019	0.41064491	0.6160	0.5690	0.4192	0.2371
	20	0.2482	0.2796	0.2727	0.2920	1786	0.2805	0.71984436	0.5480	0.9389	0.4519	0.2735
	19	0.4605	0.5233	0.4800	0.5000	1196	0.5936	0.43004115	1.0000	0.9526	0.3641	0.2844
	14	0.4139	0.4513	0.4353	0.4554	3801	0.3760	0.47175379	0.6420	0.6476	0.3064	0.3847
	5	0.4453	0.4753	0.4706	0.4433	2891	0.3459	0.4616605	0.4440	0.8052	0.5165	0.4242
	8	0.3310	0.3783	0.3649	0.4150	2219	0.4187	0.44031008	0.5280	0.9337	0.6106	0.2255
	9	0.3214	0.3589	0.3386	0.3693	1870	0.5508	0.31428571	0.5530	0.9758	0.4987	0.6807
	24	0.4567	0.5370	0.5357	0.4857	6060	0.9619	0.84415584	0.4440	0.7619	0.4350	0.3619
	36	0.4856	0.5365	0.5071	0.5355	4555	0.5974	0.39258451	0.6040	0.4345	0.2400	0.1909
	10	0.3250	0.3439	0.3522	0.3960	1793	0.3062	0.71784566	0.3070	0.4053	0.5859	0.5176
	30	0.4130	0.5385	0.4651	0.4000	570	0.6982	0.4244186	0.6370	0.6563	0.5596	0.2188
	21	0.2475	0.2812	0.2909	0.2411	1603	0.3500	0.5950096	0.3920	0.8091	0.5666	0.3571
	11	0.3675	0.3962	0.4023	0.3854	2023	0.3747	0.38023715	0.4710	0.7218	0.6383	0.2972
	25	0.3006	0.3641	0.3359	0.2961	5326	0.2899	0.02855632	0.1360	0.2088	0.3194	0.5738
	15	0.1469	0.1629	0.1624	0.1709	2262	0.4859	0.22098022	0.5510	0.4874	0.4676	0.0000
	31	0.3820	0.4090	0.3986	0.3988	5912	0.3933	0.38249233	0.7620	0.6232	0.4162	0.5915
	26	0.1949	0.2587	0.2280	0.1912	1441	0.6211	0.26007326	0.3220	0.7765	0.6640	0.6706
	3	0.3096	0.3779	0.3556	0.2269	1618	0.6520	0.39786856	0.7910	0.7094	0.1281	0.0335
	16	0.2740	0.3138	0.3015	0.2430	2550	0.3749	0.25156838	0.2510	0.8328	0.5213	0.4890
	33	0.4129	0.4758	0.4366	0.4625	4103	0.4831	0.50589345	0.4160	0.5695	0.5125	0.1575
	13	0.3529	0.3680	0.3790	0.3587	1135	0.6846	0.74022346	0.6920	0.3254	0.1208	0.0472
	12	0.5092	0.5136	0.5368	0.4237	1254	0.5463	0.69771529	0.7150	0.9856	0.3251	0.1264
	28	0.4020	0.4641	0.4392	0.3452	1650	0.4127	0.49226006		0.2513	0.6698	0.6474
	6	0.4194	0.4677	0.4450	0.1988	3826	0.3672	0.37050805	0.4330	0.6284	0.4575	0.3616
	27	0.2975	0.3466	0.3406	0.3328	3743	0.2787	0.00777778	0.1570	0.2182	0.1904	0.6595
	18	0.2857	0.3000	0.3774	0.3478	626	0.6390	0.33185841	0.5840	1.0000	0.0133	0.0750
	7	0.4597	0.4707	0.5017	0.4899	3120	0.3683	0.42567225	0.5470	0.9061	0.5114	0.3549
	22	0.4590	0.4592	0.4914	0.3651	346	0.5520	0.1483871	0.6170	1.0000	0.2903	0.1727
	17	0.3844	0.4171	0.4071	0.3735	2640	0.5848	0.55474453	0.9270	0.7921	0.4446	0.1336

SS29 (cont)

Service level outcome and service characteristics used for correlation analysis - ii. ranks (See text for details).

Site	Site code	MTR1 recovery rate	PHQ9 recovery rate	GAD7 recovery rate	Phobia questions recovery rate	Study group size	Proportion still in system	Proportion of episodes finished 'completed'	Proportion of therapist sessions high skill	Proportion of pts with high intensity therapy having CBT	Proportion of patients having low intensity only	Step fraction
	4	1	1	1	1	20	27	9	2	5	13	5
	23	14	14	11	8	9	26	17	11	23	19	19
	20	27	28	28	24	19	29	3	16	7	16	18
	19	4	5	7	3	26	8	14	1	6	21	17
	14	10	13	14	7	7	18	11	8	19	24	11
	5	8	8	8	9	11	24	12	20	12	9	10
	8	19	18	20	11	15	15	13	18	8	4	20
	9	21	22	24	17	17	11	24	14	4	12	1
	24	7	3	3	5	1	1	1	20	15	18	12
	36	3	4	4	2	4	7	19	12	25	26	22
	10	20	24	22	14	18	25	4	26	26	5	8
	30	11	2	9	12	29	2	16	9	18	7	21
	21	28	27	27	26	23	23	6	24	11	6	14
	11	17	17	16	15	16	20	21	19	16	3	16
	25	23	21	25	23	3	28	29	29	30	23	7
	15	30	30	30	30	14	13	27	15	24	14	30
	31	16	16	17	13	2	17	20	5	21	20	6
	26	29	29	29	29	24	6	25	25	14	2	2
	3	22	19	21	27	22	4	18	4	17	28	29
	16	26	25	26	25	13	19	26	27	10	8	9
	33	12	7	13	6	5	14	8	23	22	10	24
	13	18	20	18	19	27	3	2	7	27	29	28
	12	2	6	2	10	25	12	5	6	3	22	26
	28	13	11	12	21	21	16	10		28	1	4
	6	9	10	10	28	6	22	22	22	20	15	13
	27	24	23	23	22	8	30	30	28	29	27	3
	18	25	26	19	20	28	5	23	13	1	30	27
	7	5	9	5	4	10	21	15	17	9	11	15
	22	6	12	6	18	30	10	28	10	1	25	23
	17	15	15	15	16	12	9	7	3	13	17	25